Henrik Zetterberg

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2424085/publications.pdf

Version: 2024-02-01

1,898 papers	109,261 citations	228 145 h-index	750 250 g-index
2043 all docs	2043 docs citations	2043 times ranked	58843 citing authors

#	Article	IF	Citations
1	Alzheimer's disease. Lancet, The, 2006, 368, 387-403.	6.3	3,074
2	Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature Reviews Neurology, 2010, 6, 131-144.	4.9	1,598
3	Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurology, The, 2006, 5, 228-234.	4.9	1,494
4	CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurology, The, 2016, 15, 673-684.	4.9	1,413
5	Gut microbiome alterations in Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 13537.	1.6	1,256
6	Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurology, The, 2016, 15, 455-532.	4.9	1,242
7	Neurofilaments as biomarkers in neurological disorders. Nature Reviews Neurology, 2018, 14, 577-589.	4.9	1,177
8	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
9	Clearance systems in the brainâ€”implications for Alzheimer disease. Nature Reviews Neurology, 2015, 11, 457-470.	4.9	1,127
10	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. JAMA - Journal of the American Medical Association, 2009, 302, 385.	3.8	1,009
11	Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Annals of Neurology, 2017, 81, 857-870.	2.8	768
12	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurology, The, 2020, 19, 422-433.	4.9	668
13	Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurology, 2017, 74, 557.	4.5	664
14	Safety, efficacy, and biomarker findings of PBT2 in targeting Aî² as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2008, 7, 779-786.	4.9	657
15	Plasma P-tau181 in Alzheimerâ€™s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimerâ€™s dementia. Nature Medicine, 2020, 26, 379-386.	15.2	643
16	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2020, 324, 772.	3.8	640
17	Neurofilament light chain as a biomarker in neurological disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 870-881.	0.9	623
18	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Science Translational Medicine, 2014, 6, 243ra86.	5.8	600

#	Article	IF	Citations
19	Earliest accumulation of Î²-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nature Communications, 2017, 8, 1214.	5.8	596
20	Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nature Reviews Drug Discovery, 2010, 9, 560-574.	21.5	560
21	The Neuropathology and Neurobiology of Traumatic Brain Injury. Neuron, 2012, 76, 886-899.	3.8	555
22	Cerebrospinal Fluid Levels ofÎ²-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia. Archives of General Psychiatry, 2012, 69, 98.	13.8	554
23	Biomarkers for Alzheimer's disease: current status and prospects for the future. Journal of Internal Medicine, 2018, 284, 643-663.	2.7	550
24	Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1655-1661.	1.4	517
25	Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. Nature Reviews Neurology, 2013, 9, 201-210.	4.9	509
26	Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E1826-34.	3.3	492
27	Diagnostic value of plasma phosphorylated tau181 in Alzheimerâ€™s disease and frontotemporal lobar degeneration. Nature Medicine, 2020, 26, 387-397.	15.2	471
28	CSF biomarkers of Alzheimer's disease concord with amyloidâ€Î²2 PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimer's and Dementia, 2018, 14, 1470-1481.	0.4	468
29	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	4.5	455
30	Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimer's and Dementia, 2008, 4, 38-48.	0.4	447
31	Plasma Î²-amyloid in Alzheimerâ€™s disease and vascular disease. Scientific Reports, 2016, 6, 26801.	1.6	442
32	Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurology, 2019, 76, 791.	4.5	436
33	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nature Reviews Neurology, 2018, 14, 639-652.	4.9	434
34	A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimerâ€™s disease. Nature Genetics, 2021, 53, 1276-1282.	9.4	430
35	Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People. Archives of Neurology, 2010, 67, 949.	4.9	407
36	Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders. Archives of Neurology, 2012, 69, 1445.	4.9	407

#	Article	IF	Citations
37	Amyloid biomarkers in Alzheimer's disease. Trends in Pharmacological Sciences, 2015, 36, 297-309.	4.0	404
38	<scp>sTREM</scp> 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in earlyâ€stage Alzheimer's disease and associate with neuronal injury markers. EMBO Molecular Medicine, 2016, 8, 466-476.	3.3	392
39	Traumatic brain injuries. Nature Reviews Disease Primers, 2016, 2, 16084.	18.1	380
40	Plasma tau in Alzheimer disease. Neurology, 2016, 87, 1827-1835.	1.5	371
41	Current state of Alzheimerâ€™s fluid biomarkers. Acta Neuropathologica, 2018, 136, 821-853.	3.9	370
42	Blood-based NfL. Neurology, 2017, 88, 930-937.	1.5	369
43	Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. EBioMedicine, 2016, 3, 135-140.	2.7	360
44	Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurology, The, 2022, 21, 66-77.	4.9	360
45	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.4	354
46	Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology, 2016, 87, 1329-1336.	1.5	354
47	Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurology, 2016, 73, 60.	4.5	354
48	A Practical Guide to Immunoassay Method Validation. Frontiers in Neurology, 2015, 6, 179.	1.1	348
49	PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses. Journal of Alzheimer's Disease, 2010, 20, 509-516.	1.2	347
50	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.4	344
51	Blood Biomarkers for Brain Injury in Concussed Professional Ice Hockey Players. JAMA Neurology, 2014, 71, 684.	4.5	336
52	Total and phosphorylated tau protein as biological markers of Alzheimerâ€™s disease. Experimental Gerontology, 2010, 45, 30-40.	1.2	330
53	<scp>CSF</scp> AÎ²42/AÎ²40 and AÎ²42/AÎ²38 ratios: better diagnostic markers of Alzheimer disease. Annals of Clinical and Translational Neurology, 2016, 3, 154-165.	1.7	329
54	Plasma tau levels in Alzheimer's disease. Alzheimer's Research and Therapy, 2013, 5, 9.	3.0	328

#	Article	IF	Citations
55	Resistance to autosomal dominant Alzheimerâ€™s disease in an APOE3 Christchurch homozygote: a case report. Nature Medicine, 2019, 25, 1680-1683.	15.2	328
56	Advantages and disadvantages of the use of the CSF Amyloid Î² (AÎ²) 42/40 ratio in the diagnosis of Alzheimerâ€™s Disease. Alzheimer's Research and Therapy, 2019, 11, 34.	3.0	325
57	Neurochemical Aftermath of Amateur Boxing. Archives of Neurology, 2006, 63, 1277.	4.9	310
58	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. Alzheimer's and Dementia, 2019, 15, 292-312.	0.4	310
59	Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology, 2017, 89, 2230-2237.	1.5	307
60	Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology, 2020, 95, e1754-e1759.	1.5	304
61	Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid Î²-Amyloid 42. JAMA Neurology, 2014, 71, 1282.	4.5	300
62	Amyloid Î² Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization. Journal of Neuroscience, 2008, 28, 4231-4237.	1.7	293
63	Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. Alzheimer's and Dementia, 2019, 15, 888-898.	0.4	290
64	Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology, 2015, 85, 1240-1249.	1.5	288
65	Plasma p-tau231: a new biomarker for incipient Alzheimerâ€™s disease pathology. Acta Neuropathologica, 2021, 141, 709-724.	3.9	285
66	Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Diseaseâ€“Related Î²-Amyloid Status. JAMA Neurology, 2019, 76, 1060.	4.5	282
67	Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Scientific Reports, 2016, 6, 36791.	1.6	281
68	Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. Neurology, 2017, 88, 1788-1794.	1.5	280
69	The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2018, 10, 124.	3.0	273
70	Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. Lancet Neurology, The, 2017, 16, 601-609.	4.9	272
71	Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimerâ€™s disease. Acta Neuropathologica, 2010, 120, 185-193.	3.9	268
72	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1180-1190.	0.4	254

#	Article	IF	Citations
73	Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation ofÂÎ²â€amyloid (1â€“42) in human cerebrospinal fluid. Alzheimer's and Dementia, 2016, 12, 517-526.	0.4	254
74	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurology, The, 2020, 19, 951-962.	4.9	254
75	Traumatic Brain Injury and Alzheimer's Disease: The Cerebrovascular Link. EBioMedicine, 2018, 28, 21-30.	2.7	250
76	The cerebrospinal fluid â€œAlzheimer profileâ€: Easily said, but what does it mean?. Alzheimer's and Dementia, 2014, 10, 713.	0.4	249
77	Prediction of Alzheimerâ€™s Disease Using the CSF AÎ²42/AÎ²40 Ratio in Patients with Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2007, 23, 316-320.	0.7	248
78	Evaluation of plasma AÎ²40 and AÎ²42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiology of Aging, 2010, 31, 357-367.	1.5	242
79	Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2016, 11, 3.	4.4	236
80	Prediction of future Alzheimerâ€™s disease dementia using plasma phospho-tau combined with other accessible measures. Nature Medicine, 2021, 27, 1034-1042.	15.2	236
81	Microglial activation and tau propagate jointly across Braak stages. Nature Medicine, 2021, 27, 1592-1599.	15.2	235
82	CSF-Biomarkers in Olympic Boxing: Diagnosis and Effects of Repetitive Head Trauma. PLoS ONE, 2012, 7, e33606.	1.1	231
83	Steroidâ€Responsive Encephalitis in Coronavirus Disease 2019. Annals of Neurology, 2020, 88, 423-427.	2.8	230
84	Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. EMBO Molecular Medicine, 2019, 11, e11170.	3.3	228
85	Bloodâ€based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimer's and Dementia, 2017, 13, 45-58.	0.4	227
86	Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. JAMA Neurology, 2018, 75, 989.	4.5	223
87	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurology, The, 2021, 20, 739-752.	4.9	220
88	Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. EMBO Molecular Medicine, 2016, 8, 1184-1196.	3.3	219
89	A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications, 2021, 12, 3400.	5.8	219
90	SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2014, 9, 53.	4.4	216

#	Article	IF	Citations
91	Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2018, 10, 71.	3.0	216
92	Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease. Archives of Neurology, 2012, 69, 1002.	4.9	215
93	Fluid biomarkers for mild traumatic brain injury and related conditions. Nature Reviews Neurology, 2016, 12, 563-574.	4.9	215
94	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
95	CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology, 2014, 83, 1945-1953.	1.5	213
96	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurology, The, 2022, 21, 246-257.	4.9	210
97	Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntingtonâ€™s disease patients. Journal of Clinical Investigation, 2015, 125, 1979-1986.	3.9	209
98	Plasma p-tau181 accurately predicts Alzheimerâ€™s disease pathology at least 8Âyears prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathologica, 2020, 140, 267-278.	3.9	209
99	CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology, 2012, 78, 1568-1575.	1.5	208
100	CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology, 2018, 91, e867-e877.	1.5	207
101	Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimerâ€™s disease. Translational Psychiatry, 2021, 11, 27.	2.4	207
102	Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid Î²-peptides in human cerebrospinal fluid. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 11848-11853.	3.3	205
103	Biomarkers for Alzheimerâ€™s diseaseâ€”preparing for a new era of disease-modifying therapies. Molecular Psychiatry, 2021, 26, 296-308.	4.1	205
104	Serum neurofilament light in familial Alzheimer disease. Neurology, 2017, 89, 2167-2175.	1.5	204
105	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. JAMA Neurology, 2021, 78, 1471.	4.5	204
106	The Role of Biomarkers in Clinical Trials for Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2006, 20, 6-15.	0.6	203
107	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimerâ€™s continuum when only subtle changes in AÎ² pathology are detected. EMBO Molecular Medicine, 2020, 12, e12921.	3.3	202
108	AÎ² deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimerâ€™s disease. Science Advances, 2020, 6, eaaz2387.	4.7	202

#	Article	IF	Citations
109	Independent information from cerebrospinal fluid amyloid-Î² and florbetapir imaging in Alzheimer's disease. Brain, 2015, 138, 772-783.	3.7	200
110	Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimerâ€™s disease. Brain, 2015, 138, 3373-3385.	3.7	200
111	Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: Results of a pilot study. Resuscitation, 2013, 84, 351-356.	1.3	199
112	Genome-wide association study identifies four novel loci associated with Alzheimerâ€™s endophenotypes and disease modifiers. Acta Neuropathologica, 2017, 133, 839-856.	3.9	199
113	Plasma GFAP is an early marker of amyloid-Î² but not tau pathology in Alzheimerâ€™s disease. Brain, 2021, 144, 3505-3516.	3.7	198
114	Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 111-126.	1.2	197
115	A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1240-1247.	0.9	196
116	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	4.9	195
117	Head-to-Head Comparison of 8 Plasma Amyloid-Î² 42/40 Assays in Alzheimer Disease. JAMA Neurology, 2021, 78, 1375.	4.5	195
118	Cerebrospinal fluid Î±-synuclein in neurodegenerative disordersâ€”A marker of synapse loss?. Neuroscience Letters, 2009, 450, 332-335.	1.0	194
119	Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid. Neurology, 2020, 95, 445-449.	1.5	194
120	Elevated Cerebrospinal Fluid BACE1 Activity in Incipient Alzheimer Disease. Archives of Neurology, 2008, 65, 1102-7.	4.9	193
121	Cerebrospinal fluid Â-amyloid 1-42 concentration may predict cognitive decline in older women. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 461-464.	0.9	189
122	Determination of Î²-Amyloid Peptide Signatures in Cerebrospinal Fluid Using Immunoprecipitation-Mass Spectrometry. Journal of Proteome Research, 2006, 5, 1010-1016.	1.8	187
123	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimerâ€™s Disease Neuroimaging Initiative. Molecular Psychiatry, 2021, 26, 429-442.	4.1	186
124	The clinical promise of biomarkers of synapse damage or loss in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 21.	3.0	183
125	CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology, 2010, 74, 1531-1537.	1.5	182
126	Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Brain Research, 2010, 1362, 13-22.	1.1	180

#	Article	IF	Citations
127	Fluid biomarkers in Alzheimerâ€™s disease â€“ current concepts. Molecular Neurodegeneration, 2013, 8, 20.	4.4	180
128	Blood-based molecular biomarkers for Alzheimerâ€™s disease. Molecular Brain, 2019, 12, 26.	1.3	180
129	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimer's and Dementia, 2016, 12, 154-163.	0.4	179
130	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics, 2014, 23, 6139-6146.	1.4	178
131	CSF biomarkers and clinical progression of Parkinson disease. Neurology, 2015, 84, 57-63.	1.5	178
132	Neurofilament Light: A Dynamic Cross-Disease Fluid Biomarker for Neurodegeneration. Neuron, 2016, 91, 1-3.	3.8	178
133	Gâ€quadruplexâ€binding small molecules ameliorate C9orf72 <scp>FTD</scp> / <scp>ALS</scp> pathology inÂvitro and inÂvivo. EMBO Molecular Medicine, 2018, 10, 22-31.	3.3	178
134	Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology, 2018, 90, e518-e524.	1.5	176
135	Obstructive Sleep Apnea Severity Affects Amyloid Burden in Cognitively Normal Elderly. A Longitudinal Study. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 933-943.	2.5	174
136	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1145-1156.	0.4	174
137	Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e76523.	1.1	173
138	Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology, 2016, 86, 829-835.	1.5	170
139	The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimerâ€™s disease risk. Science Translational Medicine, 2019, 11, .	5.8	170
140	Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neuroscience Letters, 2007, 419, 18-22.	1.0	169
141	Levels of cerebrospinal fluid Î±-synuclein oligomers are increased in Parkinsonâ€™s disease with dementia and dementia with Lewy bodies compared to Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2014, 6, 25.	3.0	169
142	Neurofilaments: neurobiological foundations for biomarker applications. Brain, 2020, 143, 1975-1998.	3.7	167
143	Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults. Neurology, 2017, 89, 445-453.	1.5	166
144	Diagnostic Performance of Cerebrospinal Fluid Total Tau and Phosphorylated Tau in Creutzfeldt-Jakob Disease. JAMA Neurology, 2014, 71, 476.	4.5	164

#	Article	IF	Citations
145	Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Annals of Clinical and Translational Neurology, 2016, 3, 216-225.	1.7	163
146	Molecular biomarkers of Alzheimer's disease: progress and prospects. DMM Disease Models and Mechanisms, 2018, 11, .	1.2	163
147	Biomarkers for tau pathology. Molecular and Cellular Neurosciences, 2019, 97, 18-33.	1.0	163
148	Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid. International Journal of Alzheimer's Disease, 2010, 2010, 1-11.	1.1	161
149	Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. JAMA Neurology, 2019, 76, 318.	4.5	161
150	Plasma and CSF neurofilament light. Neurology, 2019, 93, e252-e260.	1.5	160
151	Fluid Biomarkers in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006221-a006221.	2.9	159
152	APP Metabolism Regulates Tau Proteostasis in Human Cerebral Cortex Neurons. Cell Reports, 2015, 11, 689-696.	2.9	158
153	Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest. JAMA Neurology, 2019, 76, 64.	4.5	158
154	Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neuroscience Letters, 2003, 352, 67-69.	1.0	157
155	Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease. Molecular Systems Biology, 2020, 16, e9356.	3.2	157
156	¹⁸Fâ€AVâ€1451 and CSF Tâ€tau and Pâ€tau as biomarkers in Alzheimer's disease. EMBO Molecular Medicine, 2017, 9, 1212-1223.	3.3	156
157	Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype. Neurobiology of Aging, 2017, 51, 104-112.	1.5	154
158	Cerebrospinal fluid tau and amyloid-Î²₁₋₄₂in patients with dementia. Brain, 2015, 138, 2716-2731.	3.7	152
159	Cerebrospinal Fluid Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Combination with Subcortical and Cortical Biomarkers in Vascular Dementia and Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 27, 665-676.	1.2	150
160	Hypoxia Due to Cardiac Arrest Induces a Time-Dependent Increase in Serum Amyloid Î² Levels in Humans. PLoS ONE, 2011, 6, e28263.	1.1	149
161	Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Multiple Sclerosis Journal, 2018, 24, 1046-1054.	1.4	149
162	Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease. JAMA Neurology, 2015, 72, 1175.	4.5	148

#	Article	IF	Citations
163	Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease. JAMA Neurology, 2017, 74, 41.	4.5	147
164	Neurofilament light and tau as blood biomarkers for sports-related concussion. Neurology, 2018, 90, e1780-e1788.	1.5	147
165	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA Neurology, 2021, 78, 396.	4.5	146
166	Biological markers of amyloid Î²-related mechanisms in Alzheimer's disease. Experimental Neurology, 2010, 223, 334-346.	2.0	145
167	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nature Reviews Neurology, 2015, 11, 41-55.	4.9	144
168	Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration. Brain, 2018, 141, 459-471.	3.7	143
169	Cerebrospinal Fluid and Neuroimaging Biomarker Abnormalities Suggest Early Neurological Injury in a Subset of Individuals During Primary HIV Infection. Journal of Infectious Diseases, 2013, 207, 1703-1712.	1.9	142
170	Neurological consequences of traumatic brain injuries in sports. Molecular and Cellular Neurosciences, 2015, 66, 114-122.	1.0	141
171	Idiopathic normal-pressure hydrocephalus. Neurology, 2013, 80, 1385-1392.	1.5	140
172	Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid AÎ²42 Levels in Cognitively Normal Elderly. Sleep, 2016, 39, 2041-2048.	0.6	140
173	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	5.8	140
174	Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease. Neurology, 2013, 81, 2103-2106.	1.5	139
175	Cerebrospinal fluid neurogranin and <scp>YKL</scp> â€40 as biomarkers of Alzheimer's disease. Annals of Clinical and Translational Neurology, 2016, 3, 12-20.	1.7	137
176	A novel pathway for amyloid precursor protein processing. Neurobiology of Aging, 2011, 32, 1090-1098.	1.5	136
177	<scp>L</scp>ongitudinal <scp>M</scp>easurements of <scp>C</scp>erebrospinal <scp>F</scp>luid <scp>B</scp>iomarkers in <scp>P</scp>arkinson's <scp>D</scp>isease. Movement Disorders, 2016, 31, 898-905.	2.2	136
178	Modified ketogenic diet is associated with improved cerebrospinal fluid biomarker profile, cerebral perfusion, and cerebral ketone body uptake in older adults at risk for Alzheimerâ€™s disease: a pilot study. Neurobiology of Aging, 2020, 86, 54-63.	1.5	136
179	Time course and diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI. Neurology, 2020, 95, e623-e636.	1.5	136
180	Characterization of Amyloid Î² Peptides in Cerebrospinal Fluid by an Automated Immunoprecipitation Procedure Followed by Mass Spectrometry. Journal of Proteome Research, 2007, 6, 4433-4439.	1.8	135

#	Article	IF	Citations
181	CSF AÎ² ₄₂ predicts early-onset dementia in Parkinson disease. Neurology, 2014, 82, 1784-1790.	1.5	135
182	Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntingtonâ€™s disease. Science Translational Medicine, 2018, 10, .	5.8	134
183	Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's and Dementia, 2019, 15, 776-787.	0.4	134
184	Monitoring of 30 marker candidates in early Parkinson disease as progression markers. Neurology, 2016, 87, 168-177.	1.5	133
185	Association of Cerebral Amyloid-Î² Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
186	Mass Spectrometryâ€“Based Candidate Reference Measurement Procedure for Quantification of Amyloid-Î² in Cerebrospinal Fluid. Clinical Chemistry, 2014, 60, 987-994.	1.5	132
187	Novel Panel of Cerebrospinal Fluid Biomarkers for the Prediction of Progression to Alzheimer Dementia in Patients With Mild Cognitive Impairment. Archives of Neurology, 2007, 64, 366.	4.9	131
188	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses. Clinical Infectious Diseases, 2021, 73, e3019-e3026.	2.9	131
189	Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos. European Journal of Human Genetics, 2002, 10, 113-118.	1.4	130
190	A Serum Protein Biomarker Panel Improves Outcome Prediction in Human Traumatic Brain Injury. Journal of Neurotrauma, 2019, 36, 2850-2862.	1.7	129
191	Biomarker Evidence of Axonal Injury in Neuroasymptomatic HIV-1 Patients. PLoS ONE, 2014, 9, e88591.	1.1	128
192	Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimerâ€™s disease. Acta Neuropathologica, 2019, 137, 279-296.	3.9	128
193	Monitoring of brain interstitial total tau and beta amyloid proteins by microdialysis in patients with traumatic brain injury. Journal of Neurosurgery, 2009, 110, 1227-1237.	0.9	127
194	Olympic boxing is associated with elevated levels of the neuronal protein tau in plasma. Brain Injury, 2013, 27, 425-433.	0.6	127
195	Neurofilament light as a biomarker in traumatic brain injury. Neurology, 2020, 95, e610-e622.	1.5	127
196	Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurology, 2009, 9, 63.	0.8	126
197	Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 550-561.	1.4	126
198	Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-Î² changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathologica, 2013, 126, 631-641.	3.9	125

#	Article	IF	Citations
199	Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathologica Communications, 2019, 7, 5.	2.4	125
200	Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Annals of Neurology, 2008, 63, 621-631.	2.8	124
201	Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsingâ€remitting multiple sclerosis. Journal of Neurochemistry, 2017, 141, 296-304.	2.1	124
202	Time course of phosphorylated-tau181 in blood across the Alzheimerâ€™s disease spectrum. Brain, 2021, 144, 325-339.	3.7	124
203	Untangling the association of amyloid-Î² and tau with synaptic and axonal loss in Alzheimerâ€™s disease. Brain, 2021, 144, 310-324.	3.7	123
204	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 18, 413-417.	1.2	122
205	Plasma amyloid Î² 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 764-775.	0.4	122
206	Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis. Lancet Neurology, The, 2020, 19, 502-512.	4.9	122
207	Lower CSF Amyloid Beta Peptides and Higher F2-Isoprostanes in Cognitively Intact Elderly Individuals With Major Depressive Disorder. American Journal of Psychiatry, 2012, 169, 523-530.	4.0	121
208	Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Molecular Neurodegeneration, 2015, 10, 64.	4.4	121
209	The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2016, 8, 41.	3.0	121
210	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nature Reviews Neurology, 2020, 16, 265-284.	4.9	121
211	Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum. Alzheimer's and Dementia, 2020, 16, 1358-1371.	0.4	120
212	Rapid Progression from Mild Cognitive Impairment to Alzheimerâ€™s Disease in Subjects with Elevated Levels of Tau in Cerebrospinal Fluid and the <i>APOE </i>Îµ<i>4</i>/Îµ<i>4</i> Genotype. Dementia and Geriatric Cognitive Disorders, 2009, 27, 458-464.	0.7	119
213	Biomarkers in dementia: clinical utility and new directions. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1426-1434.	0.9	119
214	Evaluating Amyloid-Î² Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e66381.	1.1	119
215	Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. European Journal of Neurology, 2007, 14, 1329-1333.	1.7	118
216	Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e271.	3.1	118

#	Article	IF	Citations
217	Human Induced Pluripotent Stem Cell-Derived Microglia-Like Cells Harboring TREM2 Missense Mutations Show Specific Deficits in Phagocytosis. Cell Reports, 2018, 24, 2300-2311.	2.9	118
218	CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms. Neurology, 2021, 96, e294-e300.	1.5	118
219	Intra-Individual Stability of CSF Biomarkers for Alzheimer's Disease over Two Years. Journal of Alzheimer's Disease, 2007, 12, 255-260.	1.2	117
220	Câ€terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1461-1469.	0.4	117
221	Review: Tau in biofluids â€“ relation to pathology, imaging and clinical features. Neuropathology and Applied Neurobiology, 2017, 43, 194-199.	1.8	117
222	Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimer's Research and Therapy, 2021, 13, 68.	3.0	117
223	An Alzheimer's disease-specific Î²-amyloid fragment signature in cerebrospinal fluid. Neuroscience Letters, 2006, 409, 215-219.	1.0	114
224	Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Review of Molecular Diagnostics, 2017, 17, 761-770.	1.5	114
225	Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathologica, 2018, 136, 363-376.	3.9	114
226	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. JAMA Neurology, 2021, 78, 1108.	4.5	114
227	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's and Dementia, 2017, 13, 274-284.	0.4	113
228	A common challenge in older adults: Classification, overlap, and therapy of depression and dementia. Alzheimer's and Dementia, 2017, 13, 59-71.	0.4	112
229	Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia. BMC Neurology, 2013, 13, 54.	0.8	111
230	A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Alzheimer's Research and Therapy, 2018, 10, 8.	3.0	111
231	Early predictors of mortality in parkinsonism and Parkinson disease. Neurology, 2018, 91, e2045-e2056.	1.5	111
232	Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years. Journal of Alzheimer's Disease, 2010, 21, 1119-1128.	1.2	110
233	Serum Neurofilament Light in American Football Athletes over the Course of a Season. Journal of Neurotrauma, 2016, 33, 1784-1789.	1.7	110
234	Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. International Journal of Geriatric Psychiatry, 2010, 25, 403-410.	1.3	109

#	Article	IF	Citations
235	The interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals. Neurobiology of Aging, 2014, 35, 1318-1324.	1.5	109
236	Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2015, 7, 74.	3.0	109
237	Alzheimerâ€™s disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715.	3.7	109
238	Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology, 2015, 85, 1834-1842.	1.5	109
239	Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVIDâ€19 and associated with neurological symptoms and disease severity. European Journal of Neurology, 2021, 28, 3324-3331.	1.7	109
240	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's and Dementia, 2017, 13, 285-295.	0.4	108
241	Pittsburgh compound B imaging and cerebrospinal fluid amyloid-Î² in a multicentre European memory clinic study. Brain, 2016, 139, 2540-2553.	3.7	107
242	The Cerebrospinal Fluid in Multiple Sclerosis. Frontiers in Immunology, 2019, 10, 726.	2.2	107
243	Postoperative delirium is associated with increased plasma neurofilament light. Brain, 2020, 143, 47-54.	3.7	107
244	Microglial Markers are Elevated in the Prodromal Phase of Alzheimer's Disease and Vascular Dementia. Journal of Alzheimer's Disease, 2012, 33, 45-53.	1.2	106
245	The Past and the Future of Alzheimerâ€™s Disease Fluid Biomarkers. Journal of Alzheimer's Disease, 2018, 62, 1125-1140.	1.2	106
246	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 263-270.	0.9	106
247	Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. EBioMedicine, 2021, 70, 103512.	2.7	106
248	Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimer's and Dementia, 2013, 9, 137-140.	0.4	105
249	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020. Biochemical Pharmacology, 2014, 88, 426-449.	2.0	105
250	Amyloid Î² and APP as biomarkers for Alzheimerâ€™s disease. Experimental Gerontology, 2010, 45, 23-29.	1.2	104
251	Cerebrospinal Fluid Microglial Markers in Alzheimerâ€™s Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility. NeuroMolecular Medicine, 2011, 13, 151-159.	1.8	104
252	Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimerâ€™s disease patients and healthy controls. Alzheimer's Research and Therapy, 2015, 7, 40.	3.0	104

#	Article	IF	Citations
253	CSF AÎ²1â€“42 â€“ an excellent but complicated Alzheimer's biomarker â€“ a route to standardisation. Clinica Chimica Acta, 2017, 467, 27-33.	0.5	104
254	Serum Neurofilament Light Protein as a Marker for Diffuse Axonal Injury: Results from a Case Series Study. Journal of Neurotrauma, 2017, 34, 1124-1127.	1.7	104
255	Microstructural white matter alterations in preclinical Alzheimerâ€™s disease detected using free water elimination diffusion tensor imaging. PLoS ONE, 2017, 12, e0173982.	1.1	104
256	Cerebrospinal fluid concentrations of inflammatory markers in Parkinsonâ€™s disease and atypical parkinsonian disorders. Scientific Reports, 2018, 8, 13276.	1.6	104
257	NFL is a marker of treatment response in children with SMA treated with nusinersen. Journal of Neurology, 2019, 266, 2129-2136.	1.8	104
258	Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. Movement Disorders, 2020, 35, 1999-2008.	2.2	104
259	Soluble TNF receptors are associated with AÎ² metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiology of Aging, 2010, 31, 1877-1884.	1.5	101
260	Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 43-50.	1.4	101
261	Cerebrospinal Fluid Markers of Alzheimerâ€™s Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 50, 873-886.	1.2	101
262	Moving fluid biomarkers for Alzheimerâ€™s disease from research tools to routine clinical diagnostics. Molecular Neurodegeneration, 2021, 16, 10.	4.4	101
263	Cerebrospinal fluid biomarkers of white matter lesions â€“ crossâ€sectional results from the LADIS study. European Journal of Neurology, 2010, 17, 377-382.	1.7	100
264	A Selected Reaction Monitoring (SRM)-Based Method for Absolute Quantification of AÎ²38, AÎ²40, and AÎ²42 in Cerebrospinal Fluid of Alzheimer's Disease Patients and Healthy Controls. Journal of Alzheimer's Disease, 2013, 33, 1021-1032.	1.2	100
265	Plasma Amyloid-Î² (AÎ²42) Correlates with Cerebrospinal Fluid AÎ²42 in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 62, 1857-1863.	1.2	100
266	Correlation of Longitudinal Cerebrospinal Fluid Biomarkers With Cognitive Decline in Healthy Older Adults. Archives of Neurology, 2010, 67, 217-23.	4.9	99
267	Low Incidence of Post-Lumbar Puncture Headache in 1,089 Consecutive Memory Clinic Patients. European Neurology, 2010, 63, 326-330.	0.6	99
268	Identification of Novel Î±-Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method. Neurochemical Research, 2011, 36, 2029-2042.	1.6	99
269	Metabolite and Peptide Levels in Plasma and CSF Differentiating Healthy Controls from Patients with Newly Diagnosed Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 549-560.	1.5	99
270	Serum SNTF Increases in Concussed Professional Ice Hockey Players and Relates to the Severity of Postconcussion Symptoms. Journal of Neurotrauma, 2015, 32, 1294-1300.	1.7	99

#	Article	IF	Citations
271	Single-Molecule Imaging of Individual Amyloid Protein Aggregates in Human Biofluids. ACS Chemical Neuroscience, 2016, 7, 399-406.	1.7	99
272	Familial Alzheimerâ€™s disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. Molecular Psychiatry, 2020, 25, 2919-2931.	4.1	99
273	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nature Reviews Neurology, 2022, 18, 400-418.	4.9	99
274	Low Circulating Acute Brain-Derived Neurotrophic Factor Levels Are Associated With Poor Long-Term Functional Outcome After Ischemic Stroke. Stroke, 2016, 47, 1943-1945.	1.0	98
275	Young CSF restores oligodendrogenesis and memory in aged mice via Fgf17. Nature, 2022, 605, 509-515.	13.7	98
276	Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction. PLoS ONE, 2015, 10, e0135886.	1.1	97
277	Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsingâ€“remitting multiple sclerosis. European Journal of Neurology, 2017, 24, 703-712.	1.7	97
278	Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. JAMA Neurology, 2017, 74, 1492.	4.5	97
279	Elevated CSF GAPâ€43 is Alzheimer's disease specific and associated with tau and amyloid pathology. Alzheimer's and Dementia, 2019, 15, 55-64.	0.4	97
280	Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study. Lancet Neurology, The, 2020, 19, 513-521.	4.9	97
281	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
282	Increased cerebrospinal fluid levels of transforming growth factor-Î²1 in Alzheimerâ€™s disease. Neuroscience Letters, 2004, 367, 194-196.	1.0	96
283	Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Annals of Clinical and Translational Neurology, 2014, 1, 534-543.	1.7	96
284	Neurochemical Aftermath of Repetitive Mild Traumatic Brain Injury. JAMA Neurology, 2016, 73, 1308.	4.5	96
285	Association of Changes in Plasma Neurofilament Light and Tau Levels With Anesthesia and Surgery. JAMA Neurology, 2018, 75, 542.	4.5	96
286	Trisomy of human chromosome 21 enhances amyloid-Î² deposition independently of an extra copy ofAPP. Brain, 2018, 141, 2457-2474.	3.7	96
287	Cerebrospinal fluid tau, AÎ², and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration. Alzheimer's and Dementia, 2018, 14, 1159-1170.	0.4	96
288	AÎ²40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease. PLoS ONE, 2010, 5, e15725.	1.1	96

#	Article	IF	Citations
289	Cerebrospinal Fluid (CSF) Neuronal Biomarkers across the Spectrum of HIV Infection: Hierarchy of Injury and Detection. PLoS ONE, 2014, 9, e116081.	1.1	95
290	Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis. Journal of Neuroinflammation, 2018, 15, 209.	3.1	94
291	Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2018, 10, 5.	3.0	94
292	Learnings about the complexity of extracellular tau aid development of a bloodâ€based screen for Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 487-496.	0.4	94
293	Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. JAMA Neurology, 2020, 77, 377.	4.5	94
294	Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nature Aging, 2021, 1, 114-123.	5.3	94
295	Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study. Clinical Neurophysiology, 2021, 132, 1733-1740.	0.7	94
296	Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment. PLoS ONE, 2016, 11, e0157160.	1.1	93
297	Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid-Î² Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 473-484.	1.2	93
298	Diagnostic and prognostic value of serum NfL and p-Tau₁₈₁in frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 960-967.	0.9	93
299	Cerebrospinal Fluid Biomarker and Brain Biopsy Findings in Idiopathic Normal Pressure Hydrocephalus. PLoS ONE, 2014, 9, e91974.	1.1	91
300	Alzheimer's disease biomarkerâ€guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ_{1â€“42}, totalâ€tau, phosphorylatedâ€tau, NFL, neurogranin, and YKLâ€40. Alzheimer's and Dementia, 2018, 14, 492-501.	0.4	91
301	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. Alzheimer's and Dementia, 2019, 15, 644-654.	0.4	90
302	Neurofilament light as an outcome predictor after cardiac arrest: a post hoc analysis of the COMACARE trial. Intensive Care Medicine, 2021, 47, 39-48.	3.9	90
303	Lysosomal Network Proteins as Potential Novel CSF Biomarkers for Alzheimerâ€™s Disease. NeuroMolecular Medicine, 2014, 16, 150-160.	1.8	89
304	The Gothenburg H70 Birth cohort study 2014â€“16: design, methods and study population. European Journal of Epidemiology, 2019, 34, 191-209.	2.5	89
305	Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 1141-1154.	0.4	89
306	Pathophysiological subtypes of Alzheimerâ€™s disease based on cerebrospinal fluid proteomics. Brain, 2020, 143, 3776-3792.	3.7	89

#	Article	IF	Citations
307	Plasma biomarkers for Alzheimerâ€™s Disease in relation to neuropathology and cognitive change. Acta Neuropathologica, 2022, 143, 487-503.	3.9	89
308	S-100B is superior to NSE, BDNF and GFAP in predicting outcome of resuscitation from cardiac arrest with hypothermia treatment. Resuscitation, 2011, 82, 26-31.	1.3	87
309	Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. Journal of Neurology, 2013, 260, 620-626.	1.8	87
310	The immune response of the human brain to abdominal surgery. Annals of Neurology, 2017, 81, 572-582.	2.8	87
311	A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease. Proteomics - Clinical Applications, 2018, 12, 1700131.	0.8	87
312	Sex-specific genetic predictors of Alzheimerâ€™s disease biomarkers. Acta Neuropathologica, 2018, 136, 857-872.	3.9	87
313	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. Alzheimer's and Dementia, 2018, 14, 1313-1333.	0.4	87
314	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimerâ€™s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	3.9	87
315	Blood-based biomarkers for Alzheimerâ€™s diseaseâ€”An update. Journal of Neuroscience Methods, 2019, 319, 2-6.	1.3	87
316	Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimer's Research and Therapy, 2021, 13, 198.	3.0	87
317	Serum tau and neurological outcome in cardiac arrest. Annals of Neurology, 2017, 82, 665-675.	2.8	86
318	Plasma tau complements CSF tau and Pâ€tau in the diagnosis of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 483-492.	1.2	86
319	Clinical proteomics in neurodegenerative disorders. Acta Neurologica Scandinavica, 2008, 118, 1-11.	1.0	85
320	A novel AÎ² isoform pattern in CSF reflects Î³-secretase inhibition in Alzheimer disease. Alzheimer's Research and Therapy, 2010, 2, 7.	3.0	85
321	Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease. JAMA Psychiatry, 2014, 71, 1183.	6.0	85
322	CSF T-Tau/AÎ²42 Predicts White Matter Microstructure in Healthy Adults at Risk for Alzheimerâ€™s Disease. PLoS ONE, 2012, 7, e37720.	1.1	84
323	An Integrated Workflow for Multiplex CSF Proteomics and Peptidomicsâ€”Identification of Candidate Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Disease. Journal of Proteome Research, 2015, 14, 654-663.	1.8	84
324	Novel Trimodal MALDI Imaging Mass Spectrometry (IMS3) at 10 Î¼m Reveals Spatial Lipid and Peptide Correlates Implicated in AÎ² Plaque Pathology in Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2017, 8, 2778-2790.	1.7	84

#	Article	IF	Citations
325	CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. Neurobiology of Aging, 2017, 59, 1-9.	1.5	84
326	Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. Neurology, 2021, 96, e671-e683.	1.5	84
327	Characterization of preâ€analytical sample handling effects on a panel of Alzheimer's diseaseâ€“related bloodâ€based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. Alzheimer's and Dementia, 2022, 18, 1484-1497.	0.4	84
328	Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1065-1075.	0.9	83
329	Comparing ¹⁸ F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. Neurology, 2018, 90, e388-e395.	1.5	83
330	The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2140-2156.	3.3	83
331	Biomarker-based dissection of neurodegenerative diseases. Progress in Neurobiology, 2011, 95, 520-534.	2.8	82
332	Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2014, 4, 297-304.	0.6	82
333	Neuronal and Glia-Related Biomarkers in Cerebrospinal Fluid of Patients with Acute Ischemic Stroke. Journal of Central Nervous System Disease, 2014, 6, JCNSD.S13821.	0.7	82
334	Prevalence of preclinical Alzheimer disease. Neurology, 2018, 90, e1682-e1691.	1.5	82
335	Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimer's Research and Therapy, 2019, 11, 27.	3.0	82
336	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimer's and Dementia, 2019, 15, 742-753.	0.4	82
337	Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. Molecular and Cellular Neurosciences, 2019, 97, 3-17.	1.0	82
338	Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Scientific Reports, 2016, 6, 38737.	1.6	81
339	Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 62-71.	1.4	81
340	Human iPS-Derived Astroglia from a Stable Neural Precursor State Show Improved Functionality Compared with Conventional Astrocytic Models. Stem Cell Reports, 2018, 10, 1030-1045.	2.3	81
341	Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimerâ€™s Disease Pathology and Neuronal Damage. Journal of Alzheimer's Disease, 2018, 62, 385-397.	1.2	81
342	Barrier Properties and Transcriptome Expression in Human iPSC-Derived Models of the Bloodâ€“Brain Barrier. Stem Cells, 2018, 36, 1816-1827.	1.4	81

#	Article	IF	Citations
343	Headâ€toâ€head comparison of clinical performance of CSF phosphoâ€tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. Alzheimer's and Dementia, 2021, 17, 755-767.	0.4	81
344	Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical parkinsonian disorders. Parkinsonism and Related Disorders, 2010, 16, 142-145.	1.1	80
345	Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid-Î² and tau. Neurobiology of Aging, 2019, 80, 11-20.	1.5	80
346	An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum. Alzheimer's and Dementia, 2021, 17, 431-445.	0.4	80
347	Distinct cerebrospinal fluid amyloid Î² peptide signatures in sporadic and PSEN1A431E-associated familial Alzheimer's disease. Molecular Neurodegeneration, 2010, 5, 2.	4.4	79
348	The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimer's and Dementia, 2015, 11, 772-791.	0.4	79
349	Cerebrospinal fluid in the differential diagnosis of Alzheimerâ€™s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alzheimer's Research and Therapy, 2018, 10, 32.	3.0	79
350	Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease. PLoS ONE, 2009, 4, e6294.	1.1	79
351	Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. Clinical Chemistry and Laboratory Medicine, 2010, 48, 603-607.	1.4	78
352	An online nanoâ€LCâ€ESIâ€FTICRâ€MS method for comprehensive characterization of endogenous fragments from amyloid Î² and amyloid precursor protein in human and cat cerebrospinal fluid. Journal of Mass Spectrometry, 2012, 47, 591-603.	0.7	78
353	A highly sensitive novel immunoassay specifically detects low levels of soluble AÎ² oligomers in human cerebrospinal fluid. Alzheimer's Research and Therapy, 2015, 7, 14.	3.0	78
354	Reference measurement procedure for <scp>CSF</scp> amyloid beta (AÎ²)_{1â€“42} and the <scp>CSF</scp> AÎ²_{1â€“42}/AÎ²_{1â€“40} ratio â€“ a crossâ€validation study against amyloid <scp>PET</scp>. Journal of Neurochemistry, 2016, 139, 651-658.	2.1	78
355	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiology of Aging, 2016, 38, 214.e7-214.e10.	1.5	78
356	Amyloid-Î²42 is Associated with Cognitive Impairment in Healthy Elderly and Subjective Cognitive Impairment. Journal of Alzheimer's Disease, 2011, 26, 135-142.	1.2	77
357	Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 455-463.	1.2	77
358	Longitudinal Cerebrospinal Fluid Biomarkers over Four Years in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2012, 30, 767-778.	1.2	76
359	Reference measurement procedures for Alzheimerâ€™s disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid Î²42. Biomarkers in Medicine, 2012, 6, 409-417.	0.6	76
360	Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers. Neurology, 2017, 89, 1782-1788.	1.5	76

#	Article	IF	Citations
361	Increased midlife triglycerides predict brain Î²-amyloid and tau pathology 20 years later. Neurology, 2018, 90, e73-e81.	1.5	76
362	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimerâ€™s disease: a longitudinal cohort study. Molecular Psychiatry, 2021, 26, 5967-5976.	4.1	76
363	Restoring miR-132 expression rescues adult hippocampal neurogenesis and memory deficits in Alzheimerâ€™s disease. Cell Stem Cell, 2021, 28, 1805-1821.e8.	5.2	76
364	Higher CSF interleukin-6 and CSF interleukin-8 in current depression in older women. Results from a population-based sample. Brain, Behavior, and Immunity, 2014, 41, 55-58.	2.0	75
365	Biomarkers in Sporadic and Familial Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 47, 291-317.	1.2	75
366	Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. Journal of Psychiatry and Neuroscience, 2015, 40, 250-258.	1.4	75
367	Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease. JAMA Neurology, 2015, 72, 699.	4.5	75
368	Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimerâ€™s disease pathogenesis. Cellular and Molecular Life Sciences, 2019, 76, 1833-1863.	2.4	75
369	Association between plasma tau and postoperative delirium incidence and severity: a prospective observational study. British Journal of Anaesthesia, 2021, 126, 458-466.	1.5	75
370	Characterization of Tau in Cerebrospinal Fluid Using Mass Spectrometry. Journal of Proteome Research, 2008, 7, 2114-2120.	1.8	74
371	Altered Concentrations of Amyloid Precursor Protein Metabolites in the Cerebrospinal Fluid of Patients with Bipolar Disorder. Neuropsychopharmacology, 2013, 38, 664-672.	2.8	74
372	Identification of neurotoxic cross-linked amyloid-Î² dimers in the Alzheimerâ€™s brain. Brain, 2019, 142, 1441-1457.	3.7	74
373	Fluid Biomarkers for Synaptic Dysfunction and Loss. Biomarker Insights, 2020, 15, 117727192095031.	1.0	74
374	Axonal marker neurofilament light predicts long-term outcomes and progressive neurodegeneration after traumatic brain injury. Science Translational Medicine, 2021, 13, eabg9922.	5.8	74
375	Aspects of Î²-amyloid as a biomarker for Alzheimerâ€™s disease. Biomarkers in Medicine, 2007, 1, 59-78.	0.6	73
376	Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases. Frontiers in Aging Neuroscience, 2011, 3, 1.	1.7	73
377	Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimerâ€™s Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study. PLoS ONE, 2012, 7, e38639.	1.1	73
378	Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. Multiple Sclerosis Journal, 2016, 22, 1587-1595.	1.4	73

#	Article	IF	Citations
379	Sleep deprivation and cerebrospinal fluid biomarkers for Alzheimerâ€™s disease. Sleep, 2018, 41, .	0.6	73
380	NfL as a biomarker for neurodegeneration and survival in Parkinson disease. Neurology, 2020, 95, e827-e838.	1.5	73
381	Biomarker modeling of Alzheimerâ€™s disease using PET-based Braak staging. Nature Aging, 2022, 2, 526-535.	5.3	73
382	Tau oligomers in cerebrospinal fluid in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2017, 4, 226-235.	1.7	72
383	CSF evidence of pericyte damage in Alzheimerâ€™s disease is associated with markers of blood-brain barrier dysfunction and disease pathology. Alzheimer's Research and Therapy, 2019, 11, 81.	3.0	72
384	Exercise as a potential modulator of inflammation in patients with Alzheimer's disease measured in cerebrospinal fluid and plasma. Experimental Gerontology, 2019, 121, 91-98.	1.2	72
385	Proteomic blood profiling in mild, severe and critical COVID-19 patients. Scientific Reports, 2021, 11, 6357.	1.6	72
386	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma AÎ²42/AÎ²40 and pâ€tau. Alzheimer's and Dementia, 2022, 18, 283-293.	0.4	72
387	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. Lancet Neurology, The, 2022, 21, 329-341.	4.9	72
388	Pyroglutamate Amyloid Î² (AÎ²) Aggravates Behavioral Deficits in Transgenic Amyloid Mouse Model for Alzheimer Disease. Journal of Biological Chemistry, 2012, 287, 8154-8162.	1.6	71
389	Serum Tau Fragments Predict Return to Play in Concussed Professional Ice Hockey Players. Journal of Neurotrauma, 2016, 33, 1995-1999.	1.7	71
390	Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathologyâ€based cohort. European Journal of Neurology, 2017, 24, 1326.	1.7	71
391	Cerebrospinal Fluid Profiles of Amyloid Î²-Related Biomarkers in Alzheimerâ€™s Disease. NeuroMolecular Medicine, 2012, 14, 65-73.	1.8	70
392	A 9-Year Prospective Population-Based Study on the Association Between the APOE*E4 Allele and Late-Life Depression in Sweden. Biological Psychiatry, 2015, 78, 730-736.	0.7	70
393	Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia. Movement Disorders, 2016, 31, 1203-1208.	2.2	70
394	Plasma concentrations of free amyloid Î² cannot predict the development of Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 778-782.	0.4	70
395	Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke. BMC Neurology, 2017, 17, 170.	0.8	70
396	A metaboliteâ€based machine learning approach to diagnose Alzheimerâ€type dementia in blood: Results from the European Medicalâ€‰Information Framework for Alzheimer disease biomarker discovery cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 933-938.	1.8	70

#	Article	IF	Citations
397	Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Neurobiology of Aging, 2009, 30, 165-173.	1.5	69
398	Abnormality in glutamineâ€“glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder: a 3-year follow-up study. Translational Psychiatry, 2016, 6, e744-e744.	2.4	69
399	Markers of neuroinflammation and neuronal injury in bipolar disorder: Relation to prospective clinical outcomes. Brain, Behavior, and Immunity, 2017, 65, 195-201.	2.0	69
400	Measuring longitudinal cognition: Individual tests versus composites. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 74-84.	1.2	69
401	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Diagnostic Performance in a Homogeneous Mono-Center Population. Journal of Alzheimer's Disease, 2011, 24, 537-546.	1.2	68
402	Elevated Concentrations of Neurofilament Light Chain in the Cerebrospinal Fluid of Bipolar Disorder Patients. Neuropsychopharmacology, 2014, 39, 2349-2356.	2.8	68
403	CSF Î±-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders. Parkinsonism and Related Disorders, 2014, 20, 382-387.	1.1	68
404	Bidirectional links between Alzheimer's disease and Niemannâ€“Pick type C disease. Neurobiology of Disease, 2014, 72, 37-47.	2.1	68
405	Understanding Biomarkers of Neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding. Nature Medicine, 2015, 21, 217-219.	15.2	68
406	Effect of Docosahexaenoic Acid on a Biomarker of Head Trauma in American Football. Medicine and Science in Sports and Exercise, 2016, 48, 974-982.	0.2	68
407	Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 955-961.	0.9	68
408	Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. Brain, 2020, 143, 650-660.	3.7	68
409	BACE1 Inhibition Induces a Specific Cerebrospinal Fluid Î²-Amyloid Pattern That Identifies Drug Effects in the Central Nervous System. PLoS ONE, 2012, 7, e31084.	1.1	68
410	Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimerâ€™s disease. Journal of Neural Transmission, 2012, 119, 789-797.	1.4	67
411	First effects of rising amyloid-Î² in transgenic mouse brain: synaptic transmission and gene expression. Brain, 2015, 138, 1992-2004.	3.7	67
412	The Gothenburg MCI study: Design and distribution of Alzheimerâ€™s disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 114-131.	2.4	67
413	PET Tau and Amyloid-Î² Burden in Mild Alzheimerâ€™s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2017, 60, 283-293.	1.2	67
414	Longitudinal Trajectories of Brain Volume and Cortical Thickness in Treated and Untreated Primary Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 2018, 67, 1697-1704.	2.9	67

#	Article	IF	Citations
415	An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead. Current Opinion in Neurobiology, 2020, 61, 29-39.	2.0	67
416	Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. Nature Communications, 2020, 11, 619.	5.8	67
417	Novel AβIsoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment. Current Pharmaceutical Design, 2011, 17, 2594-2602.	0.9	66
418	Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. Psychoneuroendocrinology, 2013, 38, 1729-1737.	1.3	66
419	The Role of Clusterin in Amyloid-Î²â€“Associated Neurodegeneration. JAMA Neurology, 2014, 71, 180.	4.5	66
420	Biomarkers in Amyloid-Î² Immunotherapy Trials in Alzheimerâ€™s Disease. Neuropsychopharmacology, 2014, 39, 189-201.	2.8	66
421	The past and the future of Alzheimer's disease CSF biomarkersâ€”a journey toward validated biochemical tests covering the whole spectrum of molecular events. Frontiers in Neuroscience, 2015, 9, 345.	1.4	66
422	Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability. Clinica Chimica Acta, 2015, 449, 9-15.	0.5	66
423	Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease. Neurology, 2016, 86, 1754-1761.	1.5	66
424	Delineating Amyloid Plaque Associated Neuronal Sphingolipids in Transgenic Alzheimerâ€™s Disease Mice (tgArcSwe) Using MALDI Imaging Mass Spectrometry. ACS Chemical Neuroscience, 2017, 8, 347-355.	1.7	66
425	From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 64, S271-S279.	1.2	66
426	Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. JAMA Neurology, 2019, 76, 187.	4.5	66
427	Insulin Resistance is Associated with Higher Cerebrospinal Fluid Tau Levels in Asymptomatic APOE É›4 Carriers. Journal of Alzheimer's Disease, 2015, 46, 525-533.	1.2	65
428	Amyloid precursor protein expression and processing are differentially regulated during cortical neuron differentiation. Scientific Reports, 2016, 6, 29200.	1.6	65
429	Neurofilament light protein in blood predicts regional atrophy in Huntington disease. Neurology, 2018, 90, e717-e723.	1.5	65
430	Sex differences in the genetic predictors of Alzheimerâ€™s pathology. Brain, 2019, 142, 2581-2589.	3.7	65
431	Association of Blood and Cerebrospinal Fluid Tau Level and Other Biomarkers With Survival Time in Sporadic Creutzfeldt-Jakob Disease. JAMA Neurology, 2019, 76, 969.	4.5	65
432	Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 19.	3.0	65

#	Article	IF	Citations
433	Determining Amyloid-Î² Positivity Using ¹⁸F-AZD4694 PET Imaging. Journal of Nuclear Medicine, 2021, 62, 247-252.	2.8	65
434	Largeâ€scale plasma proteomic profiling identifies a highâ€performance biomarker panel for Alzheimer's disease screening and staging. Alzheimer's and Dementia, 2022, 18, 88-102.	0.4	65
435	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. EBioMedicine, 2022, 76, 103836.	2.7	65
436	Identification of Novel APP/AÎ² Isoforms in Human Cerebrospinal Fluid. Neurodegenerative Diseases, 2009, 6, 87-94.	0.8	64
437	Development and assessment of sensitive immunoâ€<scp>PCR</scp> assays for the quantification of cerebrospinal fluid threeâ€and fourâ€repeat tau isoforms in tauopathies. Journal of Neurochemistry, 2012, 123, 396-405.	2.1	64
438	CSF AÎ²1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. , 2014, 10, 381-392.		64
439	CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease. Proteomics - Clinical Applications, 2016, 10, 1242-1253.	0.8	64
440	YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. Journal of Neuroimmunology, 2016, 292, 52-57.	1.1	64
441	Study protocol: Insight 46 â€“ a neuroscience sub-study of the MRC National Survey of Health and Development. BMC Neurology, 2017, 17, 75.	0.8	64
442	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimer's Research and Therapy, 2018, 10, 100.	3.0	64
443	Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimerâ€™s disease progression. Acta Neuropathologica Communications, 2019, 7, 120.	2.4	64
444	The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy â€“ A prospective, pilot observational study. PLoS ONE, 2019, 14, e0211184.	1.1	64
445	The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimerâ€™s disease. Acta Neuropathologica, 2019, 137, 89-102.	3.9	64
446	Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntingtonâ€™s disease. Science Translational Medicine, 2020, 12, .	5.8	64
447	Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimerâ€™s disease, frontotemporal dementia and progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 651-658.	0.9	64
448	Impaired Lipoprotein Receptor-Mediated Peripheral Binding of Plasma Amyloid-Î² is an Early Biomarker for Mild Cognitive Impairment Preceding Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 25-34.	1.2	63
449	Alzheimer's disease in Down syndrome: An overlooked population for prevention trials. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 703-713.	1.8	63
450	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. Molecular Psychiatry, 2021, 26, 5766-5788.	4.1	63

#	Article	IF	Citations
451	Effect of Race on Prediction of Brain Amyloidosis by Plasma AÎ²42/AÎ²40, Phosphorylated Tau, and Neurofilament Light. Neurology, 2022, 99, .	1.5	63
452	The amyloid-Î² degradation pattern in plasmaâ€"A possible tool for clinical trials in Alzheimer's disease. Neuroscience Letters, 2014, 573, 7-12.	1.0	62
453	Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 98-102.	1.2	62
454	Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1000-1004.	0.9	62
455	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Alzheimer's Research and Therapy, 2018, 10, 64.	3.0	62
456	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. Alzheimer's and Dementia, 2019, 15, 817-827.	0.4	62
457	Fluid biomarkers in frontotemporal dementia: past, present and future. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 204-215.	0.9	62
458	Acute Effect on the AÎ² Isoform Pattern in CSF in Response to Î³-Secretase Modulator and Inhibitor Treatment in Dogs. Journal of Alzheimer's Disease, 2010, 21, 1005-1012.	1.2	61
459	Alzheimer's disease markers, hypertension, and gray matter damage in normal elderly. Neurobiology of Aging, 2012, 33, 1215-1227.	1.5	61
460	Highly potent soluble amyloid-Î² seeds in human Alzheimer brain but not cerebrospinal fluid. Brain, 2014, 137, 2909-2915.	3.7	61
461	Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimer's and Dementia, 2018, 14, 751-763.	0.4	61
462	CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1117-1123.	0.9	61
463	Sleep oscillation-specific associations with Alzheimerâ€™s disease CSF biomarkers: novel roles for sleep spindles and tau. Molecular Neurodegeneration, 2019, 14, 10.	4.4	61
464	HSV1 VP1-2 deubiquitinates STING to block type I interferon expression and promote brain infection. Journal of Experimental Medicine, 2020, 217, .	4.2	61
465	Brain immune cells undergo cGAS/STING-dependent apoptosis during herpes simplex virus type 1 infection to limit type I IFN production. Journal of Clinical Investigation, 2021, 131, .	3.9	61
466	Magnetic Resonance Imaging Improves Cerebrospinal Fluid Biomarkers in the Early Detection of Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 351-362.	1.2	60
467	Sustained release of neuron-specific enolase to serum in amateur boxers. Brain Injury, 2009, 23, 723-726.	0.6	60
468	Validation of Alzheimerâ€™s disease CSF and plasma biological markers: The multicentre reliability study of the pilot European Alzheimerâ€™s Disease Neuroimaging Initiative (E-ADNI). Experimental Gerontology, 2009, 44, 579-585.	1.2	60

#	Article	IF	Citations
469	CSF Biomarkers. Annals of the New York Academy of Sciences, 2009, 1180, 28-35.	1.8	60
470	Acute Sleep Deprivation Increases Serum Levels of Neuron-Specific Enolase (NSE) and S100 Calcium Binding Protein B (S-100B) in Healthy Young Men. Sleep, 2014, 37, 195-198.	0.6	60
471	Pro-inflammatory S100A9 Protein as a Robust Biomarker Differentiating Early Stages of Cognitive Impairment in Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2016, 7, 34-39.	1.7	60
472	Histology-Compatible MALDI Mass Spectrometry Based Imaging of Neuronal Lipids for Subsequent Immunofluorescent Staining. Analytical Chemistry, 2017, 89, 4685-4694.	3.2	60
473	CSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults. Neurobiology of Aging, 2017, 49, 138-144.	1.5	60
474	Shedding Light on the Molecular Pathology of Amyloid Plaques in Transgenic Alzheimerâ€™s Disease Mice Using Multimodal MALDI Imaging Mass Spectrometry. ACS Chemical Neuroscience, 2018, 9, 1802-1817.	1.7	60
475	Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimerâ€™s disease. Brain, 2020, 143, 3793-3804.	3.7	60
476	Altered cognitive performance and synaptic function in the hippocampus of mice lacking C3. Experimental Neurology, 2014, 253, 154-164.	2.0	59
477	Sense and antisense RNA are not toxic in Drosophila models of C9orf72-associated ALS/FTD. Acta Neuropathologica, 2018, 135, 445-457.	3.9	59
478	Update on biomarkers for amyloid pathology in Alzheimer's disease. Biomarkers in Medicine, 2018, 12, 799-812.	0.6	59
479	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimerâ€™s disease. Science Advances, 2019, 5, eaau7220.	4.7	59
480	Effects of acute sleep loss on diurnal plasma dynamics of CNS health biomarkers in young men. Neurology, 2020, 94, e1181-e1189.	1.5	59
481	Protective properties of lysozyme on Î²-amyloid pathology: implications for Alzheimer disease. Neurobiology of Disease, 2015, 83, 122-133.	2.1	58
482	Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease. Journal of Neurochemistry, 2016, 139, 22-25.	2.1	58
483	Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 397-403.	1.1	58
484	Prevalence of the apolipoprotein E Îµ4 allele in amyloid Î² positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
485	Heading in soccer increases serum neurofilament light protein and SCAT3 symptom metrics. BMJ Open Sport and Exercise Medicine, 2018, 4, e000433.	1.4	58
486	Tau PET correlates with different Alzheimerâ€™s diseaseâ€related features compared to CSF and plasma pâ€tau biomarkers. EMBO Molecular Medicine, 2021, 13, e14398.	3.3	58

#	Article	IF	Citations
487	Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntingtonâ€™s Disease. PLoS ONE, 2016, 11, e0163479.	1.1	58
488	Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MS. PLoS ONE, 2012, 7, e42555.	1.1	57
489	Cerebrospinal fluid sphingolipids, Î²-amyloid, and tau in adults at risk for Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2486-2494.	1.5	57
490	Mutated Thyroid Hormone Transporter OATP1C1 Associates with Severe Brain Hypometabolism and Juvenile Neurodegeneration. Thyroid, 2018, 28, 1406-1415.	2.4	57
491	Neurofilament changes in serum and cerebrospinal fluid after acute ischemic stroke. Neuroscience Letters, 2019, 698, 58-63.	1.0	57
492	Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5â€“90 years. Brain Communications, 2022, 4, .	1.5	57
493	SILAC zebrafish for quantitative analysis of protein turnover and tissue regeneration. Journal of Proteomics, 2011, 75, 425-434.	1.2	56
494	Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration. Translational Psychiatry, 2017, 7, e995-e995.	2.4	56
495	In vivo detection of cerebral tau pathology in long-term survivors of traumatic brain injury. Science Translational Medicine, 2019, 11, .	5.8	56
496	Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 26.	3.0	56
497	Correlation of Blood Biomarkers and Biomarker Panels with Traumatic Findings on Computed Tomography after Traumatic Brain Injury. Journal of Neurotrauma, 2019, 36, 2178-2189.	1.7	56
498	Early Levels of Glial Fibrillary Acidic Protein and Neurofilament Light Protein in Predicting the Outcome of Mild Traumatic Brain Injury. Journal of Neurotrauma, 2019, 36, 1551-1560.	1.7	56
499	CSF Beta-amyloid 1â€“42 Concentration Predicts Delirium Following Elective Arthroplasty Surgery in an Observational Cohort Study. Annals of Surgery, 2019, 269, 1200-1205.	2.1	56
500	Brain and blood biomarkers of tauopathy and neuronal injury in humans and rats with neurobehavioral syndromes following blast exposure. Molecular Psychiatry, 2021, 26, 5940-5954.	4.1	56
501	Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19. Journal of Neurology, 2021, 268, 3574-3583.	1.8	56
502	Synaptic vesicle protein 2A as a potential biomarker in synaptopathies. Molecular and Cellular Neurosciences, 2019, 97, 34-42.	1.0	55
503	Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 77, 1129-1141.	1.2	55
504	Postoperative delirium and changes in the bloodâ€“brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study. British Journal of Anaesthesia, 2022, 129, 219-230.	1.5	55

#	Article	IF	Citations
505	Monitoring of Î²-Amyloid Dynamics after Human Traumatic Brain Injury. Journal of Neurotrauma, 2014, 31, 42-55.	1.7	54
506	Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 58, 1245-1254.	1.2	54
507	A user's guide for Î±â€synuclein biomarker studies in biological fluids: Perianalytical considerations. Movement Disorders, 2017, 32, 1117-1130.	2.2	54
508	Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2018, 10, 113.	3.0	54
509	PDXK mutations cause polyneuropathy responsive to pyridoxal 5â€²â€phosphate supplementation. Annals of Neurology, 2019, 86, 225-240.	2.8	54
510	Salivary Biomarkers for Alzheimerâ€™s Disease and Related Disorders. Neurology and Therapy, 2019, 8, 83-94.	1.4	54
511	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. Journal of Internal Medicine, 2021, 290, 583-601.	2.7	54
512	OUP accepted manuscript. Brain, 2021, 144, 434-449.	3.7	54
513	Increased CSF Levels of Phosphorylated Neurofilament Heavy Protein following Bout in Amateur Boxers. PLoS ONE, 2013, 8, e81249.	1.1	54
514	The Application of Cerebrospinal Fluid Biomarkers in Early Diagnosis of Alzheimer Disease. Medical Clinics of North America, 2013, 97, 369-376.	1.1	53
515	Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: A Longitudinal Study. Journal of Infectious Diseases, 2016, 214, 1822-1825.	1.9	53
516	Serum concentrations of the axonal injury marker neurofilament light protein are not influenced by blood-brain barrier permeability. Brain Research, 2017, 1668, 12-19.	1.1	53
517	Phenotypic Screening Identifies Modulators of Amyloid Precursor Protein Processing in Human Stem Cell Models of Alzheimerâ€™s Disease. Stem Cell Reports, 2017, 8, 870-882.	2.3	53
518	Familial Alzheimerâ€™s Disease Mutations in PSEN1 Lead to Premature Human Stem Cell Neurogenesis. Cell Reports, 2021, 34, 108615.	2.9	53
519	Methylenetetrahydrofolate reductase and transcobalamin genetic polymorphisms in human spontaneous abortion: biological and clinical implications. Reproductive Biology and Endocrinology, 2004, 2, 7.	1.4	52
520	No neurochemical evidence for brain injury caused by heading in soccer. British Journal of Sports Medicine, 2007, 41, 574-577.	3.1	52
521	Synaptic Retrogenesis and Amyloid-Î² in Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 1-14.	1.2	52
522	Levels of brain related proteins in cerebrospinal fluid: An aid in the differential diagnosis of parkinsonian disorders. Parkinsonism and Related Disorders, 2009, 15, 205-212.	1.1	52

#	Article	IF	Citations
523	Determining cut-points for Alzheimerâ€™s disease biomarkers: statistical issues, methods and challenges. Biomarkers in Medicine, 2012, 6, 391-400.	0.6	52
524	Cerebral white matter lesions â€“ associations with AÎ² isoforms and amyloid PET. Scientific Reports, 2016, 6, 20709.	1.6	52
525	Effects of preâ€analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12168.	1.2	52
526	Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid. Cerebrospinal Fluid Research, 2010, 7, 10.	0.5	51
527	CSF levels of YKL-40 are increased in MS and decrease with immunosuppressive treatment. Journal of Neuroimmunology, 2014, 269, 87-89.	1.1	51
528	Increased cerebrospinal fluid interleukin-8 in bipolar disorder patients associated with lithium and antipsychotic treatment. Brain, Behavior, and Immunity, 2015, 43, 198-204.	2.0	51
529	Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults. Journal of Alzheimer's Disease, 2016, 52, 1373-1383.	1.2	51
530	Moderate intensity physical activity associates with CSF biomarkers in a cohort at risk for Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 188-195.	1.2	51
531	CSF biomarkers in delirium: a systematic review. International Journal of Geriatric Psychiatry, 2018, 33, 1479-1500.	1.3	51
532	Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy. Experimental Neurology, 2018, 307, 129-132.	2.0	51
533	No association of salivary total tau concentration with Alzheimer's disease. Neurobiology of Aging, 2018, 70, 125-127.	1.5	51
534	Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimerâ€™s and Parkinsonâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 82.	3.0	51
535	Detection of Î²-amyloid positivity in Alzheimerâ€™s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. Brain Communications, 2021, 3, fcab008.	1.5	51
536	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid Î² and tau. Alzheimer's and Dementia, 2021, 17, 1575-1582.	0.4	51
537	Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimerâ€™s disease: a focused review on recent advances. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1231-1241.	0.9	51
538	Influence of the apolipoprotein E Îµ4 allele on human embryonic development. Neuroscience Letters, 2002, 324, 189-192.	1.0	50
539	CSF amyloid Â38 as a novel diagnostic marker for dementia with Lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 160-164.	0.9	50
540	Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 215, 1132-1140.	1.9	50

#	Article	IF	Citations
541	Association of Plasma Neurofilament Light Chain with Neocortical Amyloid-Î² Load and Cognitive Performance in Cognitively Normal Elderly Participants. Journal of Alzheimer's Disease, 2018, 63, 479-487.	1.2	50
542	NFL blood levels are moderated by subconcussive impacts in a cohort of college football players. Brain Injury, 2019, 33, 456-462.	0.6	50
543	CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e512.	3.1	50
544	Propagation of Tau Pathology: Integrating Insights From Postmortem and InÂVivo Studies. Biological Psychiatry, 2020, 87, 808-818.	0.7	50
545	Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease. Neurology, 2020, 95, e953-e961.	1.5	50
546	Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. Neurology, 2021, 97, .	1.5	50
547	Serum markers of brain injury can predict good neurological outcome after out-of-hospital cardiac arrest. Intensive Care Medicine, 2021, 47, 984-994.	3.9	50
548	Targeted proteomics in Alzheimerâ€™s disease: focus on amyloid-Î². Expert Review of Proteomics, 2008, 5, 225-237.	1.3	49
549	Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism. BMC Neurology, 2010, 10, 51.	0.8	49
550	Cerebrospinal fluid biomarkers in patients with varicella-zoster virus CNS infections. Journal of Neurology, 2013, 260, 1813-1821.	1.8	49
551	Heart fatty acid binding protein and AÎ²-associated Alzheimerâ€™s neurodegeneration. Molecular Neurodegeneration, 2013, 8, 39.	4.4	49
552	Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition. Journal of the International Neuropsychological Society, 2015, 21, 841-850.	1.2	49
553	Assessing the commutability of reference material formats for the harmonization of amyloid-Î² measurements. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1177-1191.	1.4	49
554	Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntingtonâ€™s disease R6/2 mice. Scientific Reports, 2017, 7, 14114.	1.6	49
555	Stability of bloodâ€based biomarkers of Alzheimer's disease over multiple freezeâ€thaw cycles. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 448-451.	1.2	49
556	Circulating neurofilament light in ischemic stroke: temporal profile and outcome prediction. Journal of Neurology, 2019, 266, 2796-2806.	1.8	49
557	Mass Spectrometric Analysis of Lewy Body-Enriched Î±-Synuclein in Parkinsonâ€™s Disease. Journal of Proteome Research, 2019, 18, 2109-2120.	1.8	49
558	Pyroglutamation of amyloid-Î²x-42 (AÎ²x-42) followed by AÎ²1â€“40 deposition underlies plaque polymorphism in progressing Alzheimerâ€™s disease pathology. Journal of Biological Chemistry, 2019, 294, 6719-6732.	1.6	49

#	Article	IF	Citations
559	Accurate risk estimation of Î²â€amyloid positivity to identify prodromal Alzheimer's disease: Crossâ€validation study of practical algorithms. Alzheimer's and Dementia, 2019, 15, 194-204.	0.4	49
560	Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimerâ€™s disease pathology and clinical disease progression. Alzheimer's Research and Therapy, 2021, 13, 65.	3.0	49
561	Association between CSF alpha-synuclein seeding activity and genetic status in Parkinsonâ€™s disease and dementia with Lewy bodies. Acta Neuropathologica Communications, 2021, 9, 175.	2.4	49
562	The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimer's Research and Therapy, 2022, 14, 26.	3.0	49
563	Plasma AÎ² in Alzheimer's diseaseâ€”up or down?. Lancet Neurology, The, 2006, 5, 638-639.	4.9	48
564	To Know or Not to Know: Ethical Issues Related to Early Diagnosis of Alzheimer's Disease. International Journal of Alzheimer's Disease, 2010, 2010, 1-4.	1.1	48
565	Evaluation of Plasma AÎ² as Predictor of Alzheimer's Disease in Older Individuals Without Dementia: A Population-Based Study. Journal of Alzheimer's Disease, 2012, 28, 231-238.	1.2	48
566	Increased amyloidogenic APP processing in APOE É›4-negative individuals with cerebral Î²-amyloidosis. Nature Communications, 2016, 7, 10918.	5.8	48
567	Neurofilament relates to white matter microstructure in older adults. Neurobiology of Aging, 2018, 70, 233-241.	1.5	48
568	Biomarker-guided clustering of Alzheimer's disease clinical syndromes. Neurobiology of Aging, 2019, 83, 42-53.	1.5	48
569	Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloidâ€positive individuals. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 679-689.	1.2	48
570	Genome-scale metabolic network reconstruction of model animals as a platform for translational research. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	48
571	THE ROAD AHEAD TO CURE ALZHEIMER'S DISEASE: DEVELOPMENT OF BIOLOGICAL MARKERS AND NEUROIMAGING METHODS FOR PREVENTION TRIALS ACROSS ALL STAGES AND TARGET POPULATIONS. journal of prevention of Alzheimer's disease, The, 2014, 1, 1-22.	1.5	48
572	Association of the RAGE G82S polymorphism with Alzheimerâ€™s disease. Journal of Neural Transmission, 2010, 117, 861-867.	1.4	47
573	Understanding the cause of sporadic Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2014, 14, 621-630.	1.4	47
574	CSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment. European Neuropsychopharmacology, 2015, 25, 1091-1098.	0.3	47
575	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. Neurobiology of Aging, 2019, 77, 169-177.	1.5	47
576	Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. Alzheimer's and Dementia, 2020, 16, 262-272.	0.4	47

#	Article	IF	Citations
577	Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis. Journal of Allergy and Clinical Immunology, 2021, 148, 96-98.	1.5	47
578	Neurofilaments in progressive multiple sclerosis: a systematic review. Journal of Neurology, 2021, 268, 3212-3222.	1.8	47
579	A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimerâ€™s disease pathology. Translational Psychiatry, 2016, 6, e952-e952.	2.4	46
580	Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict longâ€term outcome in patients with autoimmune encephalitis. European Journal of Neurology, 2016, 23, 796-806.	1.7	46
581	Round robin test on quantification of amyloidâ€Î² 1â€“42 in cerebrospinal fluid by mass spectrometry. Alzheimer's and Dementia, 2016, 12, 55-59.	0.4	46
582	Applying fluid biomarkers to Alzheimer's disease. American Journal of Physiology - Cell Physiology, 2017, 313, C3-C10.	2.1	46
583	Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease. Neurochemistry International, 2017, 108, 355-360.	1.9	46
584	Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis. Journal of Neuroimmunology, 2017, 312, 15-18.	1.1	46
585	Autocatalytic amplification of Alzheimer-associated AÎ²42 peptide aggregation in human cerebrospinal fluid. Communications Biology, 2019, 2, 365.	2.0	46
586	Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. Journal of the Peripheral Nervous System, 2019, 24, 314-319.	1.4	46
587	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's and Dementia, 2019, 15, 1478-1488.	0.4	46
588	CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 846-853.	0.9	46
589	Potential human transmission of amyloid Î² pathology: surveillance and risks. Lancet Neurology, The, 2020, 19, 872-878.	4.9	46
590	Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis. BMJ Neurology Open, 2021, 3, e000143.	0.7	46
591	Subcortical Vascular Dementia Biomarker Pattern in Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2009, 28, 348-356.	0.7	45
592	Evaluation of the Cerebrospinal Fluid Amyloid-Î²₁₋₄₂/Amyloid-Î²₁₋₄₀ Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders. Dementia and Geriatric Cognitive Disorders, 2013, 36, 99-110.	0.7	45
593	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 13333.	1.6	45
594	Association of cerebrospinal fluid Î±â€synuclein with total and phosphoâ€tau‹sub›181‹/sub› protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. Alzheimer's and Dementia, 2018, 14, 1623-1631.	0.4	45

#	Article	IF	Citations
595	Comparative Evaluation of MS-based Metabolomics Software and Its Application to Preclinical Alzheimerâ€™s Disease. Scientific Reports, 2018, 8, 9291.	1.6	45
596	Comparing Glial Fibrillary Acidic Protein (GFAP) in Serum and Plasma Following Mild Traumatic Brain Injury in Older Adults. Frontiers in Neurology, 2020, 11, 1054.	1.1	45
597	Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates. Journal of Alzheimer's Disease, 2016, 55, 303-313.	1.2	44
598	Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 27-34.	1.2	44
599	Orexin-A is Associated with Increases in Cerebrospinal Fluid Phosphorylated-Tau in Cognitively Normal Elderly Subjects. Sleep, 2016, 39, 1253-1260.	0.6	44
600	The Vanderbilt Memory & Aging Project: Study Design and Baseline Cohort Overview. Journal of Alzheimer's Disease, 2016, 52, 539-559.	1.2	44
601	Cerebrospinal fluid ratios with AÎ²₄₂ predict preclinical brain Î²â€amyloid accumulation. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 2, 27-38.	1.2	44
602	Antibodyâ€based methods for the measurement of Î±â€synuclein concentration in human cerebrospinal fluid â€“ method comparison and round robin study. Journal of Neurochemistry, 2019, 149, 126-138.	2.1	44
603	Models of the blood-brain barrier using iPSC-derived cells. Molecular and Cellular Neurosciences, 2020, 107, 103533.	1.0	44
604	Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-BarrÃ© syndrome. Journal of Neuroinflammation, 2020, 17, 86.	3.1	44
605	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clinical Chemistry and Laboratory Medicine, 2022, 60, 207-219.	1.4	44
606	Diagnostic value of 14-3-3beta immunoblot and T-tau/P-tau ratio in clinically suspected Creutzfeldt-Jakob disease. International Journal of Molecular Medicine, 2005, 16, 1147-9.	1.8	44
607	Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimerâ€™s disease. Brain, 2023, 146, 690-699.	3.7	44
608	Soluble amyloid precursor protein Î± and Î² in CSF in Alzheimer's disease. Brain Research, 2013, 1513, 117-126.	1.1	43
609	Cerebrospinal fluid biomarkers of Î²-amyloid metabolism in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 543-552.	1.4	43
610	Fluid markers of traumatic brain injury. Molecular and Cellular Neurosciences, 2015, 66, 99-102.	1.0	43
611	Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis. Journal of Neuroimmunology, 2016, 299, 112-117.	1.1	43
612	Longitudinal Performance of Plasma Neurofilament Light and Tau in Professional Fighters: The Professional Fighters Brain Health Study. Journal of Neurotrauma, 2018, 35, 2351-2356.	1.7	43

#	Article	IF	Citations
613	Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome. Alzheimer's Research and Therapy, 2018, 10, 39.	3.0	43
614	Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup. Alzheimer's Research and Therapy, 2018, 10, 79.	3.0	43
615	Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy. Brain, 2019, 142, 1227-1241.	3.7	43
616	A distinct brain beta amyloid signature in cerebral amyloid angiopathy compared to Alzheimerâ€™s disease. Neuroscience Letters, 2019, 701, 125-131.	1.0	43
617	Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity. Archives of Toxicology, 2020, 94, 2517-2522.	1.9	43
618	2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimerâ€™s disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2121-2139.	3.3	43
619	Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes. Brain Communications, 2021, 3, fcab099.	1.5	43
620	Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification. Alzheimer's and Dementia, 2021, 17, 1365-1382.	0.4	43
621	Alzheimerâ€™s diseaseâ€”subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 95-113.	2.4	42
622	Age-accelerated cognitive decline in asymptomatic adults with CSF Î²-amyloid. Neurology, 2018, 90, e1306-e1315.	1.5	42
623	Gait in Mild Alzheimerâ€™s Disease: Feasibility of Multi-Center Measurement in the Clinic and Home with Body-Worn Sensors: A Pilot Study. Journal of Alzheimer's Disease, 2018, 63, 331-341.	1.2	42
624	Neurogranin as a predictor of memory and executive function decline in MCI patients. Neurology, 2018, 90, e887-e895.	1.5	42
625	Genome-wide association study of Alzheimerâ€™s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. Translational Psychiatry, 2020, 10, 403.	2.4	42
626	First amyloid Î²1â€42 certified reference material for reâ€calibrating commercial immunoassays. Alzheimer's and Dementia, 2020, 16, 1493-1503.	0.4	42
627	Relevance of biomarkers across different neurodegenerative diseases. Alzheimer's Research and Therapy, 2020, 12, 56.	3.0	42
628	Plasma pâ€tau231, pâ€tau181, <scp>PET</scp> Biomarkers, and Cognitive Change in Older Adults. Annals of Neurology, 2022, 91, 548-560.	2.8	42
629	Rarity of the Alzheimer Diseaseâ€“ProtectiveAPPA673T Variant in the United States. JAMA Neurology, 2015, 72, 209.	4.5	41
630	Brain Amyloid-Beta Fragment Signatures in Pathological Ageing and Alzheimer's Disease by Hybrid Immunoprecipitation Mass Spectrometry. Neurodegenerative Diseases, 2015, 15, 50-57.	0.8	41

#	Article	IF	Citations
631	Explorative and targeted neuroproteomics in Alzheimer's disease. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 769-778.	1.1	41
632	Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife. Brain, 2016, 139, 2261-2274.	3.7	41
633	Plasma tau is increased in frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 804-807.	0.9	41
634	Neurofilament Light in Serum and Cerebrospinal Fluid of Hip Fracture Patients with Delirium. Dementia and Geriatric Cognitive Disorders, 2018, 46, 346-357.	0.7	41
635	Plasma neurofilament light chain and amyloid-Î² are associated with the kynurenine pathway metabolites in preclinical Alzheimerâ€™s disease. Journal of Neuroinflammation, 2019, 16, 186.	3.1	41
636	Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. Journal of Neurology, 2019, 266, 2157-2163.	1.8	41
637	Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7793-7798.	3.3	41
638	Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy. Neurology, 2019, 92, e1205-e1211.	1.5	41
639	Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial. EBioMedicine, 2020, 59, 102844.	2.7	41
640	The nonlinear relationship between cerebrospinal fluid AÎ²42 and tau in preclinical Alzheimerâ€™s disease. PLoS ONE, 2018, 13, e0191240.	1.1	41
641	Infection of Brain Pericytes Underlying Neuropathology of COVID-19 Patients. International Journal of Molecular Sciences, 2021, 22, 11622.	1.8	41
642	Is there a CSF biomarker profile related to depression in elderly women?. Psychiatry Research, 2010, 176, 174-178.	1.7	40
643	Increased Cerebrospinal Fluid Level ofÂInsulin-like Growth Factor-II in Male Patients with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 48, 637-646.	1.2	40
644	Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis. European Journal of Neurology, 2015, 22, 328-333.	1.7	40
645	Associations between Performance onÂanÂAbbreviated CogState Battery, OtherÂMeasures of Cognitive Function, andÂBiomarkers in People at Risk forÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 54, 1395-1408.	1.2	40
646	Cerebrospinal Fluid Amyloid Beta and Tau Concentrations Are Not Modulated by 16 Weeks of Moderate- to High-Intensity Physical Exercise in Patients with Alzheimer Disease. Dementia and Geriatric Cognitive Disorders, 2016, 42, 146-158.	0.7	40
647	Structural Brain Abnormalities in Successfully Treated HIV Infection: Associations With Disease and Cerebrospinal Fluid Biomarkers. Journal of Infectious Diseases, 2018, 217, 69-81.	1.9	40
648	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. Alzheimer's Research and Therapy, 2018, 10, 30.	3.0	40

#	Article	IF	Citations
649	Neuroinflammation and Tau Interact with Amyloid in Predicting Sleep Problems in Aging Independently of Atrophy. Cerebral Cortex, 2018, 28, 2775-2785.	1.6	40
650	Serum Neurofilament Light Chain Concentration Correlates with Infarct Volume but Not Prognosis in Acute Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 2242-2249.	0.7	40
651	KLOTHO heterozygosity attenuates APOE4 -related amyloid burden in preclinical AD. Neurology, 2019, 92, e1878-e1889.	1.5	40
652	CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET. Neurology, 2021, 97, e2065-e2078.	1.5	40
653	Associations between air pollution and biomarkers of Alzheimerâ€™s disease in cognitively unimpaired individuals. Environment International, 2021, 157, 106864.	4.8	40
654	Amyloid-Î²1-15/16 as a Marker for Î³-Secretase Inhibition in Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 31, 335-341.	1.2	39
655	Amyloid-Î² metabolism in Niemann-Pick C disease models and patients. Metabolic Brain Disease, 2012, 27, 573-585.	1.4	39
656	Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. Parkinsonism and Related Disorders, 2012, 18, 69-72.	1.1	39
657	Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. Translational Psychiatry, 2014, 4, e419-e419.	2.4	39
658	Amyloid-beta 42 adsorption following serial tube transfer. Alzheimer's Research and Therapy, 2014, 6, 5.	3.0	39
659	Amyloid-Î² and Tau Dynamics in Human Brain Interstitial Fluid in Patients with Suspected Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2015, 46, 261-269.	1.2	39
660	Cerebrospinal fluid biomarkers for AlzheimerÊ¼s disease. Current Opinion in Psychiatry, 2015, 28, 402-409.	3.1	39
661	Dissecting IWG-2 typical and atypical Alzheimerâ€™s disease: insights from cerebrospinal fluid analysis. Journal of Neurology, 2015, 262, 2722-2730.	1.8	39
662	Increased neurogranin concentrations in cerebrospinal fluid of Alzheimerâ€™s disease and in mild cognitive impairment due to AD. Journal of Neural Transmission, 2016, 123, 1443-1447.	1.4	39
663	Astroglial activation and altered amyloid metabolism in human repetitive concussion. Neurology, 2017, 88, 1400-1407.	1.5	39
664	Twoâ€level diagnostic classification using cerebrospinal fluid YKLâ€40 in Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 993-1003.	0.4	39
665	Cerebrospinal fluid Î²-amyloid42 and neurofilament light relate to white matter hyperintensities. Neurobiology of Aging, 2018, 68, 18-25.	1.5	39
666	Integration of magnetic resonance imaging and protein and metabolite CSF measurements to enable early diagnosis of secondary progressive multiple sclerosis. Theranostics, 2018, 8, 4477-4490.	4.6	39

#	Article	IF	Citations
667	Multimodal Chemical Imaging of Amyloid Plaque Polymorphism Reveals AÎ² Aggregation Dependent Anionic Lipid Accumulations and Metabolism. Analytical Chemistry, 2018, 90, 8130-8138.	3.2	39
668	Levels of ADAM10 are reduced in Alzheimerâ€™s disease CSF. Journal of Neuroinflammation, 2018, 15, 213.	3.1	39
669	Head trauma in sports â€“ clinical characteristics, epidemiology and biomarkers. Journal of Internal Medicine, 2019, 285, 624-634.	2.7	39
670	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarkerâ€“based caseâ€“control study. PLoS Medicine, 2020, 17, e1003289.	3.9	39
671	Haemoglobin causes neuronal damage in vivo which is preventable by haptoglobin. Brain Communications, 2020, 2, fcz053.	1.5	39
672	Proteomic profiling of cerebrospinal fluid in parkinsonian disorders. Parkinsonism and Related Disorders, 2010, 16, 545-549.	1.1	38
673	Measurement of AÎ²1â€“42 in cerebrospinal fluid is influenced by matrix effects. Journal of Neurochemistry, 2012, 120, 325-333.	2.1	38
674	Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease. Psychoneuroendocrinology, 2013, 38, 1058-1066.	1.3	38
675	Cognitive Performance and Cerebrospinal Fluid Biomarkers of Neurodegeneration: A Study of Patients with Bipolar Disorder and Healthy Controls. PLoS ONE, 2015, 10, e0127100.	1.1	38
676	Amyloid mis-metabolism in idiopathic normal pressure hydrocephalus. Fluids and Barriers of the CNS, 2016, 13, 13.	2.4	38
677	Effects of methylprednisolone on blood-brain barrier and cerebral inflammation in cardiac surgeryâ€”a randomized trial. Journal of Neuroinflammation, 2018, 15, 283.	3.1	38
678	Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia. Neurology, 2018, 91, e436-e443.	1.5	38
679	Serum neurofilament light chain in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2018, 56, 98-101.	1.1	38
680	Ultrasensitive Detection of Plasma Amyloid-Î² as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 71, 775-783.	1.2	38
681	Comparison of variables associated with cerebrospinal fluid neurofilament, totalâ€tau, and neurogranin. Alzheimer's and Dementia, 2019, 15, 1437-1447.	0.4	38
682	Blood Biomarkers: Democratizing Alzheimerâ€™s Diagnostics. Neuron, 2020, 106, 881-883.	3.8	38
683	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy. Journal of Alzheimer's Disease, 2020, 74, 1189-1201.	1.2	38
684	Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. JAMA Neurology, 2022, 79, 32.	4.5	38

#	Article	IF	Citations
685	Gene-gene interaction between fetal MTHFR 677C>T and transcobalamin 776C>G polymorphisms in human spontaneous abortion. Human Reproduction, 2003, 18, 1948-1950.	0.4	37
686	Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease. Neuroscience Letters, 2009, 450, 56-59.	1.0	37
687	Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid. Experimental Neurology, 2010, 223, 351-358.	2.0	37
688	Approach to Cerebrospinal Fluid (CSF) Biomarker Discovery and Evaluation in HIV Infection. Journal of NeuroImmune Pharmacology, 2013, 8, 1147-1158.	2.1	37
689	Identification of an important potential confound in CSF AD studies: aliquot volume. Clinical Chemistry and Laboratory Medicine, 2013, 51, 2311-7.	1.4	37
690	Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples. Alzheimer's Research and Therapy, 2013, 5, 47.	3.0	37
691	Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. Clinical Chemistry, 2018, 64, 927-937.	1.5	37
692	Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment. Aids, 2018, 32, 2171-2178.	1.0	37
693	SILK studies â€" capturing the turnover of proteins linked to neurodegenerative diseases. Nature Reviews Neurology, 2019, 15, 419-427.	4.9	37
694	Longitudinal change in regional brain volumes with exposure to repetitive head impacts. Neurology, 2020, 94, e232-e240.	1.5	37
695	Plasma Pâ€tau181 to AÎ²42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease. Alzheimer's and Dementia, 2021, 17, 1649-1662.	0.4	37
696	Post-acute blood biomarkers and disease progression in traumatic brain injury. Brain, 2022, 145, 2064-2076.	3.7	37
697	Bloodâ€"cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment. Psychiatry Research, 2014, 217, 143-146.	1.7	36
698	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Frontiers in Neurology, 2015, 6, 216.	1.1	36
699	Bloodâ€"brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e300.	3.1	36
700	The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimerâ€™s pathology. Alzheimer's Research and Therapy, 2017, 9, 31.	3.0	36
701	CSF sTREM2 in deliriumâ€"relation to Alzheimerâ€™s disease CSF biomarkers AÎ²42, t-tau and p-tau. Journal of Neuroinflammation, 2018, 15, 304.	3.1	36
702	The Transcobalamin (TC) Codon 259 Genetic Polymorphism Influences Holo-TC Concentration in Cerebrospinal Fluid from Patients with Alzheimer Disease. Clinical Chemistry, 2003, 49, 1195-1198.	1.5	35

#	Article	IF	Citations
703	Association of APOE with age at onset of sporadic amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2008, 273, 67-69.	0.3	35
704	Screening for New Biomarkers for Subcortical Vascular Dementia and Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders Extra, 2011, 1, 31-42.	0.6	35
705	Greater Specificity for Cerebrospinal Fluid P-tau231 over P-tau181 in the Differentiation of Healthy Controls from Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 49, 93-100.	1.2	35
706	Preclinical Amyloid-Î² and Axonal Degeneration Pathology in Delirium. Journal of Alzheimer's Disease, 2016, 55, 371-379.	1.2	35
707	Calcium supplementation and risk of dementia in women with cerebrovascular disease. Neurology, 2016, 87, 1674-1680.	1.5	35
708	Cardiorespiratory fitness alters the influence of a polygenic risk score on biomarkers of AD. Neurology, 2017, 88, 1650-1658.	1.5	35
709	Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. Journal of Alzheimer's Disease, 2017, 59, 1327-1334.	1.2	35
710	Combined tissue and fluid proteomics with Tandem Mass Tags to identify low-abundance protein biomarkers of disease in peripheral body fluid: An Alzheimer's Disease case study. Rapid Communications in Mass Spectrometry, 2017, 31, 153-159.	0.7	35
711	Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy. Journal of NeuroVirology, 2018, 24, 695-701.	1.0	35
712	Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 700-709.	1.2	35
713	Ionized calcium in human cerebrospinal fluid and its influence on intrinsic and synaptic excitability of hippocampal pyramidal neurons in the rat. Journal of Neurochemistry, 2019, 149, 452-470.	2.1	35
714	Cardiomyopathy with lethal arrhythmias associated with inactivation of KLHL24. Human Molecular Genetics, 2019, 28, 1919-1929.	1.4	35
715	Review: Fluid biomarkers for frontotemporal dementias. Neuropathology and Applied Neurobiology, 2019, 45, 81-87.	1.8	35
716	A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer's disease. Neurobiology of Aging, 2020, 94, 60-70.	1.5	35
717	Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12005.	1.2	35
718	Association between polygenic risk score of Alzheimerâ€™s disease and plasma phosphorylated tau in individuals from the Alzheimerâ€™s Disease Neuroimaging Initiative. Alzheimer's Research and Therapy, 2021, 13, 17.	3.0	35
719	Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12179.	1.2	35
720	Amyloid processing in <scp>COVID</scp>â€19â€associated neurological syndromes. Journal of Neurochemistry, 2022, 161, 146-157.	2.1	35

#	Article	IF	Citations
721	Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic Symptoms. JAMA Network Open, 2022, 5, e2213253.	2.8	35
722	Converging molecular pathways in human neural development and degeneration. Neuroscience Research, 2010, 66, 330-332.	1.0	34
723	Analysis of Amino-Terminal Variants of Amyloid-Î² Peptides by Capillary Isoelectric Focusing Immunoassay. Analytical Chemistry, 2013, 85, 8142-8149.	3.2	34
724	Quantification of total apolipoprotein E and its specific isoforms in cerebrospinal fluid and blood in Alzheimerâ€™s disease and other neurodegenerative diseases. EuPA Open Proteomics, 2015, 8, 137-143.	2.5	34
725	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2015, 48, S171-S191.	1.2	34
726	Absence of Cerebrospinal Fluid Signs of Neuronal Injury Before and After Immediate Antiretroviral Therapy in Acute HIV Infection. Journal of Infectious Diseases, 2015, 212, 1759-1767.	1.9	34
727	Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. Parkinsonism and Related Disorders, 2017, 37, 65-71.	1.1	34
728	Molecular imaging mass spectrometry for probing protein dynamics in neurodegenerative disease pathology. Journal of Neurochemistry, 2019, 151, 488-506.	2.1	34
729	Sex difference in CHI3L1 expression levels in human brain aging and in Alzheimerâ€™s disease. Brain Research, 2019, 1720, 146305.	1.1	34
730	Biomarkers for Alzheimerâ€™s disease beyond amyloid and tau. Nature Medicine, 2019, 25, 201-203.	15.2	34
731	Neuroinflammatory markers associate with cognitive decline after major surgery: Findings of an explorative study. Annals of Neurology, 2020, 87, 370-382.	2.8	34
732	Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimerâ€™s disease. Neurobiology of Aging, 2020, 95, 143-153.	1.5	34
733	Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease. BMC Medicine, 2020, 18, 140.	2.3	34
734	Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2021, 13, 69.	3.0	34
735	Neuroinflammation and Alzheimerâ€™s Disease: A Machine Learning Approach to CSF Proteomics. Cells, 2021, 10, 1930.	1.8	34
736	Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET. EBioMedicine, 2022, 76, 103837.	2.7	34
737	No association between the MTHFR A1298C and transcobalamin C776G genetic polymorphisms and hyperhomocysteinemia in thrombotic disease. Thrombosis Research, 2002, 108, 127-131.	0.8	33
738	Cerebrospinal Fluid Brain Injury Biomarkers in Children: A Multicenter Study. Pediatric Neurology, 2013, 49, 31-39.e2.	1.0	33

#	Article	IF	Citations
739	Cerebrovascular Biomarker Profile Is Related to White Matter Disease and Ventricular Dilation in a LADIS Substudy. Dementia and Geriatric Cognitive Disorders Extra, 2014, 4, 385-394.	0.6	33
740	Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2016, 6, 283-294.	0.6	33
741	Genome-wide association study identifies MAPT locus influencing human plasma tau levels. Neurology, 2017, 88, 669-676.	1.5	33
742	Evolution and clustering of prodromal parkinsonian features in GBA1 carriers. Movement Disorders, 2019, 34, 1365-1373.	2.2	33
743	Neurofilament light chain as a potential biomarker for monitoring neurodegeneration in X-linked adrenoleukodystrophy. Nature Communications, 2021, 12, 1816.	5.8	33
744	Association of plasma P-tau181 with memory decline in non-demented adults. Brain Communications, 2021, 3, fcab136.	1.5	33
745	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimerâ€™s disease in adults with Down syndrome. Nature Communications, 2021, 12, 4304.	5.8	33
746	The transcobalamin codon 259 polymorphism influences the risk of human spontaneous abortion. Human Reproduction, 2002, 17, 3033-3036.	0.4	32
747	Cerebrospinal Fluid Total Tau Is Associated with Shorter Survival in Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders, 2009, 28, 314-319.	0.7	32
748	Cerebrospinal Fluid Biomarkers Mirror Rate of Cognitive Decline. Journal of Alzheimer's Disease, 2013, 34, 949-956.	1.2	32
749	Post-cardiac arrest serum levels of glial fibrillary acidic protein for predicting neurological outcome. Resuscitation, 2014, 85, 1654-1661.	1.3	32
750	The effects of different familial Alzheimerâ€™s disease mutations on APP processing in vivo. Alzheimer's Research and Therapy, 2017, 9, 9.	3.0	32
751	Intrathecal treatment trial of rituximab in progressive MS. Neurology, 2018, 91, e1893-e1901.	1.5	32
752	Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers. PLoS ONE, 2018, 13, e0194828.	1.1	32
753	Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1556-1564.	1.4	32
754	Improved Differential Diagnosis of Alzheimerâ€™s Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2019, 67, 639-651.	1.2	32
755	Association of longitudinal white matter degeneration and cerebrospinal fluid biomarkers of neurodegeneration, inflammation and Alzheimerâ€™s disease in late-middle-aged adults. Brain Imaging and Behavior, 2019, 13, 41-52.	1.1	32
756	Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases courseâ€”a joint PhD student course at University College London and University of Gothenburg. Alzheimer's Research and Therapy, 2020, 12, 20.	3.0	32

#	Article	IF	Citations
757	AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy. Gene Therapy, 2021, 28, 659-675.	2.3	32
758	Association of Apolipoprotein E É›4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. JAMA Neurology, 2021, 78, 937.	4.5	32
759	Increased levels of total tau protein in the cerebrospinal fluid in Huntingtonâ€™s disease. Parkinsonism and Related Disorders, 2011, 17, 714-715.	1.1	31
760	The zebrafish amyloid precursor protein-b is required for motor neuron guidance and synapse formation. Developmental Biology, 2013, 381, 377-388.	0.9	31
761	Î²-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces AÎ²5-X peptides through alternative amyloid precursor protein cleavage. Alzheimer's Research and Therapy, 2014, 6, 75.	3.0	31
762	Inflammation, Amyloid, and Atrophy in The Aging Brain: Relationships with Longitudinal Changes in Cognition. Journal of Alzheimer's Disease, 2017, 58, 829-840.	1.2	31
763	Evolution of cerebrospinal fluid total Î±-synuclein in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 49, 4-8.	1.1	31
764	Cerebrospinal Fluid S100B and Alzheimerâ€™s Disease Biomarkers in Hip Fracture Patients with Delirium. Dementia and Geriatric Cognitive Disorders Extra, 2018, 7, 374-385.	0.6	31
765	No change in plasma tau and serum neurofilament light concentrations in adolescent athletes following sport-related concussion. PLoS ONE, 2018, 13, e0206466.	1.1	31
766	Commentary: Global, regional, and national burden of neurological disorders during 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Frontiers in Neurology, 2018, 9, 201.	1.1	31
767	CSF synaptic protein concentrations are raised in those with atypical Alzheimerâ€™s disease but not frontotemporal dementia. Alzheimer's Research and Therapy, 2019, 11, 105.	3.0	31
768	Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. Neurology, 2020, 95, e3026-e3035.	1.5	31
769	Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics. Scientific Reports, 2021, 11, 22128.	1.6	31
770	The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis. Journal of Neuroimmunology, 2013, 264, 100-105.	1.1	30
771	Single Lipid Vesicle Assay for Characterizing Single-Enzyme Kinetics of Phospholipid Hydrolysis in a Complex Biological Fluid. Journal of the American Chemical Society, 2013, 135, 14151-14158.	6.6	30
772	Neurological Assessment and Its Relationship to CSF Biomarkers in Amateur Boxers. PLoS ONE, 2014, 9, e99870.	1.1	30
773	Cerebrospinal fluid analysis in Alzheimerâ€™s disease: technical issues and future developments. Journal of Neurology, 2014, 261, 1234-1243.	1.8	30
774	CSF biomarkers for Alzheimerâ€™s pathology and the effect size of APOE É›4. Molecular Psychiatry, 2014, 19, 148-149.	4.1	30

#	Article	IF	Citations
775	Evolving brain structural changes in PSEN1 mutation carriers. Neurobiology of Aging, 2015, 36, 1261-1270.	1.5	30
776	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiology of Aging, 2015, 36, 2587-2596.	1.5	30
777	Labelâ€free quantitative comparison of cerebrospinal fluid glycoproteins and endogenous peptides in subjects with Alzheimer's disease, mild cognitive impairment, and healthy individuals. Proteomics - Clinical Applications, 2016, 10, 1225-1241.	0.8	30
778	Alzheimer's disease markers in the aged sheep (Ovis aries). Neurobiology of Aging, 2017, 58, 112-119.	1.5	30
779	CSF neurogranin or tau distinguish typical and atypical Alzheimer disease. Annals of Clinical and Translational Neurology, 2018, 5, 162-171.	1.7	30
780	Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer's disease. Clinica Chimica Acta, 2019, 494, 79-93.	0.5	30
781	Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1152-1163.	3.3	30
782	GM1 locates to mature amyloid structures implicating a prominent role for glycolipid-protein interactions in Alzheimer pathology. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2019, 1867, 458-467.	1.1	30
783	Serum neurofilament light chain withstands delayed freezing and repeated thawing. Scientific Reports, 2020, 10, 19982.	1.6	30
784	Plasma neurofilament light chain as a potential biomarker in Charcotâ€Marieâ€Tooth disease. European Journal of Neurology, 2021, 28, 974-981.	1.7	30
785	Association of Early Î²-Amyloid Accumulation and Neuroinflammation Measured With [¹¹ C]PBR28 in Elderly Individuals Without Dementia. Neurology, 2021, 96, e1608-e1619.	1.5	30
786	Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases. Molecular Psychiatry, 2021, 26, 5955-5966.	4.1	30
787	Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression. PLoS ONE, 2021, 16, e0250987.	1.1	30
788	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1206-1214.	0.9	30
789	Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimerâ€™s continuum. Alzheimer's Research and Therapy, 2021, 13, 135.	3.0	30
790	Pâ€tau235: a novel biomarker for staging preclinical Alzheimerâ€™s disease. EMBO Molecular Medicine, 2021, 13, e15098.	3.3	30
791	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2022, 17, 27.	4.4	30
792	Evolving Character of Chronic Central Nervous System HIV Infection. Seminars in Neurology, 2014, 34, 007-013.	0.5	29

#	Article	IF	Citations
793	Modulation of Î²-amyloid by a single dose of GSK933776 in patients with mild Alzheimerâ€™s disease: a phase I study. Alzheimer's Research and Therapy, 2014, 6, 19.	3.0	29
794	Human cerebrospinal fluid increases the excitability of pyramidal neurons in the in vitro brain slice. Journal of Physiology, 2015, 593, 231-243.	1.3	29
795	APOE Îµ4 carriers may undergo synaptic damage conferring risk ofÂAlzheimer's disease. Alzheimer's and Dementia, 2016, 12, 1159-1166.	0.4	29
796	Blood Biomarkers for Alzheimerâ€™s Disease: Much Promise, Cautious Progress. Molecular Diagnosis and Therapy, 2017, 21, 13-22.	1.6	29
797	Blood-based cerebral biomarkers in preeclampsia: Plasma concentrations of NfL, tau, S100B and NSE during pregnancy in women who later develop preeclampsia - A nested case control study. PLoS ONE, 2018, 13, e0196025.	1.1	29
798	Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X. Human Molecular Genetics, 2019, 28, 3528-3542.	1.4	29
799	Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 768-773.	0.9	29
800	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	2.1	29
801	Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases. Alzheimer's Research and Therapy, 2020, 12, 19.	3.0	29
802	Tau aggregation and increased neuroinflammation in athletes after sports-related concussions and in traumatic brain injury patients â€“ A PET/MR study. NeuroImage: Clinical, 2021, 30, 102665.	1.4	29
803	Alzheimer's disease biomarkers in Black and nonâ€Hispanic White cohorts: A contextualized review of the evidence. Alzheimer's and Dementia, 2022, 18, 1545-1564.	0.4	29
804	Effects of Î³-Secretase Inhibition on the Amyloid Î² Isoform Pattern in a Mouse Model of Alzheimerâ€™s Disease. Neurodegenerative Diseases, 2009, 6, 258-262.	0.8	28
805	B-type natriuretic peptide plasma levels are elevated in subcortical vascular dementia. NeuroReport, 2009, 20, 825-827.	0.6	28
806	Altered Cerebrospinal Fluid Levels of Amyloid Î² and Amyloid Precursor-Like Protein 1 Peptides in Downâ€™s Syndrome. NeuroMolecular Medicine, 2014, 16, 510-516.	1.8	28
807	Intracranial arterial fourâ€dimensional flow is associated with metrics ofÂbrain health and Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 420-428.	1.2	28
808	Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-Î² Levels inÂPatients with Alzheimerâ€™s Disease?. Journal of Alzheimer's Disease, 2015, 47, 1069-1078.	1.2	28
809	A Genetic Variant of the Sortilin 1 Gene isÂAssociated with Reduced Risk ofÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 53, 1353-1363.	1.2	28
810	C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease. Scientific Reports, 2017, 7, 2477.	1.6	28

#	Article	IF	Citations
811	Expanding the cerebrospinal fluid endopeptidome. Proteomics, 2017, 17, 1600384.	1.3	28
812	Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders. Proteomics - Clinical Applications, 2017, 11, 1700100.	0.8	28
813	Plasma Markers of Neurodegeneration Are Raised in Friedreichâ€™s Ataxia. Frontiers in Cellular Neuroscience, 2018, 12, 366.	1.8	28
814	Comparison of different MRI-based morphometric estimates for defining neurodegeneration across the Alzheimer's disease continuum. NeuroImage: Clinical, 2019, 23, 101895.	1.4	28
815	Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings. Progress in Molecular Biology and Translational Science, 2019, 168, 3-23.	0.9	28
816	APOE Îµ4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 65.	3.0	28
817	Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 5989-6001.	4.1	28
818	Longitudinal brain atrophy and CSF biomarkers in early-onset Alzheimerâ€™s disease. NeuroImage: Clinical, 2021, 32, 102804.	1.4	28
819	Serum Neurofilament Light, Glial Fibrillary Acidic Protein and Tau Are Possible Serum Biomarkers for Activity of Brain Metastases and Gliomas. World Journal of Oncology, 2019, 10, 169-175.	0.6	28
820	Blood biomarkers for Alzheimer's disease and related disorders. Acta Neurologica Scandinavica, 2022, 146, 51-55.	1.0	28
821	Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease. International Journal of Alzheimer's Disease, 2010, 2010, 1-5.	1.1	27
822	A novel ARC gene polymorphism is associated with reduced risk of Alzheimerâ€™s disease. Journal of Neural Transmission, 2012, 119, 833-842.	1.4	27
823	First Administration of the Fc-Attenuated Anti-Î² Amyloid Antibody GSK933776 to Patients with Mild Alzheimerâ€™s Disease: A Randomized, Placebo-Controlled Study. PLoS ONE, 2015, 10, e0098153.	1.1	27
824	The Distribution of Apolipoprotein E Genotype Over The Adult Lifespan and in Relation to Country of Birth. American Journal of Epidemiology, 2015, 181, 214-217.	1.6	27
825	Commutability of the certified reference materials for the standardization of Î²-amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and Î²-amyloid 1-40 measurements. Clinical Chemistry and Laboratory Medicine, 2018, 56, 2058-2066.	1.4	27
826	Neuromodulation via the Cerebrospinal Fluid: Insights from Recent in Vitro Studies. Frontiers in Neural Circuits, 2018, 12, 5.	1.4	27
827	Serum Neurofilament Light Is Elevated Differentially in Older Adults with Uncomplicated Mild Traumatic Brain Injuries. Journal of Neurotrauma, 2019, 36, 2400-2406.	1.7	27
828	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	1.4	27

#	Article	IF	Citations
829	Comparing progression biomarkers in clinical trials of early Alzheimerâ€™s disease. Annals of Clinical and Translational Neurology, 2020, 7, 1661-1673.	1.7	27
830	Human plasma biomarker responses to inhalational general anaesthesia without surgery. British Journal of Anaesthesia, 2020, 125, 282-290.	1.5	27
831	Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype. Dementia and Geriatric Cognitive Disorders, 2020, 49, 56-76.	0.7	27
832	ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration. Alzheimer's and Dementia, 2021, 17, 822-830.	0.4	27
833	Seven day pre-analytical stability of serum and plasma neurofilament light chain. Scientific Reports, 2021, 11, 11034.	1.6	27
834	Plasma Neurofilament Light Chain Predicts Cognitive Progression in Prodromal and Clinical Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2021, 82, 913-919.	1.2	27
835	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathologica Communications, 2020, 8, 5.	2.4	27
836	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain, 2022, 145, 1805-1817.	3.7	27
837	Analytical aspects of molecular Alzheimerâ€™s disease biomarkers. Biomarkers in Medicine, 2012, 6, 377-389.	0.6	26
838	Extreme Stability of Chitotriosidase in Cerebrospinal Fluid makes it a Suitable Marker for Microglial Activation in Clinical Trials. Journal of Alzheimer's Disease, 2012, 32, 273-276.	1.2	26
839	Targeting Synaptic Pathology with a Novel Affinity Mass Spectrometry Approach. Molecular and Cellular Proteomics, 2014, 13, 2584-2592.	2.5	26
840	The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention. Journal of Neuroimmunology, 2014, 277, 153-159.	1.1	26
841	Preclinical Cerebrospinal Fluid and Volumetric Magnetic Resonance Imaging Biomarkers in Swedish Familial Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 1393-1402.	1.2	26
842	Genetic Variants of GSK3B are Associated with Biomarkers for Alzheimer's Disease and Cognitive Function. Journal of Alzheimer's Disease, 2015, 44, 1313-1322.	1.2	26
843	Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9â€year study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 403-411.	1.2	26
844	Binding of Human Proteins to Amyloid-Î² Protofibrils. ACS Chemical Biology, 2015, 10, 766-774.	1.6	26
845	Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 883-888.	0.9	26
846	Plasma neurofilament light chain concentration is increased in anorexia nervosa. Translational Psychiatry, 2019, 9, 180.	2.4	26

#	Article	IF	Citations
847	Accelerated neuronal and synaptic maturation by BrainPhys medium increases AÎ² secretion and alters AÎ² peptide ratios from iPSC-derived cortical neurons. Scientific Reports, 2020, 10, 601.	1.6	26
848	Plasma NfL, clinical subtypes and motor progression in Parkinson's disease. Parkinsonism and Related Disorders, 2021, 87, 41-47.	1.1	26
849	Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: A realâ€world investigation. Journal of Neurochemistry, 2021, 159, 618-628.	2.1	26
850	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.4	26
851	High Education May Offer Protection Against Tauopathy in Patients with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2010, 21, 221-228.	1.2	25
852	Miglustat Treatment May Reduce Cerebrospinal Fluid Levels of the Axonal Degeneration Marker Tau in Niemannâ€“Pick Type C. JIMD Reports, 2011, 3, 45-52.	0.7	25
853	Levels of cerebrospinal fluid neurofilament light protein in healthy elderly vary as a function of TOMM40 variants. Experimental Gerontology, 2012, 47, 347-352.	1.2	25
854	Cerebrospinal fluid biomarkers in cardiac arrest survivors. Resuscitation, 2014, 85, 227-232.	1.3	25
855	Alzheimer's disease â€" Recent biomarker developments in relation to updated diagnostic criteria. Clinica Chimica Acta, 2015, 449, 3-8.	0.5	25
856	A study on the specificity of the association between hippocampal volume and delayed primacy performance in cognitively intact elderly individuals. Neuropsychologia, 2015, 69, 1-8.	0.7	25
857	Serum visinin-like protein-1 in concussed professional ice hockey players. Brain Injury, 2015, 29, 872-876.	0.6	25
858	Cerebrospinal fluid-induced retardation of amyloid Î² aggregation correlates with Alzheimer's disease and the APOE Îµ4 allele. Brain Research, 2016, 1651, 11-16.	1.1	25
859	Cerebrospinal fluid neurogranin and TREM2 in Huntingtonâ€™s disease. Scientific Reports, 2018, 8, 4260.	1.6	25
860	CSF pro-orexin and amyloid-Î²38 expression in Alzheimer's disease and frontotemporal dementia. Neurobiology of Aging, 2018, 72, 171-176.	1.5	25
861	A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimerâ€™s Disease. Neuroscience, 2019, 420, 136-144.	1.1	25
862	Acute symptomatic seizures and epilepsy after mechanical thrombectomy. Epilepsy and Behavior, 2020, 104, 106520.	0.9	25
863	Plasma phosphorylated tau181 and neurodegeneration in Alzheimerâ€™s disease. Annals of Clinical and Translational Neurology, 2021, 8, 259-265.	1.7	25
864	Polygenic risk scores for Alzheimer's disease are related to dementia risk in APOE É›4 negatives. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12142.	1.2	25

#	Article	IF	Citations
865	Tau and neurofilament lightâ€chain as fluid biomarkers in spinocerebellar ataxia type 3. European Journal of Neurology, 2022, 29, 2439-2452.	1.7	25
866	Diagnostic value of serum versus plasma phospho-tau for Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2022, 14, 65.	3.0	25
867	Alzheimerâ€™s disease and CSF biomarkers: key challenges for broad clinical applications. Biomarkers in Medicine, 2009, 3, 735-737.	0.6	24
868	Antihypertensive Therapy Is Associated with Reduced Rate of Conversion to Alzheimer's Disease in Midregional Proatrial Natriuretic Peptide Stratified Subjects with Mild Cognitive Impairment. Biological Psychiatry, 2011, 70, 145-151.	0.7	24
869	Proficiency testing programs for Alzheimerâ€™s disease cerebrospinal fluid biomarkers. Biomarkers in Medicine, 2012, 6, 401-407.	0.6	24
870	Increased Levels of Inflammatory Immune Mediators in Vitreous From Pseudophakic Eyes. , 2015, 56, 3407.		24
871	Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 59, 1017-1026.	1.2	24
872	The chitinases expression is related to Simian Immunodeficiency Virus Encephalitis (SIVE) and in HIV encephalitis (HIVE). Virus Research, 2017, 227, 220-230.	1.1	24
873	Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-BarrÃ© syndrome: A pilot study. Acta Neurologica Scandinavica, 2018, 138, 143-150.	1.0	24
874	Socioeconomic status, gender and dementia: The influence of work environment exposures and their interactions with APOE Ɛ›4. SSM - Population Health, 2018, 5, 171-179.	1.3	24
875	Cerebrospinal fluid biomarkers of neurofibrillary tangles and synaptic dysfunction are associated with longitudinal decline in white matter connectivity: A multi-resolution graph analysis. NeuroImage: Clinical, 2019, 21, 101586.	1.4	24
876	Association of Aortic Stiffness With Biomarkers of Neuroinflammation, Synaptic Dysfunction, and Neurodegeneration. Neurology, 2021, 97, e329-e340.	1.5	24
877	Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury. Journal of Immunology, 2021, 207, 90-100.	0.4	24
878	Plasma proteins, cognitive decline, and 20â€year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies. Alzheimer's and Dementia, 2022, 18, 612-624.	0.4	24
879	Neuroimaging and biomarker evidence of neurodegeneration in asthma. Journal of Allergy and Clinical Immunology, 2022, 149, 589-598.e6.	1.5	24
880	RIPOSTE: a framework for improving the design and analysis of laboratory-based research. ELife, 2015, 4, .	2.8	24
881	Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings. Alzheimer's and Dementia, 2022, 18, 2218-2233.	0.4	24
882	Slowing gait speed precedes cognitive decline by several years. Alzheimer's and Dementia, 2022, 18, 1667-1676.	0.4	24

#	Article	IF	Citations
883	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.4	24
884	Biofluidâ€based biomarkers for Alzheimer's diseaseâ€“related pathologies: An update and synthesis of the literature. Alzheimer's and Dementia, 2022, 18, 1687-1693.	0.4	24
885	Testâ€retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models. Alzheimer's and Dementia, 2023, 19, 797-806.	0.4	24
886	Comparative analytical performance of multiple plasma AÎ²42 and AÎ²40 assays and their ability to predict positron emission tomography amyloid positivity. Alzheimer's and Dementia, 2023, 19, 956-966.	0.4	24
887	Biomarkers for Microglial Activation in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-5.	1.1	23
888	Blood biomarkers indicate mild neuroaxonal injury and increased amyloidÎ²production after transient hypoxia during breath-hold diving. Brain Injury, 2016, 30, 1226-1230.	0.6	23
889	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimerâ€™s Disease: Analytical and Diagnostic Characterization. Journal of Alzheimer's Disease, 2016, 55, 159-170.	1.2	23
890	Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study. BMC Infectious Diseases, 2016, 16, 176.	1.3	23
891	Effect of physical exercise on markers of neuronal dysfunction in cerebrospinal fluid in patients with Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 284-290.	1.8	23
892	Impaired synaptic function is linked to cognition in Parkinson's disease. Annals of Clinical and Translational Neurology, 2017, 4, 700-713.	1.7	23
893	Induction of Amyloid-Î²42 Production by Fipronil and Other Pyrazole Insecticides. Journal of Alzheimer's Disease, 2018, 62, 1663-1681.	1.2	23
894	AÎ²42/AÎ²40 and AÎ²42/AÎ²38 Ratios Are Associated with Measures of Gait Variability and Activities of Daily Living in Mild Alzheimerâ€™s Disease: A Pilot Study. Journal of Alzheimer's Disease, 2018, 65, 1377-1383.	1.2	23
895	Atrial fibrillation increases the risk of dementia amongst older adults even in the absence of stroke. Journal of Internal Medicine, 2019, 286, 101-110.	2.7	23
896	Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 740-746.	0.9	23
897	Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease. Neurobiology of Aging, 2019, 79, 131-141.	1.5	23
898	Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. Alzheimer's Research and Therapy, 2020, 12, 147.	3.0	23
899	Predicting neurological outcome after out-of-hospital cardiac arrest with cumulative information; development and internal validation of an artificial neural network algorithm. Critical Care, 2021, 25, 83.	2.5	23
900	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. Alzheimer's and Dementia, 2021, 17, 1628-1640.	0.4	23

#	Article	IF	Citations
901	Plasma neurofilament light protein correlates with diffusion tensor imaging metrics in frontotemporal dementia. PLoS ONE, 2020, 15, e0236384.	1.1	23
902	A case series on the value of tau and neurofilament protein levels to predict and detect delirium in cardiac surgery patients. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2019, 163, 241-246.	0.2	23
903	Neurofilament Light Regulates Axon Caliber, Synaptic Activity, and Organelle Trafficking in Cultured Human Motor Neurons. Frontiers in Cell and Developmental Biology, 2021, 9, 820105.	1.8	23
904	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: More to Come?. Journal of Alzheimer's Disease, 2012, 33, S361-S369.	1.2	22
905	Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies. International Journal of Geriatric Psychiatry, 2013, 28, 738-744.	1.3	22
906	Automated cerebrospinal fluid cell count â€" New reference ranges and evaluation of its clinical use in central nervous system infections. Clinical Biochemistry, 2014, 47, 25-30.	0.8	22
907	Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis. Journal of the Neurological Sciences, 2015, 358, 201-206.	0.3	22
908	Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry. Clinical Proteomics, 2016, 13, 4.	1.1	22
909	Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals. Journal of NeuroVirology, 2017, 23, 106-112.	1.0	22
910	Preclinical effects of APOE Îµ4 on cerebrospinal fluid AÎ²42 concentrations. Alzheimer's Research and Therapy, 2017, 9, 87.	3.0	22
911	Increase of neuronal injury markers Tau and neurofilament light proteins in umbilical blood after intrapartum asphyxia. Journal of Maternal-Fetal and Neonatal Medicine, 2018, 31, 2468-2472.	0.7	22
912	Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection. Journal of Neuroinflammation, 2019, 16, 16.	3.1	22
913	Differential effects of neurodegeneration biomarkers on subclinical cognitive decline. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 129-138.	1.8	22
914	Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 3.	3.0	22
915	Cerebrospinal Fluid Levels of Neurogranin in Parkinsonian Disorders. Movement Disorders, 2020, 35, 513-518.	2.2	22
916	Plasma glial fibrillary acidic protein and neurofilament light chain, but not tau, are biomarkers of sports-related mild traumatic brain injury. Brain Communications, 2020, 2, fcaa137.	1.5	22
917	Contribution of CSF biomarkers to earlyâ€onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures. Human Brain Mapping, 2020, 41, 2004-2013.	1.9	22
918	Cardiac Surgery is Associated with Biomarker Evidence of Neuronal Damage. Journal of Alzheimer's Disease, 2020, 74, 1211-1220.	1.2	22

#	Article	IF	Citations
919	Decrease in sleep depth is associated with higher cerebrospinal fluid neurofilament light levels in patients with Alzheimerâ€™s disease. Sleep, 2021, 44, .	0.6	22
920	Following spatial AÎ² aggregation dynamics in evolving Alzheimerâ€™s disease pathology by imaging stable isotope labeling kinetics. Science Advances, 2021, 7, .	4.7	22
921	Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 875-887.	0.4	22
922	Neurofilament light predicts neurological outcome after subarachnoid haemorrhage. Brain, 2021, 144, 761-768.	3.7	22
923	CSF biomarkers and plasma pâ€tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design. Alzheimer's and Dementia, 2022, 18, 2614-2626.	0.4	22
924	Inflammation, tau pathology, and synaptic integrity associated with sleep spindles and memory prior to Î²-amyloid positivity. Sleep, 2022, 45, .	0.6	22
925	Methylenetetrahydrofolate Reductase Genetic Polymorphisms in Patients with Primary Open-Angle Glaucoma. Ophthalmic Genetics, 2007, 28, 47-50.	0.5	21
926	Monitoring concussion in a knocked-out boxer by CSF biomarker analysis. Knee Surgery, Sports Traumatology, Arthroscopy, 2015, 23, 2536-2539.	2.3	21
927	Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?. Journal of Alzheimer's Disease, 2016, 54, 1297-1302.	1.2	21
928	Proteomic studies of cerebrospinal fluid biomarkers of Alzheimerâ€™s disease: an update. Expert Review of Proteomics, 2017, 14, 1007-1020.	1.3	21
929	Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection. Aids, 2017, 31, 247-252.	1.0	21
930	Amyloid Î² peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 311-321.	1.2	21
931	Transient increase in CSF GAP-43 concentration after ischemic stroke. BMC Neurology, 2018, 18, 202.	0.8	21
932	Alzheimer-associated cerebrospinal fluid fragments of neurogranin are generated by Calpain-1 and prolyl endopeptidase. Molecular Neurodegeneration, 2018, 13, 47.	4.4	21
933	Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease. PLoS ONE, 2018, 13, e0193492.	1.1	21
934	Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial. Acta Neurologica Scandinavica, 2019, 139, 462-468.	1.0	21
935	Partial reduction of amyloid Î² production by Î²-secretase inhibitors does not decrease synaptic transmission. Alzheimer's Research and Therapy, 2020, 12, 63.	3.0	21
936	Neurochemical biomarkers to study CNS effects of COVIDâ€19: A narrative review and synthesis. Journal of Neurochemistry, 2021, 159, 61-77.	2.1	21

#	Article	IF	Citations
937	Ultra-Early Differential Diagnosis of Acute Cerebral Ischemia and Hemorrhagic Stroke by Measuring the Prehospital Release Rate of GFAP. Clinical Chemistry, 2021, 67, 1361-1372.	1.5	21
938	Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional study. EClinicalMedicine, 2021, 39, 101070.	3.2	21
939	C3 deficiency ameliorates the negative effects of irradiation of the young brain on hippocampal development and learning. Oncotarget, 2016, 7, 19382-19394.	0.8	21
940	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp>: A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	2.8	21
941	Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease. Current Opinion in Psychiatry, 2013, 26, 276-282.	3.1	20
942	Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer's disease. Neuroscience Letters, 2015, 609, 58-62.	1.0	20
943	The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis. Expert Review of Clinical Immunology, 2017, 13, 1143-1153.	1.3	20
944	Inhibiting the Ca 2+ Influx Induced by Human CSF. Cell Reports, 2017, 21, 3310-3316.	2.9	20
945	Low vitamin D status in relation to cardiovascular disease and mortality in Swedish women â€“ Effect of extended follow-up. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 1143-1151.	1.1	20
946	Polymorphisms in dopamine-associated genes and cognitive decline in Parkinson's disease. Acta Neurologica Scandinavica, 2018, 137, 91-98.	1.0	20
947	Expression and secretion of synaptic proteins during stem cell differentiation to cortical neurons. Neurochemistry International, 2018, 121, 38-49.	1.9	20
948	Extrinsic Amyloid-Binding Dyes for Detection of Individual Protein Aggregates in Solution. Analytical Chemistry, 2018, 90, 10385-10393.	3.2	20
949	Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study. Neuropsychobiology, 2019, 77, 13-22.	0.9	20
950	Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 35, 228-232.	0.9	20
951	Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. Alzheimer's Research and Therapy, 2019, 11, 94.	3.0	20
952	Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. Neurology, 2020, 94, e30-e41.	1.5	20
953	CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 88.	3.0	20
954	Plasma metabolites associated with biomarker evidence of neurodegeneration in cognitively normal older adults. Journal of Neurochemistry, 2021, 159, 389-402.	2.1	20

#	Article	IF	Citations
955	NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS. Multiple Sclerosis and Related Disorders, 2020, 46, 102463.	0.9	20
956	Elevated plasma neurofilament light in aging reflects brain whiteâ€matter alterations but does not predict cognitive decline or Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12050.	1.2	20
957	Interleukin 10 and Heart Fatty Acid-Binding Protein as Early Outcome Predictors in Patients With Traumatic Brain Injury. Frontiers in Neurology, 2020, 11, 376.	1.1	20
958	One-Year Prospective Study of Plasma Biomarkers From CNS in Patients With Mild Traumatic Brain Injury. Frontiers in Neurology, 2021, 12, 643743.	1.1	20
959	Cohort Analysis of the Association of Delirium Severity With Cerebrospinal Fluid Amyloid-Tau-Neurodegeneration Pathologies. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 494-501.	1.7	20
960	Preâ€analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12137.	1.2	20
961	N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. Brain, 2022, 145, 2834-2848.	3.7	20
962	Amyloid-Î² peptide 37, 38 and 40 individually and cooperatively inhibit amyloid-Î² 42 aggregation. Chemical Science, 2022, 13, 2423-2439.	3.7	20
963	Genome-Wide Association Study of Alzheimerâ€™s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimerâ€™s Disease Multimodal Biomarker Discovery Dataset. Frontiers in Aging Neuroscience, 2022, 14, 840651.	1.7	20
964	Detection of Glial Fibrillary Acidic Protein in Patient Plasma Using On-Chip Graphene Field-Effect Biosensors, in Comparison with ELISA and Single-Molecule Array. ACS Sensors, 2022, 7, 253-262.	4.0	20
965	Hippocampal-subfield microstructures and their relation to plasma biomarkers in Alzheimerâ€™s disease. Brain, 2022, 145, 2149-2160.	3.7	20
966	Converging Pathways of Chromogranin and Amyloid Metabolism in the Brain. Journal of Alzheimer's Disease, 2010, 20, 1039-1049.	1.2	19
967	Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?. Alzheimer's Research and Therapy, 2010, 2, 8.	3.0	19
968	Cerebrospinal Fluid Levels of sAPPÎ±and sAPPÎ²in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates. International Journal of Alzheimer's Disease, 2011, 2011, 1-6.	1.1	19
969	Low Cerebrospinal Fluid Sulfatide Predicts Progression of White Matter Lesions Â– The LADIS Study. Dementia and Geriatric Cognitive Disorders, 2012, 34, 61-67.	0.7	19
970	Evaluation of the Performance of Novel AÎ² Isoforms as Theragnostic Markers in Alzheimerâ€™s Disease: From the Cell to the Patient. Neurodegenerative Diseases, 2012, 10, 138-140.	0.8	19
971	CSF in Alzheimer's Disease. Advances in Clinical Chemistry, 2014, 65, 143-172.	1.8	19
972	The Expression of Transthyretin and Amyloid-Î² Protein Precursor is Altered in the Brain of Idiopathic Normal Pressure Hydrocephalus Patients. Journal of Alzheimer's Disease, 2015, 48, 959-968.	1.2	19

#	Article	IF	Citations
973	Neurogranin Levels in Cerebrospinal Fluid. JAMA Neurology, 2015, 72, 1237.	4.5	19
974	Î²-Amyloid precursor protein-b is essential for Mauthner cell development in the zebrafish in a Notch-dependent manner. Developmental Biology, 2016, 413, 26-38.	0.9	19
975	CACNA1Cpolymorphism and altered phosphorylation of tau in bipolar disorder. British Journal of Psychiatry, 2016, 208, 195-196.	1.7	19
976	Cognitive impairment in Glucocerebrosidase (GBA)â€associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles. Movement Disorders, 2017, 32, 1780-1783.	2.2	19
977	The predictive value of T-tau and AB1-42 levels in idiopathic normal pressure hydrocephalus. Acta Neurochirurgica, 2017, 159, 2293-2300.	0.9	19
978	Cerebrospinal fluid monoamine metabolite profiles in bipolar disorder, ADHD, and controls. Journal of Neural Transmission, 2017, 124, 1135-1143.	1.4	19
979	High Interferon-Î³ Uniquely in VÎ´1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis. Frontiers in Immunology, 2017, 8, 260.	2.2	19
980	Abnormal CSF amyloid-Î²42 and tau levels in hip fracture patients without dementia. PLoS ONE, 2018, 13, e0204695.	1.1	19
981	Dementia and CSFâ€biomarkers for Alzheimer's disease predict mortality after acute hip fracture. Acta Anaesthesiologica Scandinavica, 2020, 64, 93-103.	0.7	19
982	Cell stemness is maintained upon concurrent expression of RB and the mitochondrial ribosomal protein S18-2. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 15673-15683.	3.3	19
983	Dynamics of cerebrospinal fluid levels of matrix metalloproteinases in human traumatic brain injury. Scientific Reports, 2020, 10, 18075.	1.6	19
984	Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12131.	1.2	19
985	Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease. Alzheimer's Research and Therapy, 2021, 13, 86.	3.0	19
986	An amylin and calcitonin receptor agonist modulates alcohol behaviors by acting on reward-related areas in the brain. Progress in Neurobiology, 2021, 200, 101969.	2.8	19
987	Multiâ€cohort profiling reveals elevated CSF levels of brainâ€enriched proteins in Alzheimerâ€™s disease. Annals of Clinical and Translational Neurology, 2021, 8, 1456-1470.	1.7	19
988	Cognitive and Neuronal Link With Inflammation: A Longitudinal Study in People With and Without HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 617-625.	0.9	19
989	Changes in Blood Biomarkers of Brain Injury and Degeneration Following Long-Duration Spaceflight. JAMA Neurology, 2021, 78, 1525.	4.5	19
990	Characterization of the Brain Î²-Amyloid Isoform Pattern at Different Ages of Tg2576 Mice. Neurodegenerative Diseases, 2011, 8, 352-363.	0.8	18

#	Article	IF	Citations
991	Cerebrospinal fluid biomarkers in neurological diseases inÂchildren. European Journal of Paediatric Neurology, 2013, 17, 7-13.	0.7	18
992	Semagacestat's fall: where next for AD therapies?. Nature Medicine, 2013, 19, 1214-1215.	15.2	18
993	Non-neurological surgery and cerebrospinal fluid biomarkers for neuronal and astroglial integrity. Journal of Neural Transmission, 2014, 121, 649-653.	1.4	18
994	Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years. Journal of Alzheimer's Disease, 2015, 49, 733-741.	1.2	18
995	Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with AÎ²42 and influence of disease on the totalâ€AÎ²42/AÎ²40 ratio. Journal of Neurochemistry, 2015, 135, 1049-1058.	2.1	18
996	Association between APOE Genotype and Change in Physical Function in a Population-Based Swedish Cohort of Older Individuals Followed Over Four Years. Frontiers in Aging Neuroscience, 2016, 8, 225.	1.7	18
997	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. Journal of Alzheimer's Disease, 2016, 52, 51-64.	1.2	18
998	Increased levels of ascorbic acid in the cerebrospinal fluid of cognitively intact elderly patients with major depression: a preliminary study. Scientific Reports, 2017, 7, 3485.	1.6	18
999	Cerebrospinal Fluid Stanniocalcin-1 as a Biomarker for Alzheimerâ€™s Disease and Other Neurodegenerative Disorders. NeuroMolecular Medicine, 2017, 19, 154-160.	1.8	18
1000	Biomarkers in cerebrospinal fluid of patients with bipolar disorder versus healthy individuals: A systematic review. European Neuropsychopharmacology, 2018, 28, 783-794.	0.3	18
1001	Vitamin D supplementation and neurofilament light chain in multiple sclerosis. Acta Neurologica Scandinavica, 2019, 139, 172-176.	1.0	18
1002	Association of plasma YKL-40 with brain amyloid-Î² levels, memory performance, and sex in subjective memory complainers. Neurobiology of Aging, 2020, 96, 22-32.	1.5	18
1003	In the blood: biomarkers for amyloid pathology and neurodegeneration in Alzheimerâ€™s disease. Brain Communications, 2020, 2, fcaa054.	1.5	18
1004	Amyloid precursor protein-b facilitates cell adhesion during early development in zebrafish. Scientific Reports, 2020, 10, 10127.	1.6	18
1005	Cerebrospinal Fluid Levels of Interleukin-8 in Delirium, Dementia, and Cognitively Healthy Patients. Journal of Alzheimer's Disease, 2020, 73, 1363-1372.	1.2	18
1006	Neurofilament light is a biomarker of brain involvement in lupus and primary SjÃ¶grenâ€™s syndrome. Journal of Neurology, 2021, 268, 1385-1394.	1.8	18
1007	A Non-APOE Polygenic Risk Score for Alzheimerâ€™s Disease Is Associated With Cerebrospinal Fluid Neurofilament Light in a Representative Sample of Cognitively Unimpaired 70-Year Olds. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 983-990.	1.7	18
1008	Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers. Alzheimer's and Dementia, 2021, 17, 801-812.	0.4	18

#	Article	IF	Citations
1009	TREM2 expression in the brain and biological fluids in prion diseases. Acta Neuropathologica, 2021, 141, 841-859.	3.9	18
1010	Interaction of amyloid and tau on cortical microstructure in cognitively unimpaired adults. Alzheimer's and Dementia, 2022, 18, 65-76.	0.4	18
1011	Plasma ACE2 species are differentially altered in COVIDâ€19 patients. FASEB Journal, 2021, 35, e21745.	0.2	18
1012	Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment. PLoS ONE, 2017, 12, e0176760.	1.1	18
1013	Plasma pâ€tau‹sub›181‹/sub› shows stronger network association to Alzheimer's disease dementia than neurofilament light and total tau. Alzheimer's and Dementia, 2022, 18, 1523-1536.	0.4	18
1014	Cerebrospinal fluid biomarkers that reflect clinical symptoms in idiopathic normal pressure hydrocephalus patients. Fluids and Barriers of the CNS, 2022, 19, 11.	2.4	18
1015	A translatable RNAi-driven gene therapy silences PMP22/Pmp22 genes and improves neuropathy in CMT1A mice. Journal of Clinical Investigation, 2022, 132, .	3.9	18
1016	Hyperphosphorylation of tau protein in superficial CNS siderosis. Journal of the Neurological Sciences, 2008, 273, 130-132.	0.3	17
1017	The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimerâ€™s disease. AIDS Research and Therapy, 2015, 12, 23.	0.7	17
1018	Plasma amyloid Î²â€”quo vadis?. Neurobiology of Aging, 2015, 36, 2671-2673.	1.5	17
1019	Benchmarking biomarkerâ€based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem. Alzheimer's and Dementia, 2015, 11, 1470-1479.	0.4	17
1020	Total-tau and neurofilament light in CSF reflect spinal cord ischaemia after endovascular aortic repair. Neurochemistry International, 2016, 93, 1-5.	1.9	17
1021	Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies. Journal of Neuroimmunology, 2017, 306, 25-30.	1.1	17
1022	Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid Î² clearance pathway. Molecular Neurodegeneration, 2017, 12, 18.	4.4	17
1023	Low fasting serum insulin and dementia in nondiabetic women followed for 34 years. Neurology, 2018, 91, e427-e435.	1.5	17
1024	Reduced vascular endothelial growth factor levels in the cerebrospinal fluid in patients with treatment resistant major depression and the effects of electroconvulsive therapyâ€”A pilot study. Journal of Affective Disorders, 2019, 253, 449-453.	2.0	17
1025	Cerebrospinal Fluid Spermidine, Glutamine and Putrescine Predict Postoperative Delirium Following Elective Orthopaedic Surgery. Scientific Reports, 2019, 9, 4191.	1.6	17
1026	Neurofilaments in blood is a new promising preclinical biomarker for the screening of natural scrapie in sheep. PLoS ONE, 2019, 14, e0226697.	1.1	17

#	Article	IF	Citations
1027	Tau, S100B and NSE as Blood Biomarkers in Acute Cerebrovascular Events. In Vivo, 2020, 34, 2577-2586.	0.6	17
1028	Association between cerebrospinal fluid biomarkers of neuronal injury or amyloidosis and cognitive decline after major surgery. British Journal of Anaesthesia, 2021, 126, 467-476.	1.5	17
1029	Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging preâ€analytical conditions. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12145.	1.2	17
1030	Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers. Acta Neuropathologica Communications, 2021, 9, 19.	2.4	17
1031	Signs of neuroaxonal injury in preeclampsiaâ€"A case control study. PLoS ONE, 2021, 16, e0246786.	1.1	17
1032	Prediction of Outcome After Endovascular Embolectomy in Anterior Circulation Stroke Using Biomarkers. Translational Stroke Research, 2022, 13, 65-76.	2.3	17
1033	Biomarkers of Cerebral Injury for Prediction of Postoperative Cognitive Dysfunction in Patients Undergoing Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 125-132.	0.6	17
1034	Blood Biomarkers for Alzheimerâ€™s Disease in Down Syndrome. Journal of Clinical Medicine, 2021, 10, 3639.	1.0	17
1035	Association of deranged cerebrovascular reactivity with brain injury following cardiac arrest: a post-hoc analysis of the COMACARE trial. Critical Care, 2021, 25, 350.	2.5	17
1036	Sulfatide in health and disease. The evaluation of sulfatide in cerebrospinal fluid as a possible biomarker for neurodegeneration. Molecular and Cellular Neurosciences, 2021, 116, 103670.	1.0	17
1037	Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2. Brain Communications, 2021, 3, fcab141.	1.5	17
1038	The global Alzheimer's Association round robin study on plasma amyloid Î² methods. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12242.	1.2	17
1039	Neurochemical Markers of Traumatic Brain Injury: Relevance to Acute Diagnostics, Disease Monitoring, and Neuropsychiatric Outcome Prediction. Biological Psychiatry, 2022, 91, 405-412.	0.7	17
1040	Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimerâ€™s dementia in mild cognitive impairment patients. Alzheimer's Research and Therapy, 2022, 14, 46.	3.0	17
1041	Structural amyloid plaque polymorphism is associated with distinct lipid accumulations revealed by trapped ion mobility mass spectrometry imaging. Journal of Neurochemistry, 2022, 160, 482-498.	2.1	17
1042	Is Plasma Amyloid-β a Reliable Biomarker for Alzheimers Disease?. Recent Patents on CNS Drug Discovery, 2008, 3, 109-111.	0.9	16
1043	Future Screening for Incipient Alzheimerâ€™s Disease â€“ The Influence of Prevalence on Test Performance. European Neurology, 2009, 62, 200-203.	0.6	16
1044	cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases. International Journal of Alzheimer's Disease, 2010, 2010, 1-12.	1.1	16

#	Article	IF	Citations
1045	Neurochemical Evidence of Potential Neurotoxicity After Prophylactic Cranial Irradiation. International Journal of Radiation Oncology Biology Physics, 2014, 89, 607-614.	0.4	16
1046	Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 440-446.	1.2	16
1047	Neuromodulation of fastâ€spiking and nonâ€fastâ€spiking hippocampal CA1 interneurons by human cerebrospinal fluid. Journal of Physiology, 2016, 594, 937-952.	1.3	16
1048	No diurnal variation of classical and candidate biomarkers of Alzheimerâ€™s disease in CSF. Molecular Neurodegeneration, 2016, 11, 65.	4.4	16
1049	Cerebrospinal fluid microglia and neurodegenerative markers in twins concordant and discordant for psychotic disorders. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 391-402.	1.8	16
1050	Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 72, 525-535.	1.2	16
1051	Increased Secondary Nucleation Underlies Accelerated Aggregation of the Four-Residue N-Terminally Truncated AÎ²42 Species AÎ²5â€“42. ACS Chemical Neuroscience, 2019, 10, 2374-2384.	1.7	16
1052	Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration. Neurobiology of Disease, 2020, 134, 104645.	2.1	16
1053	Î²-Secretase1 biological markers for Alzheimerâ€™s disease: state-of-art of validation and qualification. Alzheimer's Research and Therapy, 2020, 12, 130.	3.0	16
1054	Earliest amyloid and tau deposition modulate the influence of limbic networks during closed-loop hippocampal downregulation. Brain, 2020, 143, 976-992.	3.7	16
1055	Association of Depressive Symptoms With Postoperative Delirium and CSF Biomarkers for Alzheimer's Disease Among Hip Fracture Patients. American Journal of Geriatric Psychiatry, 2021, 29, 1212-1221.	0.6	16
1056	Acute hyperglycaemia leads to altered frontal lobe brain activity and reduced working memory in type 2 diabetes. PLoS ONE, 2021, 16, e0247753.	1.1	16
1057	Plasma amyloid-Î² ratios in autosomal dominant Alzheimerâ€™s disease: the influence of genotype. Brain, 2021, 144, 2964-2970.	3.7	16
1058	Plasma Proteomic Biomarkers Relating to Alzheimerâ€™s Disease: A Meta-Analysis Based on Our Own Studies. Frontiers in Aging Neuroscience, 2021, 13, 712545.	1.7	16
1059	Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12099.	1.2	16
1060	A longitudinal and crossâ€sectional study of plasma neurofilament light chain concentration in <scp>Charcotâ€Marieâ€Tooth</scp> disease. Journal of the Peripheral Nervous System, 2022, 27, 50-57.	1.4	16
1061	Cerebrospinal fluid catecholamines in Alzheimerâ€™s disease patients with and without biological disease. Translational Psychiatry, 2022, 12, 151.	2.4	16
1062	Alzheimerâ€™s Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients. Dementia and Geriatric Cognitive Disorders, 2022, 51, 182-192.	0.7	16

#	Article	IF	Citations
1063	Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimerâ€™s continuum. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4567-4579.	3.3	16
1064	Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease. Alzheimer's Research and Therapy, 2010, 2, 32.	3.0	15
1065	No Association of LOXL1 Gene Polymorphisms with Alzheimerâ€™s Disease. NeuroMolecular Medicine, 2011, 13, 160-166.	1.8	15
1066	Imatinib treatment and AÎ²42 in humans. Alzheimer's and Dementia, 2014, 10, S374-80.	0.4	15
1067	Neural and Nonneural Contributions to Wrist Rigidity in Parkinsonâ€™s Disease: An Explorative Study Using the NeuroFlexor. BioMed Research International, 2015, 2015, 1-8.	0.9	15
1068	Beneficial effects of increased lysozyme levels in Alzheimer's disease modelled in Drosophila melanogaster. FEBS Journal, 2016, 283, 3508-3522.	2.2	15
1069	A single dose of the Î³-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans. Alzheimer's Research and Therapy, 2016, 8, 11.	3.0	15
1070	Fluid biomarkers for microglial activation and axonal injury in multiple sclerosis. Acta Neurologica Scandinavica, 2017, 136, 15-17.	1.0	15
1071	Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimerâ€™s disease, and neuronal injury in humans: a cohort study. Journal of Neuroinflammation, 2017, 14, 193.	3.1	15
1072	Intracranial Arterial 4D Flow in Individuals with Mild Cognitive Impairment is Associated with Cognitive Performance and Amyloid Positivity. Journal of Alzheimer's Disease, 2017, 60, 243-252.	1.2	15
1073	Effects of APOE Îµ4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. Neurobiology of Aging, 2018, 71, 81-90.	1.5	15
1074	Growth factors and neurotrophins in patients with stress-related exhaustion disorder. Psychoneuroendocrinology, 2019, 109, 104415.	1.3	15
1075	HOTMAQ: A Multiplexed Absolute Quantification Method for Targeted Proteomics. Analytical Chemistry, 2019, 91, 2112-2119.	3.2	15
1076	Fluidâ€based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases. Journal of Neurochemistry, 2019, 151, 417-434.	2.1	15
1077	Chemical imaging of evolving amyloid plaque pathology and associated AÎ² peptide aggregation in a transgenic mouse model of Alzheimerâ€™s disease. Journal of Neurochemistry, 2020, 152, 602-616.	2.1	15
1078	CSF sTREM2 and Tau Work Together in Predicting Increased Temporal Lobe Atrophy in Older Adults. Cerebral Cortex, 2020, 30, 2295-2306.	1.6	15
1079	Cerebrospinal fluid biomarkers of brain injury, inflammation and synaptic autoimmunity predict long-term neurocognitive outcome in herpes simplex encephalitis. Clinical Microbiology and Infection, 2020, 27, 1131-1136.	2.8	15
1080	A multi-center study of neurofilament assay reliability and inter-laboratory variability. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 452-458.	1.1	15

#	Article	IF	Citations
1081	Evaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption. Journal of Antimicrobial Chemotherapy, 2020, 75, 1311-1320.	1.3	15
1082	Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LCâ€“MS/MS Reference Method. Clinical Chemistry, 2020, 66, 587-597.	1.5	15
1083	Baseline Results: The Association Between Cardiovascular Risk and Preclinical Alzheimerâ€™s Disease Pathology (ASCEND) Study. Journal of Alzheimer's Disease, 2020, 75, 109-117.	1.2	15
1084	Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease. Movement Disorders, 2021, 36, 503-508.	2.2	15
1085	Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in the Serum and Cerebrospinal Fluid of Patients With Coronavirus Disease 2019 and Neurological Symptoms. Journal of Infectious Diseases, 2022, 225, 965-970.	1.9	15
1086	Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. Brain Communications, 2021, 3, fcab073.	1.5	15
1087	Analysis of Brain Injury Biomarker Neurofilament Light and Neurodevelopmental Outcomes and Retinopathy of Prematurity Among Preterm Infants. JAMA Network Open, 2021, 4, e214138.	2.8	15
1088	Postoperative troponin increases after noncardiac surgery are associated with raised neurofilament light: a prospective observational cohort study. British Journal of Anaesthesia, 2021, 126, 791-798.	1.5	15
1089	<scp>CSF</scp> Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in <scp>PD</scp> and <scp>DLB</scp>. Movement Disorders, 2021, 36, 2595-2604.	2.2	15
1090	Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial. Journal of Alzheimer's Disease, 2021, 83, 1703-1715.	1.2	15
1091	The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimerâ€™s disease patients. Alzheimer's Research and Therapy, 2021, 13, 161.	3.0	15
1092	Interactions between dietary patterns and genetic factors in relation to incident dementia among 70-year-olds. European Journal of Nutrition, 2022, 61, 871-884.	1.8	15
1093	Ante-mortem plasma phosphorylated tau (181) predicts Alzheimerâ€™s disease neuropathology and regional tau at autopsy. Brain, 2022, 145, 3546-3557.	3.7	15
1094	Problems associated with fluid biomarkers for Parkinsonâ€™s disease. Biomarkers in Medicine, 2010, 4, 671-681.	0.6	14
1095	Biochemical markers in Alzheimerâ€™s disease clinical trials. Biomarkers in Medicine, 2010, 4, 91-98.	0.6	14
1096	CSF Biomarkers Correlate with Cerebral Blood Flow on SPECT in Healthy Elderly. Dementia and Geriatric Cognitive Disorders, 2012, 33, 156-163.	0.7	14
1097	Cerebrospinal fluid Î±â€synuclein levels in Parkinson's disease â€“ changed or unchanged?. European Journal of Neurology, 2014, 21, 365-367.	1.7	14
1098	Case Report of Complex Amyotrophic Lateral Sclerosis with Cognitive Impairment and Cortical Amyloid Deposition. Journal of Alzheimer's Disease, 2015, 47, 661-667.	1.2	14

#	Article	IF	Citations
1099	Specific Triazine Herbicides Induce Amyloid-Î²42 Production. Journal of Alzheimer's Disease, 2016, 54, 1593-1605.	1.2	14
1100	Multicenter immunoassay validation of cerebrospinal fluid neurofilament light: a biomarker for neurodegeneration. Bioanalysis, 2016, 8, 2243-2254.	0.6	14
1101	Apolipoprotein E Ïµ4 is positively related to spatial performance but unrelated to hippocampal volume in healthy young adults. Behavioural Brain Research, 2016, 299, 11-18.	1.2	14
1102	A Season of American Football Is Not Associated with Changes in Plasma Tau. Journal of Neurotrauma, 2017, 34, 3295-3300.	1.7	14
1103	Evolving Relevance of Neuroproteomics in Alzheimerâ€™s Disease. Methods in Molecular Biology, 2017, 1598, 101-115.	0.4	14
1104	Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive <scp>MS</scp> from relapsingâ€remitting <scp>MS</scp>. Journal of Neurochemistry, 2018, 146, 322-332.	2.1	14
1105	Chronic traumatic encephalopathy: fluid biomarkers. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 158, 323-333.	1.0	14
1106	S-[18F]THK-5117-PET and [11C]PIB-PET Imaging in Idiopathic Normal Pressure Hydrocephalus in Relation to Confirmed Amyloid-Î² Plaques and Tau in Brain Biopsies. Journal of Alzheimer's Disease, 2018, 64, 171-179.	1.2	14
1107	A comparison of biofluid cytokine markers across platform technologies: Correspondence or divergence?. Cytokine, 2018, 111, 481-489.	1.4	14
1108	Leptin deficiency reverses high metabolic state and weight loss without affecting central pathology in the R6/2 mouse model of Huntington's disease. Neurobiology of Disease, 2019, 132, 104560.	2.1	14
1109	Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate. PLoS ONE, 2019, 14, e0226276.	1.1	14
1110	Parkinsonâ€™s disease: evolution of cognitive impairment and CSF AÎ²_{1â€“42} profiles in a prospective longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 165-170.	0.9	14
1111	Fluid Biomarkers for Chronic Traumatic Encephalopathy. Seminars in Neurology, 2020, 40, 411-419.	0.5	14
1112	Serum and cerebrospinal fluid neurofilament light chain in patients with central nervous system infections caused by varicella-zoster virus. Journal of NeuroVirology, 2020, 26, 719-726.	1.0	14
1113	Lower Left Ventricular Ejection Fraction Relates to Cerebrospinal Fluid Biomarker Evidence of Neurodegeneration in Older Adults. Journal of Alzheimer's Disease, 2020, 74, 965-974.	1.2	14
1114	Postanoxic electrographic status epilepticus and serum biomarkers of brain injury. Resuscitation, 2021, 158, 253-257.	1.3	14
1115	Age-Related Tau Burden and Cognitive Deficits Are Attenuated in KLOTHO KL-VS Heterozygotes. Journal of Alzheimer's Disease, 2021, 79, 1297-1305.	1.2	14
1116	Cerebral amyloidâ€Î²2 load is associated with neurodegeneration and gliosis: Mediation by pâ€tau and interactions with risk factors early in the Alzheimer'scontinuum. Alzheimer's and Dementia, 2021, 17, 788-800.	0.4	14

#	Article	IF	Citations
1117	Growth differentiation factor 15 increases in both cerebrospinal fluid and serum during pregnancy. PLoS ONE, 2021, 16, e0248980.	1.1	14
1118	The blood biomarkers puzzle â€“ A review of protein biomarkers in neurodegenerative diseases. Journal of Neuroscience Methods, 2021, 361, 109281.	1.3	14
1119	High-throughput analysis of sulfatides in cerebrospinal fluid using automated extraction and UPLC-MS/MS. Journal of Lipid Research, 2017, 58, 1482-1489.	2.0	14
1120	Assessing Neurofilaments as Biomarkers of Neuroprotection in Progressive Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	14
1121	Serum biomarkers of brain injury after uncomplicated cardiac surgery: Secondary analysis from a randomized trial. Acta Anaesthesiologica Scandinavica, 2022, 66, 447-453.	0.7	14
1122	New developments of biofluidâ€based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 2292-2307.	0.4	14
1123	Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 1859-1870.	1.4	14
1124	Monte Carlo feature selection and rule-based models to predict Alzheimerâ€™s disease in mild cognitive impairment. Journal of Neural Transmission, 2012, 119, 821-831.	1.4	13
1125	AÎ²1-15/16 as a Potential Diagnostic Marker in Neurodegenerative Diseases. NeuroMolecular Medicine, 2013, 15, 169-179.	1.8	13
1126	Biomarker evidence for uncoupling of amyloid build-up and toxicity in Alzheimer's disease. , 2013, 9, 459-462.		13
1127	EPHA2 polymorphisms in Estonian patients with age-related cataract. Ophthalmic Genetics, 2014, 37, 1-5.	0.5	13
1128	The ACE Gene Is Associated with Late-Life Major Depression and Age at Dementia Onset in a Population-Based Cohort. American Journal of Geriatric Psychiatry, 2017, 25, 170-177.	0.6	13
1129	Low Cerebrospinal Fluid AÎ²42 and AÎ²40 are Related to White Matter Lesions in Cognitively Normal Elderly. Journal of Alzheimer's Disease, 2018, 62, 1877-1886.	1.2	13
1130	Amyloid precursor protein processing in human neurons with an allelic series of the PSEN1 intron 4 deletion mutation and total presenilin-1 knockout. Brain Communications, 2019, 1, fcz024.	1.5	13
1131	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	1.5	13
1132	Neurofilament light chain in the vitreous humor of the eye. Alzheimer's Research and Therapy, 2020, 12, 111.	3.0	13
1133	Cerebrospinal Fluid Biomarkers to Differentiate Idiopathic Normal Pressure Hydrocephalus from Subcortical Ischemic Vascular Disease. Journal of Alzheimer's Disease, 2020, 75, 937-947.	1.2	13
1134	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimerâ€™s Disease Multimodal Biomarker Discovery Cohort. Journal of Alzheimer's Disease, 2020, 74, 213-225.	1.2	13

#	Article	IF	Citations
1135	Replication study of plasma proteins relating to Alzheimer's pathology. Alzheimer's and Dementia, 2021, 17, 1452-1464.	0.4	13
1136	Amyloid-Î² positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to lower hippocampal volume. Neurobiology of Aging, 2021, 104, 24-31.	1.5	13
1137	Functional interaction of Oct transcription factors with the family of repeats in Epsteinâ€“Barr virus oriP. Journal of General Virology, 2005, 86, 1261-1267.	1.3	13
1138	Alzheimer's disease related biomarkers in bipolar disorder â€“ A longitudinal one-year case-control study. Journal of Affective Disorders, 2022, 297, 623-633.	2.0	13
1139	The extent of neuroradiological findings in COVID-19 shows correlation with blood biomarkers, Glasgow coma scale score and days in intensive care. Journal of Neuroradiology, 2022, 49, 421-427.	0.6	13
1140	GFAp and tau protein as predictors of neurological outcome after out-of-hospital cardiac arrest: A post hoc analysis of the COMACARE trial. Resuscitation, 2022, 170, 141-149.	1.3	13
1141	Apolipoprotein Epolymorphism in aneurysmal subarachnoid haemorrhage in West Sweden. Acta Neurologica Scandinavica, 2016, 133, 466-474.	1.0	12
1142	Alzheimerâ€™s Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate. Journal of Alzheimer's Disease, 2017, 58, 821-828.	1.2	12
1143	Specific patterns of whole-brain structural covariance of the anterior and posterior hippocampus in young APOE Îµ4 carriers. Behavioural Brain Research, 2017, 326, 256-264.	1.2	12
1144	No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau). Virulence, 2017, 8, 599-604.	1.8	12
1145	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiology of Aging, 2017, 49, 214.e13-214.e15.	1.5	12
1146	Dietary intervention with an Okinawan-based Nordic diet in type 2 diabetes renders decreased interleukin-18 concentrations and increased neurofilament light concentrations in plasma. Nutrition Research, 2018, 60, 13-25.	1.3	12
1147	Detection of early-stage Alzheimerâ€™s pathology using blood-based autoantibody biomarkers in elderly hip fracture repair patients. PLoS ONE, 2019, 14, e0225178.	1.1	12
1148	Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 69, 1213-1220.	1.2	12
1149	Breaking the cycle. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e562.	3.1	12
1150	The recency ratio is related to CSF amyloid beta 1â€42 levels in MCIâ€AD. International Journal of Geriatric Psychiatry, 2019, 34, 415-419.	1.3	12
1151	The impact of social networks and APOE Îµ4 on dementia among older adults: tests of possible interactions. Aging and Mental Health, 2020, 24, 395-404.	1.5	12
1152	Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. Alzheimer's Research and Therapy, 2020, 12, 8.	3.0	12

#	Article	IF	Citations
1153	The novel seizure quality index for the antidepressant outcome prediction in electroconvulsive therapy: association with biomarkers in the cerebrospinal fluid. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 911-919.	1.8	12
1154	Dextran- Versus Crystalloid-Based Prime in Cardiac Surgery: A Prospective Randomized Pilot Study. Annals of Thoracic Surgery, 2020, 110, 1541-1547.	0.7	12
1155	Neurofilamentâ€light in former athletes: a potential biomarker of neurodegeneration and progression. European Journal of Neurology, 2020, 27, 1170-1177.	1.7	12
1156	Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntingtonâ€™s disease. Scientific Reports, 2021, 11, 3481.	1.6	12
1157	Cerebrospinal fluid N-224 tau helps discriminate Alzheimerâ€™s disease from subjective cognitive decline and other dementias. Alzheimer's Research and Therapy, 2021, 13, 38.	3.0	12
1158	Neurological symptoms and blood neurofilament light levels. Acta Neurologica Scandinavica, 2021, 144, 13-20.	1.0	12
1159	Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis. , 2021, 9, e002732.		12
1160	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Frontiers in Neurology, 2021, 12, 805135.	1.1	12
1161	Development of a sensitive trial-ready poly(GP) CSF biomarker assay forC9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 761-771.	0.9	12
1162	Alzheimerâ€™s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint. Frontiers in Neuroscience, 2022, 16, 837390.	1.4	12
1163	Plasma neurofilament light chain protein as a predictor of days in delirium and deep sedation, mortality and length of stay in critically ill patients. EBioMedicine, 2022, 80, 104043.	2.7	12
1164	Plasma neuregulin 1 as a synaptic biomarker in Alzheimerâ€™s disease: a discovery cohort study. Alzheimer's Research and Therapy, 2022, 14, .	3.0	12
1165	Brain alterations in the early Alzheimerâ€™s continuum with amyloid-Î², tau, glial and neurodegeneration CSF markers. Brain Communications, 2022, 4, .	1.5	12
1166	What is a certified reference material?. Biomarkers in Medicine, 2012, 6, 369-370.	0.6	11
1167	Multiplexing and multivariate analysis in neurodegeneration. Methods, 2012, 56, 464-470.	1.9	11
1168	Update on fluid biomarkers for concussion. Concussion, 2016, 1, CNC12.	1.2	11
1169	CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers. Neurology, 2018, 90, e157-e163.	1.5	11
1170	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of Aî² species. NeuroImage: Clinical, 2018, 20, 603-610.	1.4	11

#	Article	IF	Citations
1171	Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. Alzheimer's Research and Therapy, 2018, 10, 45.	3.0	11
1172	Chemometric Strategies for Sensitive Annotation and Validation of Anatomical Regions of Interest in Complex Imaging Mass Spectrometry Data. Journal of the American Society for Mass Spectrometry, 2019, 30, 2278-2288.	1.2	11
1173	A Strategy for Discovery and Verification of Candidate Biomarkers in Cerebrospinal Fluid of Preclinical Alzheimerâ€™s Disease. Frontiers in Molecular Neuroscience, 2018, 11, 483.	1.4	11
1174	Dynamics of extracellular matrix proteins in cerebrospinal fluid and serum and their relation to clinical outcome in human traumatic brain injury. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1565-1573.	1.4	11
1175	Decreased circulating ErbB4 ectodomain fragments as a read-out of impaired signaling function in amyotrophic lateral sclerosis. Neurobiology of Disease, 2019, 124, 428-438.	2.1	11
1176	Plasma pNfH levels differentiate SBMA from ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 215-217.	0.9	11
1177	Protein aggregate formation permits millennium-old brain preservation. Journal of the Royal Society Interface, 2020, 17, 20190775.	1.5	11
1178	Thirty years after anorexia nervosa onset, serum neurofilament light chain protein concentration indicates neuronal injury. European Child and Adolescent Psychiatry, 2021, 30, 1907-1915.	2.8	11
1179	Multicentre longitudinal study of fluid and neuroimaging BIOmarkers of AXonal injury after traumatic brain injury: the BIO-AX-TBI study protocol. BMJ Open, 2020, 10, e042093.	0.8	11
1180	Herpes zoster in HIV-1 infection: The role of CSF pleocytosis in secondary CSF escape and discordance. PLoS ONE, 2020, 15, e0236162.	1.1	11
1181	Admission Levels of Total Tau and Î²-Amyloid Isoforms 1â€“40 and 1â€“42 in Predicting the Outcome of Mild Traumatic Brain Injury. Frontiers in Neurology, 2020, 11, 325.	1.1	11
1182	Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults. Neurobiology of Aging, 2020, 93, 1-15.	1.5	11
1183	Plasma glial fibrillary acidic protein and neurofilament light chain are measures of disease severity in semantic variant primary progressive aphasia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 455-456.	0.9	11
1184	Associations between mean arterial pressure during cardiopulmonary bypass and biomarkers of cerebral injury in patients undergoing cardiac surgery: secondary results from a randomized controlled trial. Interactive Cardiovascular and Thoracic Surgery, 2021, 32, 229-235.	0.5	11
1185	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12185.	1.2	11
1186	A Westernâ€style dietary pattern is associated with cerebrospinal fluid biomarker levels for preclinical Alzheimer's diseaseâ€”A populationâ€based crossâ€sectional study among 70â€yearâ€olds. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12183.	1.8	11
1187	Headâ€toâ€head comparison of amplified plasmonic exosome AÎ²42 platform and singleâ€molecule array immunoassay in a memory clinic cohort. European Journal of Neurology, 2021, 28, 1479-1489.	1.7	11
1188	Brain injury markers in new-onset seizures in adults: A pilot study. Seizure: the Journal of the British Epilepsy Association, 2021, 92, 62-67.	0.9	11

#	Article	IF	Citations
1189	Differential chemokine alteration in the variants of primary progressive aphasiaâ€"a role for neuroinflammation. Journal of Neuroinflammation, 2021, 18, 224.	3.1	11
1190	Concussion and longâ€term cognitive function among rugby playersâ€"The BRAIN Study. Alzheimer's and Dementia, 2022, 18, 1164-1176.	0.4	11
1191	Evidence of Neuroinflammation and Bloodâ€"Brain Barrier Disruption in Women with Preeclampsia and Eclampsia. Cells, 2021, 10, 3045.	1.8	11
1192	Association of APOE É›4 and Plasma p-tau181 with Preclinical Alzheimerâ€™s Disease and Longitudinal Change in Hippocampus Function. Journal of Alzheimer's Disease, 2022, 85, 1309-1320.	1.2	11
1193	Plasma and CSF NfL are differentially associated with biomarker evidence of neurodegeneration in a communityâ€based sample of 70â€yearâ€olds. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12295.	1.2	11
1194	VALZâ€Pilot: Highâ€dose valacyclovir treatment in patients with earlyâ€stage Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12264.	1.8	11
1195	A Longitudinal Study of Plasma <scp>pTau181</scp> in Mild Cognitive Impairment with Lewy Bodies and Alzheimer's Disease. Movement Disorders, 2022, 37, 1495-1504.	2.2	11
1196	Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2022, 14, .	3.0	11
1197	Memory in individuals with mild cognitive impairment in relation to APOE and CSF AÎ²42. International Psychogeriatrics, 2010, 22, 598-606.	0.6	10
1198	The ELISA-Measured Increase in Cerebrospinal Fluid Tau that Discriminates Alzheimer's Disease from other Neurodegenerative Disorders is not Attributable to Differential Recognition of Tau Assembly Forms. Journal of Alzheimer's Disease, 2013, 33, 923-928.	1.2	10
1199	Cerebrospinal fluid levels of insulin, leptin, and agoutiâ€related protein in relation to BMI in pregnant women. Obesity, 2016, 24, 1299-1304.	1.5	10
1200	The recency ratio is associated with reduced CSF glutamate in late-life depression. Neurobiology of Learning and Memory, 2017, 141, 14-18.	1.0	10
1201	Genetic Variation in FOXO3 is Associated with Self-Rated Health in a Population-Based Sample of Older Individuals. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 1453-1458.	1.7	10
1202	Tauomics and Kinetics in Human Neurons and Biological Fluids. Neuron, 2018, 97, 1202-1205.	3.8	10
1203	The anti-asthmatic drug, montelukast, modifies the neurogenic potential in the young healthy and irradiated brain. Cell Death and Disease, 2018, 9, 775.	2.7	10
1204	High Serum Serotonin Predicts Increased Risk for Hip Fracture and Nonvertebral Osteoporotic Fractures: The MrOS Sweden Study. Journal of Bone and Mineral Research, 2018, 33, 1560-1567.	3.1	10
1205	Inflammatory markers of CHMP2B-mediated frontotemporal dementia. Journal of Neuroimmunology, 2018, 324, 136-142.	1.1	10
1206	Cerebrospinal fluid neurofilament light is associated with survival in mitochondrial disease patients. Mitochondrion, 2019, 46, 228-235.	1.6	10

#	Article	IF	Citations
1207	Complement component 3 levels in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder. Biomarkers in Neuropsychiatry, 2019, 1, 100007.	0.7	10
1208	Plasma pyroglutamateâ€modified amyloid beta differentiates amyloid pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12029.	1.2	10
1209	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic dysfunction, and axonal injury relate to atrophy in structural brain regions specific to Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 883-895.	0.4	10
1210	CSF Î±-synuclein correlates with CSF neurogranin in late-life depression. International Journal of Neuroscience, 2021, 131, 357-361.	0.8	10
1211	Brevican and Neurocan Peptides as Potential Cerebrospinal Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 79, 729-741.	1.2	10
1212	Parkinsonâ€™s disease with restless legs syndromeâ€”an in vivo corneal confocal microscopy study. Npj Parkinson's Disease, 2021, 7, 4.	2.5	10
1213	Plasma Î²â€secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. Alzheimer's and Dementia, 2021, 17, 629-640.	0.4	10
1214	Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2021, 80, 1629-1642.	1.2	10
1215	Plasma neurofilament light chain levels predict improvement in late phase after stroke. European Journal of Neurology, 2021, 28, 2218-2228.	1.7	10
1216	Lumbar and ventricular CSF concentrations of extracellular matrix proteins before and after shunt surgery in idiopathic normal pressure hydrocephalus. Fluids and Barriers of the CNS, 2021, 18, 23.	2.4	10
1217	Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study. Multiple Sclerosis Journal, 2022, 28, 872-884.	1.4	10
1218	Effects of Peroral Omega-3 Fatty Acid Supplementation on Cerebrospinal Fluid Biomarkers in Patients with Alzheimerâ€™s Disease: A Randomized Controlled Trialâ€”The OmegAD Study. Journal of Alzheimer's Disease, 2021, 83, 1291-1301.	1.2	10
1219	Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives. Australian and New Zealand Journal of Psychiatry, 2022, 56, 1295-1305.	1.3	10
1220	Exploring common genetic contributors to neuroprotection from amyloid pathology. Brain Communications, 2022, 4, fcac066.	1.5	10
1221	Differences Between Plasma and Cerebrospinal Fluid p-tau181 and p-tau231 in Early Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 87, 991-997.	1.2	10
1222	Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimerâ€™s disease biomarkers. Clinical Proteomics, 2022, 19, 13.	1.1	10
1223	Association of Plasma Biomarker Levels With Their CSF Concentration and the Number and Severity of Concussions in Professional Athletes. Neurology, 2022, 99, .	1.5	10
1224	Neurological Involvement in COVID-19 Among Non-Hospitalized Adolescents and Young Adults. Frontiers in Neurology, 0, 13, .	1.1	10

#	Article	IF	Citations
1225	Biological CSF Markers of Alzheimer's Disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 261-268.	1.0	9
1226	Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease. International Journal of Alzheimer's Disease, 2010, 2010, 1-3.	1.1	9
1227	APLP1 as a cerebrospinal fluid biomarker for Î³-secretase modulator treatment. Alzheimer's Research and Therapy, 2015, 7, 77.	3.0	9
1228	Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression. Journal of Antimicrobial Chemotherapy, 2015, 70, 1513-1516.	1.3	9
1229	Serum erythropoietin and outcome after ischaemic stroke: a prospective study. BMJ Open, 2016, 6, e009827.	0.8	9
1230	Cerebrospinal fluid viral load and biomarkers of neuronal and glial cells in Ramsay Hunt syndrome. European Journal of Neuroscience, 2016, 44, 2944-2949.	1.2	9
1231	BRain health and healthy AgeINg in retired rugby union players, the BRAIN Study: study protocol for an observational study in the UK. BMJ Open, 2017, 7, e017990.	0.8	9
1232	Cognitive function in very old men does not correlate to biomarkers of Alzheimerâ€™s disease. BMC Geriatrics, 2017, 17, 208.	1.1	9
1233	Cerebrospinal fluid in the dementias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 146, 85-97.	1.0	9
1234	Central and peripheral leptin and agoutiâ€related protein during and after pregnancy in relation to weight change. Clinical Endocrinology, 2018, 88, 263-271.	1.2	9
1235	The presubiculum is preserved from neurodegenerative changes in Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2018, 6, 62.	2.4	9
1236	Midlife Stress in Relation to Late-Life Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Disease: A 25-Year Follow-Up Study. Dementia and Geriatric Cognitive Disorders, 2018, 46, 90-99.	0.7	9
1237	Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimerâ€™s disease. Clinical Mass Spectrometry, 2019, 14, 74-82.	1.9	9
1238	Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders. Current HIV/AIDS Reports, 2019, 16, 76-81.	1.1	9
1239	Cohort study of electroencephalography markers of amyloid-tau-neurodegeneration pathology. Brain Communications, 2020, 2, fcaa099.	1.5	9
1240	Is There a Value of Neurofilament Light as a Biomarker for Neurodegeneration in Parkinson's Disease?. Movement Disorders, 2020, 35, 1111-1112.	2.2	9
1241	Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?. Alzheimer's Research and Therapy, 2020, 12, 153.	3.0	9
1242	Cerebrospinal Fluid Metals and the Association with Cerebral Small Vessel Disease. Journal of Alzheimer's Disease, 2020, 78, 1229-1236.	1.2	9

#	Article	IF	Citations
1243	Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimerâ€™s Disease: A Pilot Study. Journal of Alzheimer's Disease, 2020, 76, 941-953.	1.2	9
1244	No Changes in Human Immunodeficiency Virus (HIV) Suppression and Inflammatory Markers in Cerebrospinal Fluid in Patients Randomly Switched to Dolutegravir Plus Lamivudine (Spanish HIV/AIDS) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.9	9
1245	Proinflammatory protein signatures in cryptogenic and large artery atherosclerosis stroke. Acta Neurologica Scandinavica, 2021, 143, 303-312.	1.0	9
1246	Sex differences in CSF biomarkers for neurodegeneration and bloodâ€brain barrier integrity. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12141.	1.2	9
1247	The relationship between white matter microstructure and self-perceived cognitive decline. NeuroImage: Clinical, 2021, 32, 102794.	1.4	9
1248	Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2021, 13, 46.	3.0	9
1249	Association of CSF proteins with tau and amyloid Î² levels in asymptomatic 70-year-olds. Alzheimer's Research and Therapy, 2021, 13, 54.	3.0	9
1250	Synergistic Association between Plasma AÎ²_{1â€“42} and p-tau in Alzheimerâ€™s Disease but Not in Parkinsonâ€™s Disease or Frontotemporal Dementia. ACS Chemical Neuroscience, 2021, 12, 1376-1383.	1.7	9
1251	Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population. Frontiers in Aging Neuroscience, 2021, 13, 659898.	1.7	9
1252	Characterization of monomeric and soluble aggregated AÎ² in Downâ€™s syndrome and Alzheimerâ€™s disease brains. Neuroscience Letters, 2021, 754, 135894.	1.0	9
1253	Evidence of upregulation of the cholinergic anti-inflammatory pathway in late-life depression. Journal of Affective Disorders, 2021, 286, 275-281.	2.0	9
1254	Spitting image: can saliva biomarkers reflect Alzheimer's disease?. EBioMedicine, 2021, 68, 103437.	2.7	9
1255	CSF Proteomic Alzheimerâ€™s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. Proteomes, 2021, 9, 36.	1.7	9
1256	Response to mitogenâ€activated protein kinase inhibition of neurodegeneration in Langerhans cell histiocytosis monitored by cerebrospinal fluid neurofilament light as a biomarker: a pilot study. British Journal of Haematology, 2022, 196, 248-254.	1.2	9
1257	Predicting progression and cognitive decline in amyloid-positive patients with Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2021, 13, 151.	3.0	9
1258	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Molecular Neurodegeneration, 2021, 16, 79.	4.4	9
1259	Early plasma biomarker dynamic profiles are associated with acute ischemic stroke outcomes. European Journal of Neurology, 2022, 29, 1630-1642.	1.7	9
1260	Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimerâ€™s disease CSF profile of neuronal injury and inflammation. Molecular Psychiatry, 2022, 27, 1990-1999.	4.1	9

#	Article	IF	Citations
1261	Finding Correspondence between Metabolomic Features in Untargeted Liquid Chromatographyâ€“Mass Spectrometry Metabolomics Datasets. Analytical Chemistry, 2022, 94, 5493-5503.	3.2	9
1262	Age, sex and APOE-Îµ4 modify the balance between soluble and fibrillar Î²-amyloid in non-demented individuals: topographical patterns across two independent cohorts. Molecular Psychiatry, 2022, 27, 2010-2018.	4.1	9
1263	The Karolinska NeuroCOVID study protocol: Neurocognitive impairment, biomarkers and advanced imaging in critical care survivors. Acta Anaesthesiologica Scandinavica, 2022, , .	0.7	9
1264	Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA study. Journal of NeuroVirology, 2022, 28, 54-63.	1.0	9
1265	In-Depth Site-Specific O-Glycosylation Analysis of Glycoproteins and Endogenous Peptides in Cerebrospinal Fluid (CSF) from Healthy Individuals, Mild Cognitive Impairment (MCI), and Alzheimerâ€™s Disease (AD) Patients. ACS Chemical Biology, 2022, 17, 3059-3068.	1.6	9
1266	Effect of antiretroviral treatment on blood-brain barrier integrity in HIV-1 infection. BMC Neurology, 2021, 21, 494.	0.8	9
1267	Combining biomarkers for prognostic modelling of Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 707-715.	0.9	9
1268	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. PLoS ONE, 2022, 17, e0267298.	1.1	9
1269	Reply to â€˜MTHFR C677T and A1298C polymorphisms and mutated sequences occurring in cisâ€™. European Journal of Human Genetics, 2002, 10, 579-582.	1.4	8
1270	Comment on â€œAn antidepressant decreases CSF AÎ² production in healthy individuals and in transgenic AD miceâ€•. Science Translational Medicine, 2014, 6, 268le5.	5.8	8
1271	Tau, S-100 Calcium-Binding Protein B, and Neuron-Specific Enolase as Biomarkers of Concussionâ€”Reply. JAMA Neurology, 2014, 71, 926.	4.5	8
1272	Serum 25-hydroxy vitamin D levels in middle-aged women in relationship to adiposity and height trajectories over three decades. European Journal of Clinical Nutrition, 2016, 70, 709-714.	1.3	8
1273	CSF YKLâ€40 and GAPâ€43 are related to suicidal ideation in older women. Acta Psychiatrica Scandinavica, 2017, 135, 351-357.	2.2	8
1274	Apolipoprotein E genotypes and longevity across dementia disorders. Alzheimer's and Dementia, 2018, 14, 895-901.	0.4	8
1275	Cerebrospinal fluid GAP-43 in early multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731879293.	0.5	8
1276	Enhanced xeno-free differentiation of hiPSC-derived astroglia applied in a bloodâ€“brain barrier model. Fluids and Barriers of the CNS, 2019, 16, 27.	2.4	8
1277	Cardiorespiratory Fitness Modifies Influence of Sleep Problems on Cerebrospinal Fluid Biomarkers in an At-Risk Cohort. Journal of Alzheimer's Disease, 2019, 69, 111-121.	1.2	8
1278	Sleep deprivation and plasma biomarkers for Alzheimer's disease. Sleep Medicine, 2019, 57, 92-93.	0.8	8

#	Article	IF	Citations
1279	Repeated lumbar punctures within 3Âdays may affect CSF biomarker levels. Fluids and Barriers of the CNS, 2019, 16, 37.	2.4	8
1280	Circulating levels of vascular endothelial growth factor and postâ€stroke longâ€term functional outcome. Acta Neurologica Scandinavica, 2020, 141, 405-414.	1.0	8
1281	Obinutuzumab-Induced B Cell Depletion Reduces Spinal Cord Pathology in a CD20 Double Transgenic Mouse Model of Multiple Sclerosis. International Journal of Molecular Sciences, 2020, 21, 6864.	1.8	8
1282	Admission Levels of Interleukin 10 and Amyloid Î² 1â€“40 Improve the Outcome Prediction Performance of the Helsinki Computed Tomography Score in Traumatic Brain Injury. Frontiers in Neurology, 2020, 11, 549527.	1.1	8
1283	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntingtonâ€™s disease. PLoS ONE, 2020, 15, e0233820.	1.1	8
1284	Cerebrospinal Fluid 7-Ketocholesterol Level is Associated with Amyloid-Î²42 and White Matter Microstructure in Cognitively Healthy Adults. Journal of Alzheimer's Disease, 2020, 76, 643-656.	1.2	8
1285	Cerebrospinal fluid brevican and neurocan fragment patterns in human traumatic brain injury. Clinica Chimica Acta, 2021, 512, 74-83.	0.5	8
1286	Associations between plasma neurofilament light, in vivo brain pathology, and cognition in nonâ€demented individuals with autosomalâ€dominant Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 813-821.	0.4	8
1287	Mass spectrometry analysis of tau and amyloidâ€beta in iPSCâ€derived models of Alzheimerâ€™s disease and dementia. Journal of Neurochemistry, 2021, 159, 305-317.	2.1	8
1288	Activated low-density granulocytes in peripheral and intervillous blood and neutrophil inflammation in placentas from SLE pregnancies. Lupus Science and Medicine, 2021, 8, e000463.	1.1	8
1289	Tripartite Relationship Among Synaptic, Amyloid, and Tau Proteins: An In Vivo and Postmortem Study. Neurology, 2021, , 10.1212/WNL.0000000000012145.	1.5	8
1290	Cardiac troponin T is elevated and increases longitudinally in ALS patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 58-65.	1.1	8
1291	Refining the amyloid Î² peptide and oligomer fingerprint ambiguities in Alzheimerâ€™s disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma. Journal of Neurochemistry, 2021, 159, 234-257.	2.1	8
1292	Cognitively unimpaired individuals with a low burden of AÎ² pathology have a distinct CSF biomarker profile. Alzheimer's Research and Therapy, 2021, 13, 134.	3.0	8
1293	Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimerâ€™s disease therapeutic. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 788-801.	2.4	8
1294	Comparing the effect of xenon and sevoflurane anesthesia on postoperative neural injury biomarkers: a randomized controlled trial. Medical Gas Research, 2022, 12, 10.	1.2	8
1295	Genome-wide study of immune biomarkers in cerebrospinal fluid and serum from patients with bipolar disorder and controls. Translational Psychiatry, 2020, 10, 58.	2.4	8
1296	Serum Neurofilament Light is elevated in COVID-19 Positive Adults in the ICU and is associated with Co-Morbid Cardiovascular Disease, Neurological Complications, and Acuity of Illness. Cardiology and Cardiovascular Medicine, 2021, 05, 551-565.	0.1	8

#	Article	IF	Citations
1297	Neurofilament Light in CSF and Plasma Is a Marker of Neuronal Damage in HTLV-1â€“Associated Myelopathy and Correlates With Neuroinflammation. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	8
1298	Prodromal frontotemporal dementia: clinical features and predictors of progression. Alzheimer's Research and Therapy, 2021, 13, 188.	3.0	8
1299	Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus. Journal of Neurology, 2022, 269, 3064-3074.	1.8	8
1300	Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization. Pain Reports, 2022, 7, e988.	1.4	8
1301	Crosswalk study on blood collectionâ€tube types for Alzheimer's disease biomarkers. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12266.	1.2	8
1302	Sense of Coherence Mediates the Relationship Between Cognitive Reserve and Cognition in Middle-Aged Adults. Frontiers in Psychology, 2022, 13, 835415.	1.1	8
1303	Prediction and early biomarkers of cognitive decline in Parkinson disease and atypical parkinsonism: a population-based study. Brain Communications, 2022, 4, fcac040.	1.5	8
1304	Shared CSF Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus and Subcortical Small Vessel Disease. Frontiers in Neurology, 2022, 13, 839307.	1.1	8
1305	A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging. Neurology, 2022, 99, .	1.5	8
1306	Brain disconnectome mapping derived from white matter lesions and serum neurofilament light levels in multiple sclerosis: A longitudinal multicenter study. NeuroImage: Clinical, 2022, 35, 103099.	1.4	8
1307	Biological correlates of elevated soluble TREM2 in cerebrospinal fluid. Neurobiology of Aging, 2022, 118, 88-98.	1.5	8
1308	Increased CSF-decorin predicts brain pathological changes driven by Alzheimerâ€™s AÎ² amyloidosis. Acta Neuropathologica Communications, 2022, 10, .	2.4	8
1309	The methylenetetrahydrofolate reductase C677T polymorphism is a major determinant of coffee-induced increase of plasma homocysteine: A randomized placebo controlled study. International Journal of Molecular Medicine, 2004, 13, 811.	1.8	7
1310	Update on amyloidâ€Î²homeostasis markers for sporadic Alzheimer's disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2009, 69, 18-21.	0.6	7
1311	Neurodegenerative and inflammatory biomarkers in cerebrospinal fluid in patients with Cushing's syndrome in remission. European Journal of Endocrinology, 2013, 169, 211-215.	1.9	7
1312	The relationship between cerebrospinal fluid tau markers, hippocampal volume, and delayed primacy performance in cognitively intact elderly individuals. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 81-86.	1.2	7
1313	Association between Plasma Homocysteine Levels and Neuronal Injury in HIV Infection. PLoS ONE, 2016, 11, e0158973.	1.1	7
1314	The clinical value of fluid biomarkers for dementia diagnosis â€“ Authors' reply. Lancet Neurology, The, 2016, 15, 1204-1205.	4.9	7

#	Article	IF	Citations
1315	Updating Our Definitions of Parkinsonâ€™s Disease for a Molecular Age. Journal of Parkinson's Disease, 2018, 8, S53-S57.	1.5	7
1316	Interlaboratory validation of cerebrospinal fluid Î±â€synuclein quantification in the diagnosis of sporadic Creutzfeldtâ€Jakob disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 461-470.	1.2	7
1317	Protofibrillar and Fibrillar Amyloid-Î² Binding Proteins in Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2018, 66, 1053-1064.	1.2	7
1318	Adverse Vascular Risk Relates to Cerebrospinal Fluid Biomarker Evidence of Axonal Injury in the Presence of Alzheimerâ€™s Disease Pathology. Journal of Alzheimer's Disease, 2019, 71, 281-290.	1.2	7
1319	Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection. Infectious Diseases, 2019, 51, 838-846.	1.4	7
1320	Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein. Scientific Reports, 2019, 9, 2460.	1.6	7
1321	The 12-Word Philadelphia Verbal Learning Test Performances in Older Adults: Brain MRI and Cerebrospinal Fluid Correlates and Regression-Based Normative Data. Dementia and Geriatric Cognitive Disorders Extra, 2019, 8, 476-491.	0.6	7
1322	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimerâ€™s Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368.	1.2	7
1323	Full-length and C-terminal neurogranin in Alzheimerâ€™s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays. Alzheimer's Research and Therapy, 2020, 12, 168.	3.0	7
1324	Tauopathy-Associated Tau Fragment Ending at Amino Acid 224 Is Generated by Calpain-2 Cleavage. Journal of Alzheimer's Disease, 2020, 74, 1143-1156.	1.2	7
1325	APOE-Îµ4 Shapes the Cerebral Organization in Cognitively Intact Individuals as Reflected by Structural Gray Matter Networks. Cerebral Cortex, 2020, 30, 4110-4120.	1.6	7
1326	Cerebrospinal Fluid and Plasma Lipopolysaccharide Levels in Human Immunodeficiency Virus Type 1 Infection and Associations With Inflammation, Blood-Brain Barrier Permeability, and Neuronal Injury. Journal of Infectious Diseases, 2021, 223, 1612-1620.	1.9	7
1327	Cerebrospinal fluid biomarkers of glial and axonal injury in cervical spondylotic myelopathy. Journal of Neurosurgery: Spine, 2021, 34, 1-10.	0.9	7
1328	The influence of the R47H triggering receptor expressed on myeloid cells 2 variant on microglial exosome profiles. Brain Communications, 2021, 3, fcab009.	1.5	7
1329	Effects of amyloid pathology and the APOE Îµ4 allele on the association between cerebrospinal fluid AÎ²38 and AÎ²40 and brain morphology in cognitively normal 70-years-olds. Neurobiology of Aging, 2021, 101, 1-12.	1.5	7
1330	Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment. Journal of Alzheimer's Disease, 2015, 47, 691-704.	1.2	7
1331	Sex-Specific Metabolic Pathways Were Associated with Alzheimerâ€™s Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicines, 2021, 9, 1610.	1.4	7
1332	ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease â€“ Study Protocol and Baseline Characteristics. Frontiers in Neurology, 2022, 13, 826423.	1.1	7

#	Article	IF	Citations
1333	Potential of heart fatty-acid binding protein, neurofilament light, interleukin-10 and S100 calcium-binding protein B in the acute diagnostics and severity assessment of traumatic brain injury. Emergency Medicine Journal, 2022, 39, 206-212.	0.4	7
1334	Higher levels of neurofilament light chain and total tau in CSF are associated with negative outcome after shunt surgery in patients with normal pressure hydrocephalus. Fluids and Barriers of the CNS, 2022, 19, 15.	2.4	7
1335	Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. Journal of Neural Transmission, 2022, 129, 231-237.	1.4	7
1336	Serum neurofilament light levels are correlated to long-term neurocognitive outcome measures after cardiac arrest. Brain Injury, 2022, 36, 800-809.	0.6	7
1337	Cerebral biomarkers in neurologic complications of preeclampsia. American Journal of Obstetrics and Gynecology, 2022, 227, 298.e1-298.e10.	0.7	7
1338	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2021, 17, .	0.4	7
1339	Association Between EEG Patterns and Serum Neurofilament Light After Cardiac Arrest. Neurology, 2022, 98, .	1.5	7
1340	Principal components from untargeted cerebrospinal fluid metabolomics associated with Alzheimer's disease biomarkers. Neurobiology of Aging, 2022, 117, 12-23.	1.5	7
1341	Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma. British Journal of Haematology, 2022, , .	1.2	7
1342	Association of plasma neurofilament light chain with disease activity in chronic inflammatory demyelinating polyradiculoneuropathy. European Journal of Neurology, 2022, 29, 3347-3357.	1.7	7
1343	The relationship between plasma biomarkers and amyloid PET in dementia with Lewy bodies. Parkinsonism and Related Disorders, 2022, 101, 111-116.	1.1	7
1344	Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease. International Journal of Molecular Medicine, 2007, 20, 233.	1.8	6
1345	The Szilard Hypothesis on the Nature of Aging Revisited. Genetics, 2009, 182, 3-9.	1.2	6
1346	Effects of Memantine on Cerebrospinal Fluid Biomarkers of Neurofibrillary Pathology. Journal of Alzheimer's Disease, 2009, 18, 509-513.	1.2	6
1347	Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems. International Journal of Alzheimer's Disease, 2010, 2010, 1-4.	1.1	6
1348	Complement Gene Single Nucleotide Polymorphisms and Biomarker Endophenotypes of Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 51-57.	1.2	6
1349	P1-316: The role of lysozyme in Alzheimer's disease. , 2015, 11, P477-P478.		6
1350	The APOE Genotype in Idiopathic Normal Pressure Hydrocephalus. PLoS ONE, 2016, 11, e0158985.	1.1	6

#	Article	IF	Citations
1351	Low-dose Î³-secretase inhibition increases secretion of AÎ² peptides and intracellular oligomeric AÎ². Molecular and Cellular Neurosciences, 2017, 85, 211-219.	1.0	6
1352	Validation of a new assay for Î±-synuclein detection in cerebrospinal fluid. Clinical Chemistry and Laboratory Medicine, 2017, 55, 254-260.	1.4	6
1353	Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid-Î² Concentration. Journal of Alzheimer's Disease, 2017, 56, 885-891.	1.2	6
1354	Seizures, CSF neurofilament light and tau in patients with subarachnoid haemorrhage. Acta Neurologica Scandinavica, 2018, 137, 199-203.	1.0	6
1355	A 10-Year Follow-Up of Adiposity and Dementia in Swedish Adults Aged 70 Years and Older. Journal of Alzheimer's Disease, 2018, 63, 1325-1335.	1.2	6
1356	Longstanding psychological stress in relation to biomarkers of neuronal dysfunction in cerebrospinal fluid: a 25-year follow-up study in women. Neurobiology of Aging, 2019, 80, 111-115.	1.5	6
1357	Erlangen Score Predicts Cognitive and Neuroimaging Progression in Mild Cognitive Impairment Stage of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 69, 551-559.	1.2	6
1358	APOEÎµ4 and the long arm of social inequity: estimated effects of socio-economic status and sex on the timing of dementia onset. Ageing and Society, 2019, 39, 1951-1975.	1.2	6
1359	Peptidomic analysis of cartilage and subchondral bone in OA patients. European Journal of Clinical Investigation, 2019, 49, e13082.	1.7	6
1360	Human cerebrospinal fluid promotes spontaneous gamma oscillations in the hippocampus in vitro. Hippocampus, 2020, 30, 101-113.	0.9	6
1361	Tracking the potential involvement of metabolic disease in Alzheimer's diseaseâ€”Biomarkers and beyond. International Review of Neurobiology, 2020, 154, 51-77.	0.9	6
1362	Extensive Plasmid Library to Prepare Tau Protein Variants and Study Their Functional Biochemistry. ACS Chemical Neuroscience, 2020, 11, 3117-3129.	1.7	6
1363	Neurofilament results for the phase II neuroprotection study of phenytoin in optic neuritis. European Journal of Neurology, 2021, 28, 587-594.	1.7	6
1364	Molecular forms of neurogranin in cerebrospinal fluid. Journal of Neurochemistry, 2021, 157, 816-833.	2.1	6
1365	Negligible influence of moderate to severe hyperthermia on blood-brain barrier permeability and neuronal parenchymal integrity in healthy men. Journal of Applied Physiology, 2021, 130, 792-800.	1.2	6
1366	The phosphorylation cascade hypothesis of Alzheimerâ€™s disease. Nature Aging, 2021, 1, 498-499.	5.3	6
1367	Increased immune activation and signs of neuronal injury in HIV-negative people on preexposure prophylaxis. Aids, 2021, 35, 2129-2136.	1.0	6
1368	Neurodegeneration, Alzheimer's disease biomarkers, and longitudinal verbal learning and memory performance in late middle age. Neurobiology of Aging, 2021, 102, 151-160.	1.5	6

#	Article	IF	Citations
1369	Reproductive period and preclinical cerebrospinal fluid markers for Alzheimer disease: a 25-year study. Menopause, 2021, 28, 1099-1107.	0.8	6
1370	Amyloid pathology and synaptic loss in pathological aging. Journal of Neurochemistry, 2021, 159, 258-272.	2.1	6
1371	Neurofilament light plasma concentration positively associates with age and negatively associates with weight and height in the dog. Neuroscience Letters, 2021, 744, 135593.	1.0	6
1372	Alzheimerâ€like pathology in trisomy 21 cerebral organoids amenable to pharmacological inhibition reveals BACE2 as a geneâ€doseâ€sensitive ADâ€suppressor in human brain. Alzheimer's and Dementia, 2020, 16, e043136.	0.4	6
1373	Cognitive impairment without altered levels of cerebrospinal fluid biomarkers in patients with encephalitis caused by varicella-zoster virus: a pilot study. Scientific Reports, 2020, 10, 22400.	1.6	6
1374	Differential Stimulation of Pluripotent Stem Cell-Derived Human Microglia Leads to Exosomal Proteomic Changes Affecting Neurons. Cells, 2021, 10, 2866.	1.8	6
1375	Alzheimer's Disease-Related Dementias Summit 2019: National Research Priorities for the Investigation of Traumatic Brain Injury as a Risk Factor for Alzheimer's Disease and Related Dementias. Journal of Neurotrauma, 2021, 38, 3186-3194.	1.7	6
1376	Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.4	6
1377	Cerebral Biomarkers and Blood-Brain Barrier Integrity in Preeclampsia. Cells, 2022, 11, 789.	1.8	6
1378	BACE1 gene variants do not influence BACE1 activity, levels of APP or AÎ² isoforms in CSF in Alzheimer's disease. Molecular Neurodegeneration, 2010, 5, 37.	4.4	5
1379	Do cerebrospinal fluid transfer methods affect measured amyloid Î²42, total tau, and phosphorylated tau in clinical practice?. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 380-384.	1.2	5
1380	Cerebrospinal Fluid Biomarkers are Differentially Related to Structural and Functional Changes in Dementia of the Alzheimerâ€™s Type. Journal of Alzheimer's Disease, 2018, 62, 417-427.	1.2	5
1381	Study protocol: ASCRIBED: the impact of Acute SystematiC inflammation upon cerebRospinal fluId and blood BiomarkEr s of brain inflammation and injury in dementia: a study in acute hip fracture patients. BMC Neurology, 2019, 19, 223.	0.8	5
1382	Neurogranin as a potential synaptic marker in the cerebrospinal fluid of patients with a first episode psychosis. Schizophrenia Research, 2019, 208, 490-492.	1.1	5
1383	Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis. Scientific Reports, 2019, 9, 17309.	1.6	5
1384	Quality of life of ice hockey players after retirement due to concussions. Concussion, 2020, 5, CNC78.	1.2	5
1385	Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12097.	1.2	5
1386	CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects. IBRO Reports, 2020, 8, 136-142.	0.3	5

#	Article	IF	Citations
1387	Dissecting the Structural Organization of Multiprotein Amyloid Aggregates Using a Bottom-Up Approach. ACS Chemical Neuroscience, 2020, 11, 1447-1457.	1.7	5
1388	Serumâ€neuroproteins, nearâ€infrared spectroscopy, and cognitive outcome after beachâ€chair shoulder surgery: Observational cohort study analyses. Acta Anaesthesiologica Scandinavica, 2021, 65, 26-33.	0.7	5
1389	Clinical Utility of Î²-Amyloid PET Imaging in People Living With HIV With Cognitive Symptoms. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, 826-833.	0.9	5
1390	Circulating brain injury biomarkers increase after endoscopic surgery for pituitary tumors. Journal of Clinical Neuroscience, 2021, 89, 113-121.	0.8	5
1391	Cerebrospinal fluid metallomics in cerebral amyloid angiopathy: an exploratory analysis. Journal of Neurology, 2022, 269, 1470-1475.	1.8	5
1392	Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritisâ€"a spin-off study of the NORD-STAR randomized clinical trial. Arthritis Research and Therapy, 2021, 23, 189.	1.6	5
1393	Cerebrospinal fluid proteomics targeted for central nervous system processes in bipolar disorder. Molecular Psychiatry, 2021, 26, 7446-7453.	4.1	5
1394	Extracellular fluid, cerebrospinal fluid and plasma biomarkers of axonal and neuronal injury following intracerebral hemorrhage. Scientific Reports, 2021, 11, 16950.	1.6	5
1395	Association of CSF sTREM2, a marker of microglia activation, with cholinergic basal forebrain volume in major depressive disorder. Journal of Affective Disorders, 2021, 293, 429-434.	2.0	5
1396	A genome-wide association study of plasma phosphorylated tau181. Neurobiology of Aging, 2021, 106, 304.e1-304.e3.	1.5	5
1397	Association of plasma AÎ²40/AÎ²42 ratio and brain AÎ² accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer's disease. Neurobiology of Aging, 2021, 107, 57-69.	1.5	5
1398	Serum tau concentration after diving â€“ an observational pilot study. Diving and Hyperbaric Medicine, 2019, 49, 88-95.	0.2	5
1399	Herpes Simplex Virus 1 and 2 Infections during Differentiation of Human Cortical Neurons. Viruses, 2021, 13, 2072.	1.5	5
1400	Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. Neurology: Clinical Practice, 2021, 11, 105-116.	0.8	5
1401	A Neuropsychological Perspective on Defining Cognitive Impairment in the Clinical Study of Alzheimerâ€™s Disease: Towards a More Continuous Approach. Journal of Alzheimer's Disease, 2022, 86, 511-524.	1.2	5
1402	Local Prefrontal Cortex TMS-Induced Reactivity Is Related to Working Memory and Reasoning in Middle-Aged Adults. Frontiers in Psychology, 2022, 13, 813444.	1.1	5
1403	Bloodâ€brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor proteinâ€Î² in patients with subcortical smallâ€vessel disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12296.	1.2	5
1404	Relationship between cerebrospinal fluid neurodegeneration biomarkers and temporal brain atrophy in cognitively healthy older adults. Neurobiology of Aging, 2022, 116, 80-91.	1.5	5

#	Article	IF	Citations
1405	Axonal injury in asymptomatic individuals preceding onset of multiple sclerosis. Annals of Clinical and Translational Neurology, 2022, 9, 882-887.	1.7	5
1406	Asthma amplifies dementia risk: Evidence from CSF biomarkers and cognitive decline. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	1.8	5
1407	Genotypic effects ofAPOE-Îµ4 on resting-state connectivity in cognitively intact individuals support functional brain compensation. Cerebral Cortex, 2023, 33, 2748-2760.	1.6	5
1408	New diagnostic criteria for Alzheimerâ€™s disease. Biomarkers in Medicine, 2011, 5, 407-409.	0.6	4
1409	Clinical use of cerebrospinal fluid biomarkers in Alzheimerâ€™s disease. Biomarkers in Medicine, 2012, 6, 371-376.	0.6	4
1410	Biomarker Modelling of Early Molecular Changes in Alzheimerâ€™s Disease. Molecular Diagnosis and Therapy, 2014, 18, 213-227.	1.6	4
1411	Biomarker time out. Multiple Sclerosis Journal, 2014, 20, 1560-1563.	1.4	4
1412	Quality Assessment of 25(OH)D, Insulin, Total Cholesterol, Triglycerides, and Potassium in 40-Year-Old Frozen Serum. Epidemiology Research International, 2015, 2015, 1-8.	0.2	4
1413	The impact of Tween 20 on repeatability of amyloid Î² and tau measurements in cerebrospinal fluid. Clinical Chemistry and Laboratory Medicine, 2015, 53, e329-32.	1.4	4
1414	Neurofilament Protein and Antineurofilament Antibodies Following Traumatic Brain Injuryâ€”Reply. JAMA Neurology, 2017, 74, 363.	4.5	4
1415	The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimerâ€™s disease clinical trials. Expert Review of Neurotherapeutics, 2017, 17, 767-775.	1.4	4
1416	Alterations in the Balance of Amyloid-Î² Protein Precursor Species in the Cerebrospinal Fluid of Alzheimerâ€™s Disease Patients. Journal of Alzheimer's Disease, 2017, 57, 1281-1291.	1.2	4
1417	Psychosis and biological markers. Lancet Psychiatry,the, 2017, 4, 3-5.	3.7	4
1418	Characterization of Cerebrospinal Fluid BACE1 Species. Molecular Neurobiology, 2019, 56, 8603-8616.	1.9	4
1419	Detection of Î±-Synuclein in Biological Samples Using Mass Spectrometry. Methods in Molecular Biology, 2019, 1948, 209-220.	0.4	4
1420	Twin study shows association between monocyte chemoattractant protein-1 and kynurenic acid in cerebrospinal fluid. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 933-938.	1.8	4
1421	Association of brain network dynamics with plasma biomarkers in subjective memory complainers. Neurobiology of Aging, 2020, 88, 83-90.	1.5	4
1422	Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease. Journal of Parkinson's Disease, 2020, 10, 1429-1442.	1.5	4

#	Article	IF	Citations
1423	Serum neurofilament light concentration does not increase following exposure to low velocity football heading. Science and Medicine in Football, 2021, 5, 1-7.	1.0	4
1424	CSF phosphorylated tauâ€217 is increased in Alzheimerâ€™s and Creutzfeldtâ€Jakob diseases and correlates with amyloid pathology. Alzheimer's and Dementia, 2020, 16, e045296.	0.4	4
1425	Losing the identity of a hockey player: the long-term effects of concussions. Concussion, 2020, 5, CNC74.	1.2	4
1426	Mild Cognitive Impairment Staging Yields Genetic Susceptibility, Biomarker, and Neuroimaging Differences. Frontiers in Aging Neuroscience, 2020, 12, 139.	1.7	4
1427	Cognitive Performance and Cerebrospinal Fluid Markers in Preclinical Alzheimerâ€™s Disease: Results from the Gothenburg H70 Birth Cohort Studies. Journal of Alzheimer's Disease, 2021, 79, 225-235.	1.2	4
1428	Cerebrospinal fluid CXCL10 is associated with the presence of low level CSF HIV during suppressive antiretroviral therapy. Journal of Neuroimmunology, 2021, 353, 577493.	1.1	4
1429	Cerebrospinal fluid neurofilament light levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment. F1000Research, 2021, 10, 614.	0.8	4
1430	Oligonucleotides Targeting DNA Repeats Downregulate Huntingtin Gene Expression in Huntington's Patient-Derived Neural Model System. Nucleic Acid Therapeutics, 2021, 31, 443-456.	2.0	4
1431	The localization of amyloid precursor protein to ependymal cilia in vertebrates and its role in ciliogenesis and brain development in zebrafish. Scientific Reports, 2021, 11, 19115.	1.6	4
1432	Clinical Phenotyping and Biomarkers in Spinal and Bulbar Muscular Atrophy. Frontiers in Neurology, 2020, 11, 586610.	1.1	4
1433	The Epsteinâ€“Barr virus ZEBRA protein activates transcription from the early lytic F promoter by binding to a promoter-proximal AP-1-like site. Journal of General Virology, 2002, 83, 2007-2014.	1.3	4
1434	Fluid biomarkers for disease activity in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1660-1661.	1.4	4
1435	Truncating tau reveals different pathophysiological actions of oligomers in single neurons. Communications Biology, 2021, 4, 1265.	2.0	4
1436	Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry. EBioMedicine, 2022, 75, 103793.	2.7	4
1437	Cerebrospinal Fluid Biomarkers, Brain Structural and Cognitive Performances Between Normotensive and Hypertensive Controlled, Uncontrolled and Untreated 70-Year-Old Adults. Frontiers in Aging Neuroscience, 2021, 13, 777475.	1.7	4
1438	A highâ€performance biomarker panel for Alzheimerâ€™s disease screening and staging identified by largeâ€scale plasma proteomic profiling. Alzheimer's and Dementia, 2021, 17, .	0.4	4
1439	Cerebrospinal fluid markers of central nervous system injury in decompression illness - a case-controlled pilot study. Diving and Hyperbaric Medicine, 2015, 45, 240-3.	0.2	4
1440	Serum Creatine, Not Neurofilament Light, Is Elevated in CHCHD10-Linked Spinal Muscular Atrophy. Frontiers in Neurology, 2022, 13, 793937.	1.1	4

#	Article	IF	Citations
1441	Î³â€Secretase modulators show selectivity for Î³â€secretaseâ€“mediated amyloid precursor protein intramembrane processing. Journal of Cellular and Molecular Medicine, 2022, 26, 880-892.	1.6	4
1442	NT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression. Cells, 2021, 10, 3514.	1.8	4
1443	Microglial activation and tau propagate jointly across Braak stages. Alzheimer's and Dementia, 2021, 17, .	0.4	4
1444	CSF sphingomyelin metabolites in Alzheimerâ€™s disease, neurodegeneration, and neuroinflammation. Alzheimer's and Dementia, 2021, 17, .	0.4	4
1445	Effects of age, amyloid, sex, and APOE Îµ4 on the CSF proteome in normal cognition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12286.	1.2	4
1446	Alpha-2-adrenergic receptor agonists for the prevention of delirium and cognitive decline after open heart surgery (ALPHA2PREVENT): protocol for a multicentre randomised controlled trial. BMJ Open, 2022, 12, e057460.	0.8	4
1447	Investigating the use of plasma pTau181 in retired contact sports athletes. Journal of Neurology, 2022, 269, 5582-5595.	1.8	4
1448	Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected nonâ€Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2023, 19, 807-820.	0.4	4
1449	Evaluation of Factors of Importance for Clinical Dementia Diagnosis. Dementia and Geriatric Cognitive Disorders, 2005, 19, 289-298.	0.7	3
1450	Plasma Amyloid-Î² in Patients with Tangier Disease. Journal of Alzheimer's Disease, 2013, 35, 307-312.	1.2	3
1451	Genetic Variants and Related Biomarkers in Sporadic Alzheimerâ€™s Disease. Current Genetic Medicine Reports, 2015, 3, 19-25.	1.9	3
1452	[O2â€“05â€“06]: GUT MICROBIOME ALTERATIONS IN ALZHEIMER'S DISEASE AND THE RELATIONSHIP WITH CSF BIOMARKERS. Alzheimer's and Dementia, 2017, 13, P563.	0.4	3
1453	Absolute Quantification of Aβ₁₋₄₂ in CSF Using a Mass Spectrometric Reference Measurement Procedure. Journal of Visualized Experiments, 2017, , .	0.2	3
1454	Electroconvulsive therapy does not alter the synaptic protein neurogranin in the cerebrospinal fluid of patients with major depression. Journal of Neural Transmission, 2017, 124, 1641-1645.	1.4	3
1455	[O3â€“10â€“03]: LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY. Alzheimer's and Dementia, 2017, 13, P924.	0.4	3
1456	P1â€286: TRANSFORMATION OF CSF BIOMARKER VALUES BETWEEN MEASUREMENT BATCHES. Alzheimer's and Dementia, 2018, 14, P393.	0.4	3
1457	Head trauma in sports and risk for dementia. Journal of Internal Medicine, 2019, 285, 591-593.	2.7	3
1458	Serum tau fragments as predictors of death or poor neurological outcome after out-of-hospital cardiac arrest. Biomarkers, 2019, 24, 584-591.	0.9	3

#	Article	IF	Citations
1459	Amyloid Î²42 and Total Tau Levels in Cerebrospinal Fluid Associate with Survival in an 85-Year-Old Population-Based Cohort Followed until Death. Dementia and Geriatric Cognitive Disorders, 2019, 47, 114-124.	0.7	3
1460	Serum neurofilament light and prediction of multiple sclerosis in clinically isolated syndrome. Neurology, 2019, 92, 313-314.	1.5	3
1461	Validity and Normative Data for the Biber Figure Learning Test: A Visual Supraspan Memory Measure. Assessment, 2020, 27, 1320-1334.	1.9	3
1462	Biomarkers of neuronal damage in saturation divingâ€"a controlled observational study. European Journal of Applied Physiology, 2020, 120, 2773-2784.	1.2	3
1463	Association of years to parent's sporadic onset and risk factors with neural integrity and Alzheimer biomarkers. Neurology, 2020, 95, e2065-e2074.	1.5	3
1464	Air pollution and biomarkers of Alzheimerâ€™s disease in cognitively unimpaired individuals. Alzheimer's and Dementia, 2020, 16, e044802.	0.4	3
1465	SNAP25 reflects amyloidâ€•and tauâ€•related synaptic damage: Associations between PET, VBM and cerebrospinal fluid biomarkers of synaptic disfunction in the Alzheimerâ€™s disease spectrum. Alzheimer's and Dementia, 2020, 16, e046358.	0.4	3
1466	Serum Hepcidin Levels in Cognitively Normal Older Adults with High Neocortical Amyloid-Î² Load. Journal of Alzheimer's Disease, 2020, 76, 291-301.	1.2	3
1467	Untangling the tau microtubule-binding region. Brain, 2021, 144, 359-362.	3.7	3
1468	Glial fibrillary acidic protein: a blood biomarker to differentiate neurodegenerative from psychiatric diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1253-1253.	0.9	3
1469	Enhancing the Sensitivity of Memory Tests: Reference Data for the Free and Cued Selective Reminding Test and the Logical Memory Task from Cognitively Healthy Subjects with Normal Alzheimerâ€™s Disease Cerebrospinal Fluid Biomarker Levels. Journal of Alzheimer's Disease, 2021, 84, 119-128.	1.2	3
1470	Lower plasma total tau in adolescent psychosis: Involvement of the orbitofrontal cortex. Journal of Psychiatric Research, 2021, 144, 255-261.	1.5	3
1471	Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1. Journal of Virus Eradication, 2020, 6, 19-26.	0.3	3
1472	Association between serum urate and CSF markers of Alzheimer's disease pathology in a populationâ€based sample of 70â€yearâ€olds. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12241.	1.2	3
1473	Is amyloid involved in acute neuroinflammation? A CSF analysis in encephalitis. Alzheimer's and Dementia, 2022, , .	0.4	3
1474	Isotopic N,N-dimethyl leucine tags for absolute quantification of clusterin and apolipoprotein E in Alzheimer's disease. Journal of Proteomics, 2022, 257, 104507.	1.2	3
1475	Diagnosing Alzheimerâ€™s Disease from Circulating Blood Leukocytes Using a Fluorescent Amyloid Probe. Journal of Alzheimer's Disease, 2022, 85, 1721-1734.	1.2	3
1476	CSF biomarkers for dementia. Practical Neurology, 2022, 22, 285-294.	0.5	3

#	Article	IF	Citations
1477	Cerebrospinal fluid markers of inflammation and brain injury in Lyme neuroborreliosisÂâ€“ a prospective follow-up study. Clinical Chemistry and Laboratory Medicine, 2022, 60, 1124-1132.	1.4	3
1478	Cerebrospinal fluid amyloid precursor protein as a potential biomarker of fatigue in multiple sclerosis: A pilot study. Multiple Sclerosis and Related Disorders, 2022, 63, 103846.	0.9	3
1479	Neurogranin and Neurofilament Light Chain as Preclinical Biomarkers in Scrapie. International Journal of Molecular Sciences, 2022, 23, 7182.	1.8	3
1480	Altered Balance of Reelin Proteolytic Fragments in the Cerebrospinal Fluid of Alzheimerâ€™s Disease Patients. International Journal of Molecular Sciences, 2022, 23, 7522.	1.8	3
1481	Neurochemical aftermath of amateur boxing. Scandinavian Journal of Medicine and Science in Sports, 2006, 16, 470-470.	1.3	2
1482	Identification of a Î²-amyloid-binding plasma protein, LRP1: implications for biomarker research and therapy in Alzheimerâ€™s disease. Biomarkers in Medicine, 2007, 1, 347-348.	0.6	2
1483	Unresolved questions in Alzheimerâ€™s research: will biomarkers help?. Biomarkers in Medicine, 2014, 8, 61-63.	0.6	2
1484	O1â€01â€03: Alzheimer's disease biomarkerâ€based clusters predict amyloid accumulation and cognitive decline in a preclinical cohort: Findings from the wisconsin registry for Alzheimer's prevention (WRAP). Alzheimer's and Dementia, 2015, 11, P123.	0.4	2
1485	Serum IGF-1 is higher in patients with idiopathic normal pressure hydrocephalus than in the population. Growth Hormone and IGF Research, 2015, 25, 269-273.	0.5	2
1486	Cerebral amyloid burden and Alzheimer's disease subtypes â€“ does localization information matter?. European Journal of Neurology, 2016, 23, 233-234.	1.7	2
1487	[O1â€“04â€“03]: NEIGHBORHOOD SOCIOECONOMIC CONTEXTUAL DISADVANTAGE, BASELINE COGNITION AND ALZHEIMER's DISEASE BIOMARKERS IN THE WISCONSIN REGISTRY FOR ALZHEIMER's PREVENTION (WRAP) STUDY. Alzheimer's and Dementia, 2017, 13, P195.	0.4	2
1488	[P2â€“536]: THE PREVALENCE OF PRECLINICAL ALZHEIMER's DISEASE IN A POPULATION STUDY OF 70â€YEARâ€OLDS. Alzheimer's and Dementia, 2017, 13, P848.	0.4	2
1489	Chitotriosidase: shucking the role of microglia in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 228-229.	0.9	2
1490	Screening with a high precision blood-based assay for Alzheimer disease. Neurology, 2019, 93, 10.1212/WNL.0000000000008080.	1.5	2
1491	O2â€05â€01: CEREBROSPINAL FLUID SYNAPTIC VESICLE GLYCOPROTEIN 2A IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P545.	0.4	2
1492	Reliability of serum S100B measurement following mild traumatic brain injury: a comparison of assay measurements from two laboratories. Brain Injury, 2020, 34, 1237-1244.	0.6	2
1493	Phosphoâ€tau217 and phosphoâ€tau181 in plasma and CSF as biomarkers for Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e037520.	0.4	2
1494	Correlation between cerebrospinal fluid and blood neurofilament light protein: A systematic review and metaâ€analysis. Alzheimer's and Dementia, 2020, 16, e041018.	0.4	2

#	Article	IF	Citations
1495	Aging and sex impact plasma NFL and tâ€Tau trajectories in individuals at risk for Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e041792.	0.4	2
1496	CSF NFL levels and neuroimagingâ€derived neurite density index improve prediction of MCI and dementia clinical diagnosis within the Alzheimerâ€™s pathologic framework. Alzheimer's and Dementia, 2020, 16, e043987.	0.4	2
1497	Plasma pâ€tau181 accurately predicts Alzheimerâ€™s disease pathology at least 8 years prior to postâ€mortem and improves the clinical characterisation of cognitive decline. Alzheimer's and Dementia, 2020, 16, e047539.	0.4	2
1498	Intrathecal immunoreactivity in people with or without previous infectious mononucleosis. Acta Neurologica Scandinavica, 2020, 142, 161-168.	1.0	2
1499	CXCL13 in patients with facial palsy caused by varicella zoster virus and Borrelia burgdorferi: a comparative study. Diagnostic Microbiology and Infectious Disease, 2020, 98, 115095.	0.8	2
1500	Measurement batch differences and betweenâ€batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12194.	1.2	2
1501	No neurochemical evidence of neuronal injury or glial activation in children with Paediatric Acute-onset Neuropsychiatric Syndrome. An explorative pilot study. World Journal of Biological Psychiatry, 2021, 22, 800-804.	1.3	2
1502	Cerebrospinal Fluid Concentration of Neurogranin in Hip Fracture Patients with Delirium. Journal of Alzheimer's Disease, 2021, 81, 667-677.	1.2	2
1503	CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12167.	1.2	2
1504	A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status. Journal of Visualized Experiments, 2016, , .	0.2	2
1505	Ion concentrations in cerebrospinal fluid in wakefulness, sleep and sleep deprivation in healthy humans. Journal of Sleep Research, 2022, 31, e13522.	1.7	2
1506	Functional brain activity constrained by structural connectivity reveals cohort-specific features for serum neurofilament light chain. Communications Medicine, 2022, 2, .	1.9	2
1507	Elevated Cerebrospinal Fluid Anti-CD4 Autoantibody Levels in HIV Associate with Neuroinflammation. Microbiology Spectrum, 2022, 10, e0197521.	1.2	2
1508	Cerebrospinal fluid neurofilament light chain levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment. F1000Research, 0, 10, 614.	0.8	2
1509	Multiple EBNA1-binding sites within oriP1 are required for EBNA1-dependent transactivation of the Epstein-Barr virus C promoter. International Journal of Oncology, 2004, 25, 693-6.	1.4	2
1510	Plasma Cystatin C Correlates with Plasma NfL Levels and Predicts Disease Progression in Parkinsonâ€™s Disease. Neurodegenerative Diseases, 2021, 21, 109-116.	0.8	2
1511	Decreased Electroencephalography Global Field Synchronization in Slow-Frequency Bands Characterizes Synaptic Dysfunction in Amnestic Subtypes of Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2022, 14, 755454.	1.7	2
1512	Neurochemical signs of astrocytic and neuronal injury in acute COVIDâ€19 normalizes during longâ€term followâ€up. Alzheimer's and Dementia, 2021, 17, .	0.4	2

#	Article	IF	Citations
1513	Amyloid time: Quantifying the onset of abnormal biomarkers and cognitive impairment along the Alzheimerâ€™s disease continuum. Alzheimer's and Dementia, 2021, 17, .	0.4	2
1514	Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimerâ€™s continuum. Alzheimer's and Dementia, 2021, 17, .	0.4	2
1515	Distinctive effect of biological sex in ADâ€related CSF and plasma biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.4	2
1516	Prediction of future Alzheimerâ€™s disease dementia using plasma phosphoâ€tau combined with other accessible measures. Alzheimer's and Dementia, 2021, 17, .	0.4	2
1517	Diet and APOE as moderators of the relationship between trimethylamine Nâ€oxide and biomarkers of Alzheimer's disease and glial activation. Alzheimer's and Dementia, 2021, 17, e051827.	0.4	2
1518	Plasma Neurofilament Light and p-tau181 and Risk of Psychosis in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, , 1-12.	1.5	2
1519	Blood biomarkers for HIV infection with focus on neurologic complicationsâ€”A review. Acta Neurologica Scandinavica, 2022, 146, 56-60.	1.0	2
1520	Factors influencing resilience to postoperative delirium in adults undergoing elective orthopaedic surgery. British Journal of Surgery, 0, , .	0.1	2
1521	Neurofilament Light in Cerebrospinal Fluid is Associated With Disease Staging in European Lyme Neuroborreliosis. Journal of Central Nervous System Disease, 2022, 14, 117957352210981.	0.7	2
1522	Fluid biomarkers for Alzheimerâ€™s disease: standardization and recent developments. Biomarkers in Medicine, 2012, 6, 363-364.	0.6	1
1523	P2-122: ULTRASENSITIVE DETECTION OF NEURODEGENERATIVE BIOMARKERS IN BLOOD WITH THE FULLY AUTOMATED SIMOA ANALYZER: CLINICAL APPLICATIONS. , 2014, 10, P515-P516.		1
1524	P4-004: Cardiorespiratory capacity modifies the association between a polygenic risk score and CSF biomarkers in preclinical Alzheimer's disease. , 2015, 11, P766-P766.		1
1525	IC-P-063: Alzheimer's disease biomarker-based clusters predict amyloid accumulation and cognitive decline in a preclinical cohort: Findings from the wisconsin registry for Alzheimer's prevention (WRAP). , 2015, 11, P47-P49.		1
1526	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study. , 2015, 11, P297-P297.		1
1527	Cerebrospinal Fluid Total Prion Protein. JAMA Neurology, 2015, 72, 261.	4.5	1
1528	P1-115: Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions. , 2015, 11, P384-P384.		1
1529	Laboratory Testing for Lyme Neuroborreliosis. JAMA Neurology, 2015, 72, 125.	4.5	1
1530	P3-162: Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Chain Protein in the Classification of Prodromal and Alzheimerâ€™s Disease Dementia. , 2016, 12, P881-P881.		1

#	Article	IF	Citations
1531	O1â€11â€05: CSF In the Differential Diagnosis of Alzheimer's Disease: Clinical Utility of an Extended Panel Of Biomarkers in a Specialist Cognitive Clinic. Alzheimer's and Dementia, 2016, 12, P203.	0.4	1
1532	[P4â€“182]: A NEUROBIOLOGICAL MODEL OF MEMORY IMPAIRMENT IN LATEâ€LIFE MAJOR DEPRESSIVE DISORDER. Alzheimer's and Dementia, 2017, 13, P1332.	0.4	1
1533	[P2â€“208]: CSF AND PLASMA LEVELS OF INFLAMMATION DIFFERENTIALLY RELATE TO CNS MARKERS OF ALZHEIMER'S DISEASE PATHOLOGY AND NEURONAL DAMAGE. Alzheimer's and Dementia, 2017, 13, P689.	0.4	1
1534	[P2â€“212]: EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER's DISEASE (EMIFâ€AD): THE BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2017, 13, P691.	0.4	1
1535	[O1â€“10â€“03]: BIOMARKERS OF INFLAMMATION IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P215.	0.4	1
1536	[O3â€“10â€“02]: LONGITUDINAL CSF BIOMARKER CHANGES IN MIDDLEâ€AGED ADULTS AT RISK FOR AD: THE WISCONSIN REGISTRY FOR ALZHEIMER's PREVENTION (WRAP) AND WISCONSIN ADRC COHORTS. Alzheimer's and Dementia, 2017, 13, P923.	0.4	1
1537	Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid. Journal of Visualized Experiments, 2017, , .	0.2	1
1538	Mild traumatic brain injury is associated with increased levels of axonal injury biomarkers in blood. British Journal of Sports Medicine, 2017, 51, A6.3-A7.	3.1	1
1539	Fluid Biomarkers in Alzheimerâ€™s Disease and Frontotemporal Dementia. , 2018, , 221-252.		1
1540	P3â€218: NOVEL ALZHEIMER'S DISEASE BIOMARKERâ€GUIDED DIAGNOSTIC WORKFLOW USING THE ADDED VALUE OF SIX COMBINED CEREBROSPINAL FLUID CANDIDATES: AÎ²_{1â€42}, TOTALâ€TAU, PHOSPHORYLATEDâ€TAU, NFL, NEUROGRANIN, AND YKLâ€40. Alzheimer's and Dementia, 2018, 14, P1154.	0.4	1
1541	DTâ€02â€04: DETECTING BRAIN AMYLOID STATUS USING FULLY AUTOMATED PLASMA AÎ² BIOMARKER ASSAYS. Alzheimer's and Dementia, 2018, 14, P1670.	0.4	1
1542	A tear fluid proteome of Parkinson's disease. Parkinsonism and Related Disorders, 2019, 63, 1-2.	1.1	1
1543	Disease signatures: Biomarkers/indicators of neurodegeneration. Molecular and Cellular Neurosciences, 2019, 97, 1-2.	1.0	1
1544	ICâ€Pâ€070: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN PET IN THE ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P64.	0.4	1
1545	Bloodâ€based biomarkers for Alzheimer's disease and related dementias: Keys to success and things to consider. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 784-786.	1.2	1
1546	Plasma neurofilament light in progressive multiple sclerosis. Acta Neurologica Scandinavica, 2020, 141, 14-15.	1.0	1
1547	Fatty Acid-Binding Protein 3 in Cerebrospinal Fluid of Hip Fracture Patients with Delirium. Journal of Alzheimer's Disease, 2020, 77, 183-190.	1.2	1
1548	Neurofilament light in blood â€“ What more is needed for clinical implementation in multiple sclerosis?. EBioMedicine, 2020, 57, 102826.	2.7	1

#	Article	IF	Citations
1549	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. Alzheimer's and Dementia, 2020, 16, e036954.	0.4	1
1550	Protective genetic variants in the MS4A gene cluster modulate microglial activity. Alzheimer's and Dementia, 2020, 16, e039431.	0.4	1
1551	An ultrasensitive immunoassay for detection of pâ€tau181 in blood. Alzheimer's and Dementia, 2020, 16, e041238.	0.4	1
1552	Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimerâ€™s disease in the absence of AT(N) classification as the reference standard. Alzheimer's and Dementia, 2020, 16, e041808.	0.4	1
1553	Quantification of tau phosphorylated at threonine 217 using a novel ultrasensitive immunoassay distinguishes Alzheimerâ€™s disease from healthy controls. Alzheimer's and Dementia, 2020, 16, e043467.	0.4	1
1554	Emerging betaâ€amyloid pathology is associated with tau, synaptic, neurodegeneration and gray matter volume differences. Alzheimer's and Dementia, 2020, 16, e044466.	0.4	1
1555	Impact of APOE â€Îµ4 on cerebral amyloid deposition in participants with abnormal soluble amyloid levels. Alzheimer's and Dementia, 2020, 16, e045828.	0.4	1
1556	Serum neurofilament light and whole brain volume associate with machineâ€learning derived brainâ€predicted age in the British 1946 birth cohort. Alzheimer's and Dementia, 2020, 16, e045965.	0.4	1
1557	Principal components from untargeted CSF metabolomics associated with tau. Alzheimer's and Dementia, 2020, 16, e046065.	0.4	1
1558	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e047209.	0.4	1
1559	CSF proteomic profiling of mild cognitive impairment individuals with suspected nonâ€Alzheimerâ€™s disease pathophysiology. Alzheimer's and Dementia, 2020, 16, e047247.	0.4	1
1560	Neurodegenerative dementias: screening for major threats to healthy longevity with blood biomarkers. The Lancet Healthy Longevity, 2021, 2, e58-e59.	2.0	1
1561	Dynamics of Selected Biomarkers in Cerebrospinal Fluid During Complex Endovascular Aortic Repair â€“ A Pilot Study. Annals of Vascular Surgery, 2022, 78, 141-151.	0.4	1
1562	Synaptic Molecular and Neurophysiological Markers Are Independent Predictors of Progression in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 83, 355-366.	1.2	1
1563	No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach. Journal of Virus Eradication, 2021, 7, 100056.	0.3	1
1564	Steroid-Responsive Encephalitis in Coronavirus Disease 2019. , 2020, 88, 423.		1
1565	Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos. , 0, .		1
1566	Untangling the roles of amyloid and tau in synaptic and axonal loss in the course of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e043169.	0.4	1

#	Article	IF	Citations
1567	Protein tau concentration in blood increases after SCUBA diving: an observational study. European Journal of Applied Physiology, 2022, 122, 993-1005.	1.2	1
1568	Neurofilament light chain: defining the analyte. Brain Communications, 2022, 4, fcac070.	1.5	1
1569	Tau368 in cerebrospinal fluid is associated with severity of tau pathology load in the Alzheimerâ€™s continuum. Alzheimer's and Dementia, 2021, 17, .	0.4	1
1570	Favorable cognitive effects of the BET protein inhibitor apabetalone in patients 70 and older. Alzheimer's and Dementia, 2021, 17, .	0.4	1
1571	CSF metabolites associated with CSF NeuroToolKit biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.4	1
1572	Higher levels of the astrocytic marker CSF YKL40 are associated with better memory performance only in amyloidâ€positive individuals with subjective cognitive decline. Alzheimer's and Dementia, 2021, 17, .	0.4	1
1573	CSF amyloid, tau, and neurodegeneration biomarkers are associated with longitudinal cognitive decline in preclinical AD. Alzheimer's and Dementia, 2021, 17, .	0.4	1
1574	CSF apolipoprotein B levels predict future visuospatial cognitive decline and synaptic pathology in cognitively unimpaired healthy elderly with a parental history of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	1
1575	Plasma glial fibrillary acidic protein is an early and specific marker of amyloidâ€Î² pathology in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	1
1576	Stress and Alzheimerâ€™s disease: Linking salivary cortisol to biomarkers of neurodegeneration and cognitive decline in a memory clinic cohort. Alzheimer's and Dementia, 2021, 17, .	0.4	1
1577	CSF amyloidâ€beta, tau, and neurodegenerative and inflammatory biomarkers in cognitively unimpaired late middleâ€aged and older adult APOE Îµ4 homozygotes, heterozygotes, and nonâ€carriers from the Arizona APOE Cohort. Alzheimer's and Dementia, 2021, 17, .	0.4	1
1578	Plasma pâ€Tau181 and pâ€Tau231 offer complementary information to identify Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2021, 17, .	0.4	1
1579	Baseline plasma total tau predicts longitudinal cognitive and functional decline in aging adults. Alzheimer's and Dementia, 2021, 17, .	0.4	1
1580	Differential synaptic marker involvement in the different genetic forms of frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, .	0.4	1
1581	A novel antibodyâ€free mass spectrometry panel of CSF biomarkers for synaptic dysfunction. Alzheimer's and Dementia, 2021, 17, .	0.4	1
1582	Comparative analytical performance of multiple plasma amyloidâ€beta assays and their relationship to amyloid PET. Alzheimer's and Dementia, 2021, 17, .	0.4	1
1583	Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study. Biomedicines, 2022, 10, 1045.	1.4	1
1584	Commentary on Oeckl et al., â€œSerum <scp>Betaâ€Synuclein</scp> Is Higher in Down Syndrome and Precedes Rise of <scp>pTau181</scp>â€. Annals of Neurology, 2022, 92, 3-5.	2.8	1

#	Article	IF	Citations
1585	Study bridges the gap between advanced mass spectrometry and immuno-based multiplex assays. Biomarkers in Medicine, 2008, 2, 219-219.	0.6	0
1586	What is the future for CSF biomarkers in the prediction of cognitive decline and Alzheimerâ€™s disease?. Aging Health, 2008, 4, 213-215.	0.3	0
1587	Diagnostic Tools: Fluid Biomarkers for AlzheimerÂ's Disease. Advances in Biological Psychiatry, 2012, , 71-79.	0.2	0
1588	O1-01-01: Cerebrospinal fluid biomarkers for Alzheimer's disease are associated with neuropathology in cortical brain biopsy. , 2012, 8, P83-P84.		0
1589	Cerebrospinal fluid biomarkers to monitor treatment effects in Alzheimerâ€™s disease and related conditions. Neurodegenerative Disease Management, 2012, 2, 117-123.	1.2	0
1590	Diagnosis and biomarkers: CSF. , 0, , 97-108.		0
1591	P2-087: PATTERNS OF [C-11]PIB AMYLOID BURDEN THAT ARE ASSOCIATED WITH CEREBROSPINAL FLUID AD BIOMARKERS IN PEOPLE AT RISK FOR ALZHEIMER'S DISEASE: FINDINGS FROM THE WRAP STUDY. , 2014, 10, P502-P503.		0
1592	P1-051: THE DISTRIBUTION OF APOLIPOPROTEIN E GENOTYPE OVER THE ADULT LIFESPAN AND IN RELATION TO BIRTH ORIGIN. , 2014, 10, P322-P322.		0
1593	P4-049: IMPACT OF READY TO USE CALIBRATORS AND THE USE OF UNIFIED STANDARD OPERATING PROCEDURES ON THE VARIABILITY IN ASSAY PERFORMANCE. , 2014, 10, P800-P800.		0
1594	P2-110: ELEVATED CEREBROSPINAL FLUID LEVELS OF NEUROGRANIN IN ALZHEIMER'S DISEASE. , 2014, 10, P511-P511.		0
1595	IC-P-007: PATTERNS OF [C-11]PIB AMYLOID BURDEN THAT ARE ASSOCIATED WITH CEREBROSPINAL FLUID AD BIOMARKERS IN PEOPLE AT RISK FOR ALZHEIMER'S DISEASE: FINDINGS FROM THE WRAP STUDY. , 2014, 10, P10-P10.		0
1596	P3-103: INCREASED LEVELS OF CEREBROSPINAL FLUID FATTY ACID BINDING PROTEIN 3 ARE RELATED TO DEMENTIA DEVELOPMENT IN A POPULATION-BASED SAMPLE OF ELDERLY WOMEN FOLLOWED FOR 8 YEARS. , 2014, 10, P666-P666.		0
1597	P2-063: AÎ²40 and AÎ²42 levels in plasma: Comparison of enzyme-linked immunosorbent assay (ELISA) with multiplex technology. , 2015, 11, P507-P507.		0
1598	P3-075: Development of a targeted proteomic multiplex CSF assay for neurodegenerative markers. , 2015, 11, P645-P646.		0
1599	IC-P-096: Insulin resistance is associated with altered microstructure in the medial temporal lobe and fornix of cognitively healthy APOE4 carriers. , 2015, 11, P66-P67.		0
1600	P1-069: Moderate-to-high intensity physical training does not alter cerebrospinal amyloid-Î²1-42 levels in patients with Alzheimer's disease. , 2015, 11, P364-P365.		0
1601	P1-204: Insulin resistance is associated with altered microstructure in the medial temporal lobe and fornix of cognitively healthy ApoE Îµ4 carriers. , 2015, 11, P427-P428.		0
1602	P4-264: Amyloid pathology is associated with extensive myelin alteration in preclinical Alzheimer's disease: New insights into disease process with novel brain imaging. , 2015, 11, P885-P885.		0

#	Article	IF	Citations
1603	IC-P-131: The relationship between intracranial vascular health and metrics of Alzheimer's disease. , 2015, 11, P88-P90.		0
1604	P1-099: White matter lesions but not lacunes are associated with the CSF levels of AÎ²38 and AÎ²40, and to a lesser degree with CSF AÎ²42. , 2015, 11, P376-P377.		0
1605	P4-204: LAMP-2 changes AÎ² generation, uptake, and degradation. , 2015, 11, P859-P859.		0
1606	P2-062: Are cerebrospinal fluid levels of neurogranin associated with hippocampal atrophy and brain white matter volume decrease?. , 2015, 11, P506-P507.		0
1607	O3-14-01: Dissecting IWG-2 typical and atypical Alzheimer's disease: Insights from cerebrospinal fluid analysis. , 2015, 11, P254-P254.		0
1608	O4-11-01: Multicentre performance evaluation of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of AÎ²(1-42) in human cerebrospinal fluid. , 2015, 11, P295-P296.		0
1609	P4-066: The relationship between intracranial vascular health and metrics of Alzheimer's disease. , 2015, 11, P793-P794.		0
1610	P1-010: Quantification of the synaptic protein neurogranin in cerebrospinal fluid across different neurodegenerative diseases: A selective Alzheimer's disease biomarker?. , 2015, 11, P340-P340.		0
1611	P1-110: Predictors of cognitive decline in elderly depressives. , 2015, 11, P381-P382.		0
1612	P2-074: Differences in the TREM2 levels in the CSF of Alzheimer's disease cases and controls. , 2015, 11, P511-P511.		0
1613	O1-02-01: Microglial-derived proteins in CSF are candidate biomarkers for early diagnosis of Alzheimer's disease. , 2015, 11, P126-P126.		0
1614	O5-05-02: Characterization of the postsynaptic protein neurogranin in brain tissue of Alzheimer's disease patients and healthy controls. , 2015, 11, P325-P325.		0
1615	P4-036: CSF Alzheimer's disease-related biomarkers are higher in subjects with periodontal disease. , 2015, 11, P779-P779.		0
1616	P1-033: A candidate reference method for analysis of amyloid beta 1-42 (AÃŸ1-42) peptide in human CSF using 2D-HPLC with a xevo t q-s mass spectrometer. , 2015, 11, P349-P349.		0
1617	Repetitive concussions â€" How dangerous are they?. Molecular and Cellular Neurosciences, 2015, 66, 73-74.	1.0	0
1618	USING FLORBETAPIR PET TO INCREASE DIAGNOSTIC CERTAINTY IN ATYPICAL DEMENTIAS. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.112-e4.	0.9	0
1619	Î±â€Synuclein in Neurodegenerationâ€"A Good Protein that may go Bad. Brain Pathology, 2016, 26, 387-388.	2.1	0
1620	P3-129: Psychological Stress in Midlife Associated with Higher Levels of CSF T-TAU and AB40 in Late-Life: A 25-YEAR Longitudinal Population Study of Women. , 2016, 12, P869-P869.		0

#	Article	IF	Citations
1621	O1â€05â€01: Increased Amyloidogenic app Processing in Apoe E4â€Negative Individuals with Cerebral Bâ€Amyloidosis. Alzheimer's and Dementia, 2016, 12, P182.	0.4	0
1622	O5-01-02: Stress is Associated with Greater Insulin Resistance, Higher CSF Phosphorylated TAU, and Decreased Glucose Metabolism in the Medial Temporal Lobe in apoe Î•4 Carriers. , 2016, 12, P375-P376.		0
1623	P1â€172: Combined Added Value of Cerebrospinal Fluid Neurogranin and Neurofilament Light Chain Protein in the Diagnosis and Classification Of Prodromal and Alzheimerâ€™s Disease Dementia. Alzheimer's and Dementia, 2016, 12, P468.	0.4	0
1624	ICâ€Pâ€050: MCI Status, Amyloid and TAU Biomarkers, and Composite Cognitive Impairment Scores are Associated with Cogstate Performance in The Wisconsin Registry For Alzheimer's Prevention. Alzheimer's and Dementia, 2016, 12, P41.	0.4	0
1625	P1â€322: Fourâ€Dimensional Arterial Blood Flow Metrics in The Internal Carotid Artery Predict Cognitive Performance and are Associated with CSF Biomarkers in Patients with MCI. Alzheimer's and Dementia, 2016, 12, P548.	0.4	0
1626	P1â€344: Poor Sleep Quality is Associated with CSF Markers of Amyloid Deposition in Cognitively Healthy Adults at Risk for Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P561.	0.4	0
1627	P1â€410: Lifetime Recreational Physical Activity is Associated with CSF Amyloid in Cognitively Asymptomatic Adults. Alzheimer's and Dementia, 2016, 12, P591.	0.4	0
1628	P2â€151: Cerebrospinal Fluid Biomarker Profile of Amyloid, TAU, Synaptic, Microglial, and Lysosomal Pathophysiology in Cognitively Normal Preclinical Individuals Stratified by Amyloidâ€Pet Status. Alzheimer's and Dementia, 2016, 12, P672.	0.4	0
1629	P2â€152: Characterization of the Postsynaptic Protein Neurogranin in Different Brain Regions in Patients with Familial Alzheimer's Disease, Alzheimer's Disease, Pathological Aging And Healthy Controls. Alzheimer's and Dementia, 2016, 12, P672.	0.4	0
1630	P2â€137: The CSF AB42/40 Ratio does not Mitigate Misinterpretation of AB Loss Upon Serial Tube Transfers. Alzheimer's and Dementia, 2016, 12, P664.	0.4	0
1631	P2â€142: Comparison of Tâ€Tau, Neurogranin and NFL as CSF Neurodegeneration Markers in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P667.	0.4	0
1632	ICâ€Pâ€123: Four Dimensional Arterial Blood Flow Metrics in The Internal Carotid Artery Predict Cognitive Performance and Are Associated With CSF Biomarkers in Patients With MCI. Alzheimer's and Dementia, 2016, 12, P91.	0.4	0
1633	P2â€430: The Prevalence of Pathological CSF Abetaâ€42 and ITS Relation to Education in a Population Sample of Older People from Sweden. Alzheimer's and Dementia, 2016, 12, P810.	0.4	0
1634	P3-165: Plasma Biomarker Profile of Amyloid, TAU, and Neuronal Pathophysiology in Cognitively Normal Preclinical Individuals Stratified by Amyloid-Pet Status. , 2016, 12, P882-P883.		0
1635	P3-193: Serum Neurofilament Light Protein Predicts Clinical Outcome in Traumatic Brain Injury. , 2016, 12, P896-P897.		0
1636	P4-114: Cerebrospinal Fluid Biomarkers of Neuronal Injury in Chronic Traumatic Brain Injury. , 2016, 12, P1056-P1056.		0
1637	F1â€03â€02: How adâ€Specific are ad CSF Biomarkers?. Alzheimer's and Dementia, 2016, 12, P166.	0.4	0
1638	O1â€05â€06: Stability of Amyloidâ€Beta (1â€“42) in Fresh Versus Frozen Human Cerebrospinal Fluid Samples as Measured with the Elecsys^{Â®} Bâ€Amyloid(1â€“42) Immunoassay. Alzheimer's and Dementia, 2016, 12, P185.	0.4	0

#	Article	IF	Citations
1639	O3-03-02: MCI STATUS, AMYLOID AND TAU BIOMARKERS, AND COMPOSITE COGNITIVE IMPAIRMENT SCORES ARE ASSOCIATED WITH COGSTATE PERFORMANCE IN THE WISCONSIN REGISTRY FOR ALZHEIMER's PREVENTION. , 2016, 12, P285-P286.		0
1640	O3â€09â€01: Distinct Cognitive Trajectories in Late Middleâ€Age and their Associations with Brain Structure and Alzheimer's Disease Biomarkers: Findings from the Wisconsin Registry for Alzheimer's Prevention. Alzheimer's and Dementia, 2016, 12, P306.	0.4	0
1641	O4â€10â€01: PLASMA NFL: A NEW BIOMARKER FOR DIFFERENTIAL DIAGNOSIS OF PARKINSONIAN DISORDERS. Alzheimer's and Dementia, 2016, 12, P357.	0.4	0
1642	P1-012: A Population-Based Study on the Relation Between Sleep Disturbance and Beta-Amyloid 42 in Cerebrospinal Fluid in 70-Year-Olds. , 2016, 12, P404-P404.		0
1643	P1-028: Does Calcium Supplementation Increase the Risk of Dementia in Women With Cerebrovascular Disease? A Five Year Follow-Up of Older Swedish Women. , 2016, 12, P412-P412.		0
1644	P1â€171: Added Diagnostic Value of Cerebrospinal Fluid Neurogranin in the Classification of Prodromal and Alzheimerâ€™s Disease Dementia. Alzheimer's and Dementia, 2016, 12, P468.	0.4	0
1645	P1-177: How Accurate are Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease? A Systematic Review. , 2016, 12, P471-P472.		0
1646	P1â€181: Stateâ€Dependent Alterations in CSF AÎ²42 Levels in Cognitivelyâ€Intact Elderly With Late Life Major Depression. Alzheimer's and Dementia, 2016, 12, P473.	0.4	0
1647	P1â€204: Neurogranin: a Specific Synaptic Biomarker for Amnestic Alzheimerâ€™s Disease?. Alzheimer's and Dementia, 2016, 12, P483.	0.4	0
1648	P4â€312: Progress on the Development of Certified Reference Materials for AB1â€42. Alzheimer's and Dementia, 2016, 12, P1153.	0.4	0
1649	P4â€313: Commutability of the Candidate Certified Reference Materials for the Standardization of AÎ²1â€42 Measurements in Human Cerebrospinal Fluid. Alzheimer's and Dementia, 2016, 12, P1153.	0.4	0
1650	P4â€324: Plasma Neurofilament Light Concentration Predicts Longâ€Term Outcome an Acute Stroke. Alzheimer's and Dementia, 2016, 12, P1158.	0.4	0
1651	Cerebrospinal Fluid Biomarkers in Alzheimerâ€™s Disease. Methods in Pharmacology and Toxicology, 2016, , 153-179.	0.1	0
1652	O2â€10â€05: Cerebrospinal Fluid Levels of Amyloid Beta and Tau as Endophenotypes Reveal Novel Variants Potentially Informative for Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P252.	0.4	0
1653	D4â€...Prediction of huntingtonâ€™s disease phenotype by cerebrospinal fluid biomarkers of inflammation and cell death. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A35.1-A35.	0.9	0
1654	[P3â€“297]: SUBJECTIVE COGNITIVE DECLINE AND NEUROIMAGING AND CEREBROSPINAL FLUID MARKERS OF CEREBROVASCULAR HEALTH: THE VANDERBILT MEMORY AND AGING PROJECT. Alzheimer's and Dementia, 2017, 13, P1057.	0.4	0
1655	[P2â€“141]: TRISOMY 21 CAUSES A DEFICIT IN LYSOSOMAL CATHEPSINS AND ALTERS APP/AÎ² PROCESSING, INDEPENDENTLY OF AN EXTRA COPY OF APP. Alzheimer's and Dementia, 2017, 13, P661.	0.4	0
1656	[P1â€“219]: PROBING DEVELOPMENTAL CONSEQUENCES OF PSEN1 MUTATIONS IN IPSC DIFFERENTIATION IN 2D AND 3D. Alzheimer's and Dementia, 2017, 13, P327.	0.4	0

#	Article	IF	Citations
1657	[P1â€“025]: PROBING DEVELOPMENTAL CONSEQUENCES OF PSEN1 MUTATIONS IN IPSC DIFFERENTIATION IN 2D AND 3D. Alzheimer's and Dementia, 2017, 13, P242.	0.4	0
1658	[P1â€“027]: PET TAU AND AMYLOIDâ€BETA DIFFER IN THEIR RELATIONSHIP TO AGE, COGNITION AND CSF BIOMARKERS IN MILD ALZHEIMER's DISEASE: AN OBSERVATIONAL STUDY. Alzheimer's and Dementia, 2017, 13, P243.	0.4	0
1659	[P1â€“028]: DIAGNOSTIC ACCURACY OF CSF NEUROFILAMENT LIGHT CHAIN PROTEIN IN THE UNBIASED BIOMARKERâ€GUIDED CLASSIFICATION SYSTEM FOR ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P243.	0.4	0
1660	[P3â€“084]: Nâ€TERMINAL FRAGMENT OF TAU: ASSAY DEVELOPMENT WITH INâ€HOUSE CLEAVAGEâ€SPECIFIC ANTIBODY. Alzheimer's and Dementia, 2017, 13, P964.	0.4	0
1661	[P3â€“171]: ACUTE, TRANSIENT INCREASE IN SECRETION OF NEURODEGENERATION BIOMARKERS AFTER IRRADIATION OF HUMAN CORTICAL NEURONS. Alzheimer's and Dementia, 2017, 13, P1000.	0.4	0
1662	[P3â€“174]: EFFECT OF PHYSICAL EXERCISE ON MARKERS OF NEURONAL DYSFUNCTION IN CEREBROSPINAL FLUID IN PATIENTS WITH ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1000.	0.4	0
1663	[P3â€“198]: PREDICTION PERFORMANCE OF ALPHAâ€SYNUCLEIN PROTEIN IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY AD BIOMARKERS: THE INSIGHTâ€PRE AD STUDY. Alzheimer's and Dementia, 2017, 13, P1011.	0.4	0
1664	[P3â€“423]: REGIONAL DEFICIT IN SLEEPING BRAIN ACTIVITY ASSOCIATED WITH TAU AND AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY MIDDLEâ€AGED ADULTS. Alzheimer's and Dementia, 2017, 13, P1128.	0.4	0
1665	[P3â€“425]: ELEVATED CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN IS ASSOCIATED WITH GRAY MATTER NEURODEGENERATION IN BOTH HUMANS AND TRANSGENIC RAT MODEL OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1130.	0.4	0
1666	[P4â€“143]: UTILITY OF THE ATN DEFINITION OF BIOMARKER STATUS IN THE ALZHEIMER's DISEASE NEUROIMAGING INITIATIVE. Alzheimer's and Dementia, 2017, 13, P1312.	0.4	0
1667	[P4â€“163]: STATISTICAL ALGORITHMS FOR HARMONIZING BIOMARKER DISTRIBUTIONS ACROSS DIFFERENT COHORTS, SITES AND ASSAYS: APPLICATIONS TO CSF MEASUREMENTS. Alzheimer's and Dementia, 2017, 13, P1322.	0.4	0
1668	[P1â€“150]: INVESTIGATION OF THE ASSOCIATION BETWEEN GENETIC VARIATION IN IL1RAP AND ALZHEIMER'sâ€RELATED CSFâ€BIOMARKERS. Alzheimer's and Dementia, 2017, 13, P300.	0.4	0
1669	[ICâ€Pâ€048]: ELEVATED CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN IS ASSOCIATED WITH GRAY MATTER NEURODEGENERATION IN BOTH HUMANS AND TRANSGENIC RAT MODEL OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P41.	0.4	0
1670	[ICâ€Pâ€049]: REGIONAL DEFICIT IN SLEEPING BRAIN ACTIVITY ASSOCIATED WITH TAU AND AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY MIDDLEâ€AGED ADULTS. Alzheimer's and Dementia, 2017, 13, P41.	0.4	0
1671	[P1â€“180]: DISTINCT AÎ² PRODUCTION IN STEM CELLâ€DERIVED CORTICAL NEURONS FROM PATIENTS WITH FAD MUTATION. Alzheimer's and Dementia, 2017, 13, P311.	0.4	0
1672	[P1â€“187]: NOVEL METHOD FOR OLIGOMERIC AÎ² DETECTION REVEALS INTRACELLULAR ACCUMULATION OF AÎ² UPON LOWâ€DOSE TREATMENT WITH A GAMMAâ€SECRETASE INHIBITOR. Alzheimer's and Dementia, 2017, 13, P314.	0.4	0
1673	[P1â€“268]: ANALYSIS OF NEW POTENTIAL CSF BIOMARKERS FOR ALZHEIMER's DISEASE BY PARALLEL REACTION MONITORING MASS SPECTROMETRY. Alzheimer's and Dementia, 2017, 13, P352.	0.4	0
1674	[P1â€“281]: DIAGNOSTIC PERFORMANCE USING CSF YKLâ€40 IN ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P357.	0.4	0

#	Article	IF	Citations
1675	[P1â€“282]: DIAGNOSTIC ACCURACY OF CSF AÎ²1â€“42, Pâ€TAU, Tâ€TAU, NEUROFILAMENT LIGHT CHAIN, NEUROGRANIN, YKLâ€40 COMBINED BIOMARKERS IN A MULTICENTER COHORT OF COGNITIVELY IMPAIRED PATIENTS. Alzheimer's and Dementia, 2017, 13, P358.	0.4	0
1676	[P1â€“287]: DIAGNOSTIC ACCURACY OF CSF NEUROFILAMENT LIGHT CHAIN PROTEIN IN THE UNBIASED BIOMARKERâ€GUIDED CLASSIFICATION SYSTEM FOR ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P361.	0.4	0
1677	[P1â€“348]: CSF AÎ²42 CONCENTRATION INDEPENDENTLY PREDICTS POSTOPERATIVE DELIRIUM IN AN ELDERLY ELECTIVE ARTHROPLASTY POPULATION. Alzheimer's and Dementia, 2017, 13, P390.	0.4	0
1678	[P1â€“448]: PET TAU AND AMYLOIDâ€BETA DIFFER IN THEIR RELATIONSHIP TO AGE, COGNITION AND CSF BIOMARKERS IN MILD ALZHEIMER's DISEASE: AN OBSERVATIONAL STUDY. Alzheimer's and Dementia, 2017, 13, P456.	0.4	0
1679	[P1â€“611]: LIFETIME PHYSICAL ACTIVITY IS ASSOCIATED WITH CSF AMYLOID IN COGNITIVELY ASYMPTOMATIC APOE É›4+ ADULTS. Alzheimer's and Dementia, 2017, 13, P530.	0.4	0
1680	[P2â€“158]: IS THE PRESUBICULUM PROTECTED FROM NEURODEGENERATIVE CHANGES? A PATHOLOGICAL AND BIOCHEMICAL INVESTIGATION. Alzheimer's and Dementia, 2017, 13, P668.	0.4	0
1681	[P2â€“211]: AMYLOIDâ€Î²42 (AÎ²42) DIFFERENTIALLY CORRELATES WITH CSF TOTAL AND HYPERPHOSPHORYLATED TAU IN AN AMYLOIDâ€POSITIVE VERSUS AMYLOIDâ€NEGATIVE EARLY PRODROMAL AND ASYMPTOMATIC ATâ€RISK FOR AD POPULATION. Alzheimer's and Dementia, 2017, 13, P690.	0.4	0
1682	[P2â€“241]: CSF NEUROGRANIN IS INCREASED IN FAMILIAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P703.	0.4	0
1683	[P2â€“246]: NOVEL CSF FRAGMENTS OF TAU: CANDIDATE BIOMARKERS OF ALZHEIMER's DISEASE AND TAUOPATHIES. Alzheimer's and Dementia, 2017, 13, P706.	0.4	0
1684	[P2â€“254]: SERUM FERRITIN IS INCREASED IN A SUBSET OF PATIENTS WITH FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P710.	0.4	0
1685	[P2â€“260]: TWOâ€LEVEL DIAGNOSTIC CLASSIFICATION USING CEREBROSPINAL FLUID NEUROGRANIN IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P712.	0.4	0
1686	[P2â€“262]: ASSOCIATION OF PLASMA NEUROFILAMENT LIGHT CHAIN PROTEIN WITH BRAIN AMYLOID STATUS IN A PRECLINICAL COHORT OF SUBJECTIVE MEMORY COMPLAINERS: THE INSIGHTâ€PREAD STUDY. Alzheimer's and Dementia, 2017, 13, P713.	0.4	0
1687	[F1â€“02â€“03]: VALIDATING PLASMA NEUROFILAMENT LIGHT AS A BLOOD BIOMARKER FOR NEURODEGENERATION USING NEUROIMAGING. Alzheimer's and Dementia, 2017, 13, P175.	0.4	0
1688	[O1â€“05â€“04]: CLINICAL PERFORMANCE OF NEUROGRANIN AS A CEREBROSPINAL FLUID BIOMARKER FOR ALZHEIMER's DISEASE: AN ASSAY COMPARISON STUDY. Alzheimer's and Dementia, 2017, 13, P199.	0.4	0
1689	[O1â€“08â€“02]: ELEVATED CEREBROSPINAL FLUID NEUROFILAMENT LIGHT LEVELS ARE ASSOCIATED WITH COMPROMISED WHITE MATTER INTEGRITY AMONG OLDER ADULTS. Alzheimer's and Dementia, 2017, 13, P207.	0.4	0
1690	[O1â€“10â€“01]: EVIDENCE FOR EARLY DETECTION OF CSF BETAâ€AMYLOID AND TAU AND EFFECT ON LONGITUDINAL COGNITIVE PERFORMANCE IN INDIVIDUALS AT RISK FOR ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P213.	0.4	0
1691	[O1â€“10â€“06]: ASTROGLIAL ACTIVATION AND ALTERED AMYLOID METABOLISM IN HUMAN REPETITIVE CONCUSSIVE TRAUMATIC BRAIN INJURY. Alzheimer's and Dementia, 2017, 13, P216.	0.4	0
1692	[O1â€“11â€“03]: CEREBROSPINAL FLUID ENDOPHENOTYPES PROVIDE INSIGHT INTO BIOLOGY UNDERLYING ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P218.	0.4	0

#	Article	IF	Citations
1693	[O3â€“11â€“03]: MODERATE INTENSITY PHYSICAL ACTIVITY IS ASSOCIATED WITH CSF BIOMARKERS IN PRECLINICAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P927.	0.4	0
1694	[O4â€“02â€“01]: PLASMA AND CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN CORRELATE IN ATYPICAL PARKINSONIAN SYNDROMES AND DISTINGUISH THEM FROM PARKINSON's AND ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1228.	0.4	0
1695	[O4â€“02â€“04]: SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER's DISEASE AND ASSOCIATION WITH MARKERS OF DISEASE STAGE AND SEVERITY. Alzheimer's and Dementia, 2017, 13, P1230.	0.4	0
1696	[P4â€“392]: NOVEL ASSAYS TO MONITOR AÎ² PEPTIDES GENERATED BY THE ASPARAGATE ENDOPEPTIDASE AFTER INHIBITION OF BACE. Alzheimer's and Dementia, 2017, 13, P1478.	0.4	0
1697	[P4â€“470]: PRESYNAPTIC DEGRADATION IN ALZHEIMER's DISEASE MEASURED BY NOVEL GAPâ€43 ELISA IN CSF. Alzheimer's and Dementia, 2017, 13, P1513.	0.4	0
1698	[ICâ€Pâ€171]: MODERATE INTENSITY PHYSICAL ACTIVITY ASSOCIATES WITH CSF BIOMARKERS IN PRECLINICAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P128.	0.4	0
1699	[P4â€“382]: PROTEOMIC CHANGES IN ZEBRAFISH LACKING THE AMYLOID PRECURSOR HOMOLOG, APPB, USING A HIGHâ€THROUGHPUT DIFFERENTIAL PROTEOMIC APPROACH. Alzheimer's and Dementia, 2017, 13, P1439.	0.4	0
1700	[P3â€“075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS. Alzheimer's and Dementia, 2017, 13, P960.	0.4	0
1701	O2â€03â€05: VERBAL FLUENCY MEASURES ARE ASSOCIATED WITH ALZHEIMER'S DISEASE BIOMARKERS IN CLINICALLY UNIMPAIRED, LATE MIDDLEâ€AGED ADULTS FROM THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION. Alzheimer's and Dementia, 2018, 14, P617.	0.4	0
1702	P3â€495: VERBAL EPISODIC MEMORY IS PREFERENTIALLY RELATED TO WHITE MATTER INTEGRITY IN COGNITIVELY NORMAL OLDER ADULTS: THE VANDERBILT MEMORY & AGING PROJECT. Alzheimer's and Dementia, 2018, 14, P1311.	0.4	0
1703	O5â€06â€03: NEW PARADIGMS IN TREATING APOE4â€DRIVEN DEMENTIA DISEASES: PROOF OF CONCEPT AND TRANSLATIONAL FINDINGS FROM STUDIES WITH THE ABCA1 AGONIST THERAPEUTIC CS6253. Alzheimer's and Dementia, 2018, 14, P1658.	0.4	0
1704	F5â€06â€03: BLOODâ€BASED BIOMARKERS FOR CNS INJURY IN MILD TBI: RELATION TO ACUTE INJURY, INJURY HISTORY AND LONGâ€TERM NEUROBEHAVIORAL OUTCOME. Alzheimer's and Dementia, 2018, 14, P1634.	0.4	0
1705	P3â€243: THE ASSOCIATION OF LONGITUDINAL PLASMA NFL WITH POSTMORTEM NEUROPATHOLOGY. Alzheimer's and Dementia, 2018, 14, P1165.	0.4	0
1706	P1â€318: OBSTRUCTIVE SLEEP APNEA IS ASSOCIATED WITH LOWER MEMORY FUNCTION IN MIDDLEâ€AGED ADULTS. Alzheimer's and Dementia, 2018, 14, P413.	0.4	0
1707	P2â€270: INCREASED CSF AMYLOIDâ€Î² 1â€38 AND 1â€40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY. Alzheimer's and Dementia, 2018, 14, P780.	0.4	0
1708	P1â€267: CEREBROSPINAL FLUID/PLASMA ALBUMIN RATIO PREDICTS POSTOPERATIVE DELIRIUM IN AN OLDER ELECTIVE ORTHOPAEDIC POPULATION. Alzheimer's and Dementia, 2018, 14, P384.	0.4	0
1709	P3â€238: LONGITUDINAL ASSOCIATIONS OF PLASMA NEUROFILAMENT LEVELS WITH AMYLOIDâ€PET, FDGâ€PET, AND COGNITION AMONG NONâ€DEMENTED PARTICIPANTS IN THE MAYO CLINIC STUDY ON AGING. Alzheimer's and Dementia, 2018, 14, P1163.	0.4	0
1710	P1â€248: LATENT PROFILES DERIVED FROM ATN RELATED CSF BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P374.	0.4	0

#	Article	IF	Citations
1711	P1â€302: ASSOCIATION OF PLASMA NEUROFILAMENT LIGHT CHAIN WITH COGNITIVE PERFORMANCE IN COGNITIVELY NORMAL ELDERLY PARTICIPANTS. Alzheimer's and Dementia, 2018, 14, P405.	0.4	0
1712	P3â€161: ALTERATIONS IN ALZHEIMERâ€ASSOCIATED SYNAPTIC MARKERS FOLLOWING IRRADIATION OF STEM CELLâ€DERIVED CORTICAL NEURONS. Alzheimer's and Dementia, 2018, 14, P1129.	0.4	0
1713	P3â€270: CEREBROSPINAL FLUID CONCENTRATIONS OF INFLAMMATORY MARKERS IN PARKINSON'S DISEASE AND ATYPICAL PARKINSONIAN DISORDERS. Alzheimer's and Dementia, 2018, 14, P1180.	0.4	0
1714	P4â€071: CELLâ€FREE, SINGLEâ€STRANDED DNA CONCENTRATION IN CSF AS BIOMARKER TO DIAGNOSE ALZHEIMER'S DISEASE STATUS. Alzheimer's and Dementia, 2018, 14, P1460.	0.4	0
1715	O3â€14â€06: DISSECTION OF SYNAPTIC PATHWAYS THROUGH THE ANALYSIS OF BIOMARKERS IN THE CSF: A COMBINING TOOL FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1061.	0.4	0
1716	P1â€188: MODELLING AMYLOID BETA PROFILES IN IPSCâ€DERIVED CORTICAL NEURONS OF MULTIPLE FAMILIAL ALZHEIMER'S DISEASE GENOTYPES, INCLUDING A CASE STUDY OF SAME DONOR CULTURE MEDIA, CSF AND BRAIN TISSUE. Alzheimer's and Dementia, 2018, 14, P350.	0.4	0
1717	P2â€273: CEREBROSPINAL FLUID NEUROFILAMENT LIGHT PROTEIN AND RISK OF MILD COGNITIVE IMPAIRMENT IN THE MAYO CLINIC STUDY OF AGING. Alzheimer's and Dementia, 2018, 14, P782.	0.4	0
1718	O2â€04â€04: LONGITUDINAL MEASUREMENT OF SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P623.	0.4	0
1719	P1â€007: POOR SLEEP IS ASSOCIATED WITH CSFâ€MARKERS OF ALZHEIMER'S DISEASE IN 70â€YEARâ€OLDS WITHOUT DEMENTIA. Alzheimer's and Dementia, 2018, 14, P265.	0.4	0
1720	P2â€220: CROSSâ€TALK BETWEEN WNT SIGNALLING AND AMYLOID PRECURSOR PROTEIN IN NEURONS. Alzheimer's and Dementia, 2018, 14, P753.	0.4	0
1721	F2â€02â€01: NEUROFILAMENT LIGHT CHAIN IN AD IN CSF AND BLOOD. Alzheimer's and Dementia, 2018, 14, P603.	0.4	0
1722	O3â€14â€04: THE PROTEINâ€TOâ€PEPTIDE RATIO IMPROVES THE PERFORMANCE OF MICROTUBULEâ€ASSOCIATED PROTEIN TAU IN CSF AS AN ALZHEIMER BIOMARKER. Alzheimer's and Dementia, 2018, 14, P1060.	0.4	0
1723	P1â€217: PROTEOLYTIC PROCESSING OF THE SYNAPTIC ALZHEIMER BIOMARKER NEUROGRANIN BY CALPAIN I AND PROLYL ENDOPEPTIDASE. Alzheimer's and Dementia, 2018, 14, P361.	0.4	0
1724	P2â€037: APABETALONE (AN EPIGENETIC BETâ€INHIBITOR SMALL MOLECULE) AND EFFECTS ON COGNITION IN DIABETES PATIENTS WITH CARDIOVASCULAR DISEASE. Alzheimer's and Dementia, 2018, 14, P680.	0.4	0
1725	P1â€139: THE CONTRIBUTION OF SEXâ€SPECIFIC ASSOCIATIONS IN GENETIC STUDIES OF ALZHEIMER'S DISEASE PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P327.	0.4	0
1726	O3â€14â€05: ASSOCIATIONS OF CSF BIOMARKERS OF NEUROINFLAMMATION AND CEREBROVASCULAR DYSFUNCTION WITH ALZHEIMER'S DISEASE PATHOLOGY AND CLINICAL PROGRESSION. Alzheimer's and Dementia, 2018, 14, P1061.	0.4	0
1727	P1â€279: BIMODAL DISTRIBUTION OF THE CSF AÎ²42/AÎ²40 RATIO IN CLINICAL LABORATORY PRACTICE. Alzheimer's and Dementia, 2018, 14, P389.	0.4	0
1728	ICâ€Pâ€089: OBSTRUCTIVE SLEEP APNEA IS ASSOCIATED WITH LOWER MEMORY FUNCTION IN MIDDLEâ€AGED ADULTS. Alzheimer's and Dementia, 2018, 14, P74.	0.4	0

#	Article	IF	Citations
1729	D10â€...Neurofilament light protein in blood predicts regional atrophy in huntingtonâ€™s disease. , 2018, , .		0
1730	D09â€...Parallel evaluation of mutant huntingtin and neurofilament light as biomarkers for huntingtonâ€™s disease: the hd-csf study. , 2018, , .		0
1731	P2â€237: ASSOCIATION OF CSF ALPHAâ€SYNUCLEIN AND TAU CONCENTRATIONS WITH AMYLOID MEAN CORTICAL STANDARD UPTAKE VALUE RATIOS IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY ALZHEIMER'S DISEASE BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P762.	0.4	0
1732	O1â€10â€02: NEUROGRANIN PREDICTS LONGITUDINAL COGNITIVE DECLINE IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P243.	0.4	0
1733	P3â€387: NEURODEGENERATION, AMYLOID, AND LONGITUDINAL VERBAL LEARNING AND MEMORY PERFORMANCE. Alzheimer's and Dementia, 2018, 14, P1243.	0.4	0
1734	P4â€186: INNOVATIVE BIOMARKERâ€GUIDED DIAGNOSTIC SYSTEM FROM PRECLINICAL TO ALZHEIMER'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1510.	0.4	0
1735	P1â€301: CERTAIN PLASMA Nâ€TERMINAL TAU FRAGMENTS ARE ELEVATED IN AD AND ADâ€MCI COMPARED TO CONTROLS. Alzheimer's and Dementia, 2018, 14, P405.	0.4	0
1736	O2â€09â€04: HARMONIZATION OF IMMUNOCHEMICAL METHODS FOR MEASUREMENT OF Î±â€SYNUCLEIN IN HUMAN CEREBROSPINAL FLUID: A ROUND ROBIN STUDY APPROACH. Alzheimer's and Dementia, 2018, 14, P642.	0.4	0
1737	O3â€09â€03: SERUM NEUROFILAMENT LIGHT LEVELS CORRELATE WITH SEVERITY MEASURES AND NEURODEGENERATION MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1037.	0.4	0
1738	F1â€02â€02: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN AND ALZHEIMER'S DISEASE PROGRESSION. Alzheimer's and Dementia, 2018, 14, P201.	0.4	0
1739	P1â€001: CSF CHOLINE ACETYLTRANSFERASE SHOWS DIFFERENTIAL LEVELS AMONG HEALTHY CONTROLS AND PATIENTS WITH AD AND MCI. Alzheimer's and Dementia, 2018, 14, P261.	0.4	0
1740	F1â€02â€01: RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENTâ€LIGHT AND YKLâ€40 TO AÎ², APOE Îµ4 AND COGNITION: RESULTS FROM THE EMIFâ€AD MULTIMODAL BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P201.	0.4	0
1741	P2â€458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIFâ€AD BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P895.	0.4	0
1742	F1â€02â€03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIFâ€AD BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P202.	0.4	0
1743	P3â€166: SUBCELLULAR COâ€LOCALIZATION OF APP AND APPâ€CLEAVING ENZYMES. Alzheimer's and Dementia, 2018, 14, P1131.	0.4	0
1744	P2â€241: FROM BLOODâ€BASED REDOX PROFILE TO THE IDENTIFICATION OF A LEAD BIOMARKER FOR THE TIMELY DIAGNOSIS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P765.	0.4	0
1745	Lumbar drains can affect CSF biomarker levels. Journal of Clinical Pathology, 2019, 72, 91-92.	1.0	0
1746	Biomarkers for Concussion: The Need and the Prospects for the Near Future. , 2019, , 638-645.		0

#	Article	IF	Citations
1747	P4â€531: CEREBROSPINAL FLUID APOLIPOPROTEIN E ISOFORM CONCENTRATIONS IN RELATION TO Î²â€AMYLOID POSITIVITY. Alzheimer's and Dementia, 2019, 15, P1517.	0.4	0
1748	P4â€546: THE NEURAL CELL ADHESION PROTEIN NEUROLIGIN 1 IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1526.	0.4	0
1749	P4â€579: LOWER NEURITE DENSITY AND ORIENTATION DISPERSION WITHIN GRAY AND WHITE MATTER IN THE ALZHEIMER'S DISEASE PATHOLOGIC FRAMEWORK. Alzheimer's and Dementia, 2019, 15, P1542.	0.4	0
1750	P4â€573: PROXIMITY TO PARENTAL ONSET AND APOE Îµ4 INDEPENDENTLY CONTRIBUTE TO AMYLOID BURDEN IN MIDDLEâ€AGED ADULTS WITH A FAMILY HISTORY OF SPORADIC ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1539.	0.4	0
1751	P4â€525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1515.	0.4	0
1752	O3â€02â€01: APOEâ€Îµ4 ALLELIC LOAD MODULATES THE ASSOCIATION BETWEEN CSF BETAâ€AMYLOID AND GRAY MATTER VOLUME IN COGNITIVELY UNIMPAIRED INDIVIDUALS. Alzheimer's and Dementia, 2019, 15, P877.	0.4	0
1753	F4â€05â€01: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN PET IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1224.	0.4	0
1754	P4â€473: A NOVEL MASS SPECTROMETRIC METHOD FOR THE ABSOLUTE QUANTIFICATION OF SIX AÎ² PEPTIDES IN HUMAN CEREBROSPINAL FLUID. Alzheimer's and Dementia, 2019, 15, P1492.	0.4	0
1755	P4â€535: PRESENTATION OF A ROUTINEâ€USE PREâ€ANALYTICAL PROCEDURE FOR AD CSF BIOMARKERS. Alzheimer's and Dementia, 2019, 15, P1520.	0.4	0
1756	O2â€02â€01: DIFFERENT CSF TOTAL AND PHOSPHORYLATED TAU, BUT NOT AÎ², IN OLDER AND YOUNGER AFRICAN AMERICANS AND WHITES. Alzheimer's and Dementia, 2019, 15, P535.	0.4	0
1757	P4â€589: COMPARISON OF CEREBROSPINAL FLUID NEUROFILAMENT LIGHT CHAIN PROTEIN AND THREE MRIâ€BASED MORPHOMETRIC ESTIMATES FOR DEFINING NEURODEGENERATION (N) ACROSS THE ALZHEIMER'S DISEASE CONTINUUM. Alzheimer's and Dementia, 2019, 15, P1547.	0.4	0
1758	ICâ€Pâ€093: PLASMA AMYLOIDâ€BETA AND TAU AND VISUAL CONTRAST SENSITIVITY SYNERGISTICALLY PREDICT CEREBRAL AMYLOID AND TAU DEPOSITION ON PET IN PRECLINICAL AND PRODROMAL AD. Alzheimer's and Dementia, 2019, 15, P82.	0.4	0
1759	P4â€519: MOLECULAR FORMS OF NEUROGRANIN IN CEREBROSPINAL FLUID. Alzheimer's and Dementia, 2019, 15, P1513.	0.4	0
1760	ICâ€Pâ€071: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN ATROPHY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P65.	0.4	0
1761	ICâ€Pâ€072: LONGITUDINAL ASSOCIATIONS BETWEEN PLASMA NFL AND VOXELâ€BASED MORPHOMETRY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P66.	0.4	0
1762	ICâ€Pâ€015: VOXELâ€BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER'S DISEASE CONTINUUM Alzheimer's and Dementia, 2019, 15, P24.	0.4	0
1763	CSF levels of the BACE1 substrate Neuregulin1 correlate with cognition and synaptic biomarkers in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e037097.	0.4	0
1764	Plasma phosphoâ€tau181 in over 400 cognitively healthy 69â€to 71â€yearâ€olds: Associations with cerebral amyloid, structural imaging and cognition in the Insight 46 study. Alzheimer's and Dementia, 2020, 16, e037848.	0.4	0

#	Article	IF	Citations
1765	Sex differences in CSF biomarkers for neurodegeneration and bloodâ€brain barrier integrity. Alzheimer's and Dementia, 2020, 16, e038588.	0.4	0
1766	Fluidâ€based biomarkers to facilitate clinical trial execution and interpretation. Alzheimer's and Dementia, 2020, 16, e039031.	0.4	0
1767	Premature neuronal differentiation in familial Alzheimerâ€™s disease human stem cells in vitro and in postmortem brain tissue. Alzheimer's and Dementia, 2020, 16, e039793.	0.4	0
1768	Tracking neurodegeneration in frontotemporal dementia and Alzheimerâ€™s disease: A comparative study of plasma tau and neurofilament light chain. Alzheimer's and Dementia, 2020, 16, e040015.	0.4	0
1769	Reduction of neurogranin immunostaining in the hippocampus of postâ€mortem brain of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e040707.	0.4	0
1770	AD biomarker stability for stored CSF based on immunoassay results. Alzheimer's and Dementia, 2020, 16, e040747.	0.4	0
1771	Associations of dietary patterns and CSF biomarkers for Alzheimerâ€™s disease in a populationâ€based sample of 70â€yearâ€olds. Alzheimer's and Dementia, 2020, 16, e040800.	0.4	0
1772	CSF 7â€ketocholesterol is related to Î²â€amyloid and white matter microstructure in healthy adults. Alzheimer's and Dementia, 2020, 16, e041015.	0.4	0
1773	Selective association of neurogranin gene expression with amyloid and tau pathology in the parahippocampal gyrus in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e041053.	0.4	0
1774	Serum NFL as a predictor of disease progression in dementia with Lewy bodies. Alzheimer's and Dementia, 2020, 16, e041594.	0.4	0
1775	Association of plasma YKLâ€40 with brain amyloidosis, memory performance, and sex in subjective memory complainers. Alzheimer's and Dementia, 2020, 16, e041753.	0.4	0
1776	A polygenic risk score for Alzheimerâ€™s disease determines the risk of incident dementia in APOE É›4 negative individuals over the age of 95: A populationâ€based cohort study. Alzheimer's and Dementia, 2020, 16, e042452.	0.4	0
1777	Characterization of monomeric and soluble aggregated AÎ² in Downâ€™s syndrome and Alzheimerâ€™s disease brains. Alzheimer's and Dementia, 2020, 16, e042479.	0.4	0
1778	A novel proteomics assay allows parallel quantitation of a panel of synaptic proteins in human cerebrospinal fluid. Alzheimer's and Dementia, 2020, 16, e042578.	0.4	0
1779	Association between polygenic risk score of Alzheimerâ€™s disease and CSF amyloid beta 42 in a cohort of 70â€yearâ€olds from the general population. Alzheimer's and Dementia, 2020, 16, e042616.	0.4	0
1780	Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, e042739.	0.4	0
1781	Plasma phosphoâ€tau in familial Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e042921.	0.4	0
1782	Impact of the APOE gene on amyloid deposition in participants with abnormal soluble amyloid levels. Alzheimer's and Dementia, 2020, 16, e042955.	0.4	0

#	Article	IF	Citations
1783	The interaction of amyloid and tau on decreased cortical neurite density in preclinical Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e043979.	0.4	0
1784	Amyloidâ€Î², tau, synaptic dysfunction, neurodegeneration, glial and vascular biomarkers in the preclinical stage of the Alzheimerâ€™s continuum. Alzheimer's and Dementia, 2020, 16, e044444.	0.4	0
1785	Genetically predicted telomere length and Alzheimerâ€™s disease endophenotypes: A Mendelian randomization study. Alzheimer's and Dementia, 2020, 16, e044720.	0.4	0
1786	The effect of physical activity on CSF biomarkers of Alzheimerâ€™s disease differs between men and women. Alzheimer's and Dementia, 2020, 16, e044722.	0.4	0
1787	Multiple biological pathways associate with cerebral amyloid load in the early Alzheimer's continuum. Alzheimer's and Dementia, 2020, 16, e044733.	0.4	0
1788	Higher frontoâ€parietal metabolism parallels a greater impact of amyloid and anxiety on medial temporal areas in women versus men. Alzheimer's and Dementia, 2020, 16, e044780.	0.4	0
1789	Multiple pathophysiological biomarkers are associated with gray matter volume and cerebral glucose metabolism in the early preclinical Alzheimer's continuum. Alzheimer's and Dementia, 2020, 16, e044808.	0.4	0
1790	APOE â€•Îµ4 shapes temporoâ€parietal network properties in middleâ€aged, cognitively unimpaired individuals: A graph theory analysis. Alzheimer's and Dementia, 2020, 16, e045092.	0.4	0
1791	Weight loss predicts Alzheimerâ€™s disease biomarker positivity in cognitively unimpaired middleâ€aged adults. Alzheimer's and Dementia, 2020, 16, e045137.	0.4	0
1792	Proximity to parental age at onset exacerbates amyloid burden while mental conditions exacerbate neural loss during midlife. Alzheimer's and Dementia, 2020, 16, e045171.	0.4	0
1793	Incidence of subjective cognitive decline is associated with amyloidâ€Î² pathology, whereas stability relates to neurodegeneration. Alzheimer's and Dementia, 2020, 16, e045293.	0.4	0
1794	Amyloidâ€positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to hippocampal volume. Alzheimer's and Dementia, 2020, 16, e045715.	0.4	0
1795	DNA methylation differences associated with peripheral biomarkers in the EMIFâ€AD cohort. Alzheimer's and Dementia, 2020, 16, e045853.	0.4	0
1796	Levels of amyloid Î² in cerebrospinal fluid predicts cognition five years later: A populationâ€based study of 70â€yearâ€olds. Alzheimer's and Dementia, 2020, 16, e045969.	0.4	0
1797	Multimodal genomeâ€wide metaâ€analysis of brain amyloidosis reveals heterogeneity across CSF, PET, and pathological amyloid measures. Alzheimer's and Dementia, 2020, 16, e046009.	0.4	0
1798	Baseline cerebrospinal fluid biomarkers of amyloidosis, phosphorylated tau, and total tau relate to greater longitudinal atrophy in regions susceptible to Alzheimerâ€™s diseaseâ€related neurodegeneration. Alzheimer's and Dementia, 2020, 16, e046095.	0.4	0
1799	Synaptic proteins relate to memory scores in preclinical Alzheimerâ€™s disease and cognitively healthy controls depending on amyloid. Alzheimer's and Dementia, 2020, 16, e046102.	0.4	0
1800	Microglial activation indexed by [11 C]PBR28 is associated with synaptic depletion in the Alzheimerâ€™s disease spectrum. Alzheimer's and Dementia, 2020, 16, e046191.	0.4	0

#	Article	IF	Citations
1801	Hypertension accentuates reductions in CSF AÎ²42 in elderly depressives. Alzheimer's and Dementia, 2020, 16, e046299.	0.4	0
1802	Plasma tau is negatively correlated with frontal lobe CBF in hypertensive adults on the AD spectrum. Alzheimer's and Dementia, 2020, 16, e046355.	0.4	0
1803	Exploring genetic contributors to neuroprotection from AD pathologies: A genomeâ€wide association study. Alzheimer's and Dementia, 2020, 16, e046417.	0.4	0
1804	Cerebrospinal fluid phosphorylated tau interacts with MMP2 and MMP3: Associations with cognitive performance in older adults. Alzheimer's and Dementia, 2020, 16, e046463.	0.4	0
1805	Plasmaâ€based biomarkers for AÎ² and tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e046490.	0.4	0
1806	Insulin resistance is related to cognitive decline but not biomarkers of Alzheimerâ€™s pathology in adults without dementia. Alzheimer's and Dementia, 2020, 16, e047022.	0.4	0
1807	Longitudinal changes in established and exploratory cerebrospinal fluid biomarkers by PTAU/AÎ² 42 status in cognitively unimpaired adults. Alzheimer's and Dementia, 2020, 16, e047156.	0.4	0
1808	Improved performance of Elecsys CSF Abeta measurement achieved using the simple, unified routineâ€use protocol for CSF collection. Alzheimer's and Dementia, 2020, 16, e047394.	0.4	0
1809	Analytical characteristics of the updated elecsys Abeta42 Gen 2 assay, including comparisons with the Gen 1 assay. Alzheimer's and Dementia, 2020, 16, e047517.	0.4	0
1810	Alzheimerâ€™s pathologic change indexed by CSF Bâ€amyloid42 associates with longitudinal alterations in myelin content. Alzheimer's and Dementia, 2020, 16, e047629.	0.4	0
1811	Ultraâ€performance liquid chromatographyâ€tandem mass spectrometry method for analysis of tau in human cerebrospinal fluid without the need of immunocapture. Alzheimer's and Dementia, 2020, 16, e040373.	0.4	0
1812	Author reply to the Letter to the Editor by Prof.Dr. Dr Mischak: â€œReâ€analysis of peptidomic analysis of cartilage and subchondral bone in OA patientsâ€. European Journal of Clinical Investigation, 2020, 50, e13260.	1.7	0
1813	Method and Clinical Validation of Biomarkers for Neurodegenerative Diseases. Neuromethods, 2021, , 163-173.	0.2	0
1814	Abeta CSF LC-MS. Neuromethods, 2021, , 55-69.	0.2	0
1815	Plasma metabolomics of presymptomatic PSEN1â€H163Y mutation carriers: a pilot study. Annals of Clinical and Translational Neurology, 2021, 8, 579-591.	1.7	0
1816	Alzheimerâ€™s disease in primary care: new tools for improved and simplified diagnostics. Journal of Internal Medicine, 2021, 290, 477-479.	2.7	0
1817	Circulating granulocyte colony-stimulating factor and functional outcome after ischemic stroke: an observational study. Neurological Research, 2021, 43, 1013-1022.	0.6	0
1818	Cerebrospinal fluid neurogranin in Alzheimerâ€™s disease studies: are immunoassay results interchangeable?. Clinical Chemistry and Laboratory Medicine, 2021, 60, e13-e17.	1.4	0

#	Article	IF	Citations
1819	D02â€…Cerebrospinal fluid amyloid beta and glial fibrillary acidic protein concentrations in huntingtonâ€™s disease. , 2021, , .		0
1820	F05â€…Biological and clinical characteristics of gene carriers far from predicted onset in the hd-yas study: a cross-sectional analysis. , 2021, , .		0
1821	Assessment of Protein as a in Rodent Models of Toxic-Induced Peripheral. Neuromethods, 2021, , 267-275.	0.2	0
1822	Cerebrospinal Fluid Biomarkers in Alzheimerâ€™s Disease and Frontotemporal Dementia. , 2014, , 131-157.		0
1823	A Selected Reaction Monitoring Protocol for the Measurement of sTREM2 in Cerebrospinal Fluid. Neuromethods, 2018, , 169-177.	0.2	0
1824	D08â€…Neurofilament light protein in blood as a potential biomarker of neurodegeneration in hungtingtonâ€™s disease: a retrospective cohort analysis. , 2018, , .		0
1825	Axonal Injury Partially Mediates Associations Between Increased Left Ventricular Mass Index and White Matter Damage. Stroke, 2022, 53, 808-816.	1.0	0
1826	Association of plasma neurofilament light chain (pNfL) with neuroimaging markers of neurodegeneration and cerebrovascular disease. Alzheimer's and Dementia, 2020, 16, e043060.	0.4	0
1827	White matter microstructure and cerebrospinal fluid biomarkers of Alzheimerâ€™s disease in middleâ€aged cognitively unimpaired participants (the ALFA study). Alzheimer's and Dementia, 2020, 16, e043027.	0.4	0
1828	Developments in clinical testing of cerebrospinal fluid biomarkers of Alzheimerâ€™s disease in the UK. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1829	Associations between obstructive sleep apnea, Alzheimerâ€™s disease pathology, and objective daytime sleepiness measured by the psychomotor vigilance task in cognitively unimpaired adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1830	Decorin is an early CSF biomarker of Alzheimerâ€™s AÎ² amyloidosis. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1831	Inflammatory, degeneration and neuritic growth biomarkers predict cognitive decline and dementia in Parkinsonâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1832	Measuring synaptic loss in early AD stages: Trajectories of SNAP25 and SYT1 using serial CSF sampling. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1833	The association between diabetes and Alzheimerâ€™s disease pathophysiology. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1834	Brain structural alterations in cognitively unimpaired individuals with discordant amyloidâ€Î² PET and CSF AÎ²42 status: Findings using machine learning. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1835	Machine learning on combined neuroimaging and plasma biomarkers for triaging participants of secondary prevention trials in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1836	Imaging neurodegeneration markers are associated with multiple pathophysiological mechanisms in the early stages of the Alzheimerâ€™s continuum. Alzheimer's and Dementia, 2021, 17, .	0.4	0

#	Article	IF	Citations
1837	CSF biomarkers and blood pressure trajectories in normotensive individuals and subjects with controlled and uncontrolled hypertension. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1838	Neuroâ€COVID: Does severe COVIDâ€19 infection increase the risk for cognitive impairment?. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1839	A multimodal study on the effect of sex on Alzheimer's disease clinical and biomarker changes in adults with Down syndrome. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1840	Microstructural alterations in medial temporal and frontal white matter tracts are associated with subjective cognitive decline. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1841	Positive clinical outcomes in two phase 2a studies: ADASâ€COG in Alzheimerâ€™s and MDSâ€UPDRS in Parkinsonâ€™s patients plus markers of toxic cascade that leads to nerve cell death. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1842	Plasma pâ€tau231 in the Alzheimerâ€™s disease continuum: A multiâ€cohort evaluation of diagnostic performance, detection of AÎ² pathology and preclinical application. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1843	Synergistic effects of CSF AÎ²42 and pâ€Tau on functional restingâ€state connectivity in cognitively unimpaired individuals. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1844	Subacute plasma neurofilament light predicts neurodegeneration after moderateâ€severe traumatic brain injury. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1845	Dataâ€driven approach for early detection of pathological pathways in middleâ€aged adults with family history of sporadic Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1846	Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of patients with mixed pathology. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1847	Associations between plasma pâ€tau217, in vivo brain pathology and cognition in individuals with autosomalâ€dominant Alzheimerâ€™s disease: Findings from the Colombiaâ€Boston (COLBOS) biomarker study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1848	Amyloid aggregation in temporal regions is associated with longitudinal memory decline in cognitively unimpaired Apoe â€Îµ4 carriers. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1849	Associations between mean apparent propagator MRI and cerebrospinal fluid markers of AD pathology, neurodegeneration, and glial activation, in cognitively unimpaired adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1850	Apolipoprotein Îµ genotype modifies the association between bloodâ€brain barrier permeability and both grey and white matter integrity in older adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1851	Structural, metabolic and cognitive characteristics of cognitively unimpaired subjects with mismatching Î²â€amyloid biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1852	CSF and PET biomarkers for noradrenergic dysfunction in neurodegenerative disease: A systematic review and metaâ€analysis. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1853	Plasma biomarkers distinguish clinical diagnostic groups in memory clinic patients. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1854	Inflammatory biomarkers are associated with cerebral large artery thickening and dilatation in older adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0

#	Article	IF	Citations
1855	Associations between iron deposition in the brain and grey matter volumes in cognitively unimpaired adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1856	Alzheimerâ€™s disease genetic risk variants show brain cell typeâ€specific associations with protein levels in cerebrospinal fluid. Alzheimer's and Dementia, 2021, 17, e049531.	0.4	0
1857	Amyloid status is associated with deficits in connected speech language. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1858	Interactions between dietary patterns and genetic factors in relation to incident dementia among 70â€yearâ€olds. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1859	Association of body mass index with brain structure and biomarkers of inflammation in cognitively unimpaired middleâ€aged adults with and without evidence of Î²â€amyloid pathology. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1860	Mass spectrometric measurement of six siteâ€specific tau phosphorylations in CSF and blood of Alzheimer's disease patients. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1861	CSF sTREM2 predicts markers of blood brain barrier integrity and amyloid beta metabolism independent of APOEâ€Îµ4 status. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1862	Associations of fully automated Elecsys CSF and novel plasma biomarkers with Alzheimer's disease neuropathology. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1863	Association of cerebrospinal fluid and plasma biomarkers with longitudinal tau accumulation. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1864	Plasma and cerebrospinal fluid neurofilament light protein concentrations are differentially associated with biomarker evidence of neurodegeneration in a communityâ€based population of 70â€yearâ€olds. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1865	Comparison of the prognostic value of cerebrospinal fluid and plasma neurofilament light in predicting longitudinal decline in white matter integrity among older adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1866	Association of deepâ€learningâ€“derived brain computed tomography measures with cognition and bloodâ€based biomarkers of neurodegenerative diseases. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1867	Impaired default mode network along with increased functional connectivity of the medial temporal lobe as a function of CSF pâ€Tau/Ab42 ratio in cognitively unimpaired individuals. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1868	CSF and blood biomarkers: How strongly do they reflect Alzheimer's pathophysiology and are they dynamic?. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1869	Stability of the novel bloodâ€based biomarkers under preâ€analytical sample handling conditions: Results of the SABBâ€GBSC working group. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1870	Detection of subarachnoid haemorrhage with spectrophotometry of cerebrospinal fluidÂâ€“ a comparison of two methods. Clinical Chemistry and Laboratory Medicine, 2022, 60, 1053-1057.	1.4	0
1871	Plasma Amyloid and in vivo Brain Amyloid in Late Middle-Aged Hispanics. Journal of Alzheimer's Disease, 2022, , 1-10.	1.2	0
1872	Title is missing!. , 2020, 17, e1003289.		0

#	Article	IF	Citations
1873	Title is missing!. , 2020, 17, e1003289.		0
1874	Title is missing!. , 2020, 17, e1003289.		0
1875	Title is missing!. , 2020, 17, e1003289.		0
1876	Title is missing!. , 2020, 17, e1003289.		0
1877	Title is missing!. , 2020, 17, e1003289.		0
1878	Title is missing!. , 2020, 17, e1003289.		0
1879	Title is missing!. , 2019, 14, e0226276.		0
1880	Title is missing!. , 2019, 14, e0226276.		0
1881	Title is missing!. , 2019, 14, e0226276.		0
1882	Title is missing!. , 2019, 14, e0226276.		0
1883	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntingtonâ€™s disease. , 2020, 15, e0233820.		0
1884	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntingtonâ€™s disease. , 2020, 15, e0233820.		0
1885	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntingtonâ€™s disease. , 2020, 15, e0233820.		0
1886	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntingtonâ€™s disease. , 2020, 15, e0233820.		0
1887	Title is missing!. , 2020, 15, e0236384.		0
1888	Title is missing!. , 2020, 15, e0236384.		0
1889	Title is missing!. , 2020, 15, e0236384.		0
1890	Title is missing!. , 2020, 15, e0236384.		0

#	Article	IF	Citations
1891	Cerebrospinal fluid proteomic profiling of individuals with prodromal Alzheimerâ€™s disease classified using two different neurodegenerative biomarkers (N) in A/T/N classification. Alzheimer's and Dementia, 2021, 17, e053030.	0.4	0
1892	A role for inflammaging in Î±-synuclein-associated breakdown of local sleep in the elderly.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e054208.	0.4	0
1893	Sex differences in blood-based biomarkers in individuals with autosomal dominant Alzheimer's disease.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055011.	0.4	0
1894	Immune protein levels in cerebrospinal fluid: Associations with memory scores across the AD spectrum.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055451.	0.4	0
1895	CSF AÎ²42 and AÎ²40 and their relation to brain soluble and insoluble AÎ² in the 5xFAD mouse model of Alzheimer's disease.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055684.	0.4	0
1896	Plasma neurofilament light levels as a novel biomarker for neurological involve- ment in Wilsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A6.2-A6.	0.9	0
1897	Reply to â€œPathway for ascertaining the role of uric acid in neurodegenerative diseases,â€• Roman Youssef. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	1.2	0
1898	Reply to Dr. Arieli regarding our article protein tau concentration in blood increases after SCUBA diving: an observational study published in European journal of applied physiology 2022;122:993-1005. European Journal of Applied Physiology, 0, , .	1.2	0